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Summary 
With 212 million cases worldwide and an estimated 429,000 deaths in 2015, malaria 
continues to be a serious global health threat. An effective vaccine could significantly 
decrease malaria-associated morbidity and mortality, especially in children under the age of 
five years. At present, there is no licensed malaria vaccine available. The most advanced 
malaria vaccine candidate, the RTS, S/AS01 subunit formulation, showed limited and short-
term vaccine efficacy against clinical malaria in phase 3 clinical studies in malaria-endemic 
populations in sub-Saharan Africa.  
The only vaccination approach that has ever induced complete sterile protection against 
controlled human malaria infection (CHMI) in malaria-naïve individuals, is the immunization 
with live, whole-attenuated sporozoites. The Sanaria® PfSPZ Vaccine (PfSPZ Vaccine) is a 
pre-erythrocytic vaccine, which is composed of live, radiation-attenuated, aseptic, purified, 
non-replicating, cryopreserved, whole Plasmodium falciparum (Pf) sporozoites (PfSPZ). In a 
study at the National Institutes of Health (NIH), the PfSPZ Vaccine was safe and well 
tolerated and protected 100% (6/6) of malaria-naïve volunteers against homologous CHMI 
when administered intravenously (IV) at 5 doses of 1.35 x 105 PfSPZ.  
The overall aims of this thesis included i) the evaluation of the safety, immunogenicity and 
protective efficacy against homologous CHMI of the PfSPZ Vaccine by direct venous 
inoculation (DVI) of malaria pre-exposed volunteers from Tanzania and ii) the study of 
functionally active serum and monoclonal antibody responses against Pf sporozoites induced 
by malaria pre-exposed Tanzanian volunteers upon immunization with the PfSPZ Vaccine. 
Building on these objectives, the here presented thesis is structured around three manuscripts: 
 
Manuscript 1: Safety, immunogenicity and protective efficacy against controlled human 
malaria infection of PfSPZ Vaccine in Tanzanian adults 
 
This manuscript depicts the first clinical phase I trial on the safety, immunogenicity and 
protective efficacy against homologous CHMI of PfSPZ Vaccine performed in Africa. The 
study was conducted in healthy male volunteers aged 20 to 30 years in Bagamoyo, Tanzania. 
Similar regimen as tested in the NIH study of 5 doses of 1.35 x 105 (low-dose group) or 2.7 x 
105 (high-dose group) of PfSPZ Vaccine was administered via DVI to Tanzanian adults. 
 II 
 
Homologous CHMI was conducted at 3 and 24 weeks after the last vaccination. The PfSPZ 
Vaccine was safe and well tolerated, but less immunogenic and protective against CHMI as in 
malaria-naïve US Americans. In the low-dose group, 1 of 18 (6%) vaccinees was protected 
and 4 of 20 (20%) vaccinees were protected in the high-dose group at CHM1, 3 weeks past 
last vaccination. The 4 protected subjects from the high-dose group were still protected after 
repeated CHMI2, at 24 weeks past last vaccination. It is hypothesized that higher individual 
doses and altering intervals will be required to induce improved protective efficacy and 
immunogenicity in malaria endemic target populations.  
 
Manuscript 2: Intravenous application of irradiation attenuated Plasmodium falciparum 
sporozoites elicits long-lived IgG and IgM invasion inhibitory antibodies in malaria pre-
exposed volunteers 
 
In this study we aimed i) to gain a better understanding of the vaccine-induced humoral 
immune responses in malaria pre-exposed individuals after immunization with DVI-
administered PfSPZ Vaccine and ii) to investigate if sporozoite binding and invasion 
inhibitory IgM antibodies are induced following PfSPZ vaccination. To address this, we used 
serum and plasma samples collected from a subset of volunteers who participated in the 
PfSPZ Vaccine trial described in manuscript 1. Our findings demonstrate that malaria pre-
exposed volunteers develop sporozoite invasion inhibitory antibodies and induce anti-CSP 
IgG and IgM antibodies after repeated PfSPZ vaccination. A subset of these plasma samples 
was depleted from IgG and IgA antibodies to obtain fractions containing only IgM antibodies. 
Depleted IgM antibody fractions of 3 volunteers demonstrated sporozoite invasion inhibitory 
capacity in in vitro inhibition of sporozoite invasion (ISI) assays. These results indicated for 
the first time that sporozoite-specific IgM antibodies could contribute to protection against 
malaria infection.  
 
Manuscript 3: CSP-specific human monoclonal antibodies inhibiting Plasmodium 
falciparum liver stage infection target a distinct sequence at the N-terminus 
 
To investigate the mechanisms of protection elicited by antibodies following PfSPZ 
vaccination, we isolated a panel of monoclonal antibodies from the PfSPZ-immunized 
Tanzanian volunteers who were found protected from homologous CHMI in the study 
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described in manuscript 1. Using an antigen-agnostic approach to identify antibodies that can 
bind the surface of intact sporozoites, we found that all monoclonal antibodies isolated target 
the circumsporozoite protein (CSP), confirming its known immunodominance. Functional 
characterization of these antibodies revealed, that the most effective antibodies reducing Pf 
liver burden in a humanized mouse model target a distinct epitope located at the junction 
between the N-terminal end and the NANP repeat, a region which is not included in the RTS, 
S vaccine. Our results suggest that this identified region could be a component of interest in 
the future design of effective second generation PfCSP subunit vaccines. 
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1.1 Malaria Overview 
1.1.1 The global burden of malaria 
To date, malaria is endemic in 91 countries and territories (Figure 1). Despite remarkable 
reductions in malaria morbidity and mortality due to improvements in vector control, 
therapeutics and diagnostics between the years 2000 and 2015, Malaria remains a disease of 
global health importance [1, 2]. In 2015, the World Health Organization (WHO) estimated 
212 million new malaria cases globally, of which 429,000 were fatal. An estimated 92% of 
those deaths occurred in the WHO African region with 70% of all deaths reported in children 
under the age of 5 years [1]. 
 
 
Figure 1 Countries endemic for malaria in the years of 2000 and 2016. Between 2000 and 2015 substantial 
reductions in malaria case incidence (41%) and malaria mortality rates (62%) have been achieved. The number 
of malaria-endemic countries and territories decreased from 108 in the year 2000 to 91 at the beginning of 2016 
[1]. 
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1.1.2 Malaria species infecting humans 
Malaria is caused by Plasmodium parasites and transmitted to people through the bites of 
infected female Anopheles mosquitoes [3]. Six plasmodial species are infectious to humans: 
P. falciparum is the most prevalent parasite on the African continent and responsible for most 
malaria-related deaths globally [1]. P. vivax is a major cause of illness across large parts of 
the world, mainly outside of sub-Saharan Africa. Deaths due to this parasite have been 
underestimated in the past years [4]. P. ovale curtisi, P. ovale wallikeri, and P. malariae are 
considered as more benign species [1]. The zoonotic species P. knowlesi is a malaria parasite 
infecting long-tailed macaques and is largely found in Southeast Asia [5] and there is no clear 
evidence yet of human-to-human transmission [6]. Nevertheless, a study in Malaysia reported 
that this parasite can cause severe disease [6]. 
 
1.1.3 P. falciparum life cycle and pathogenesis 
P. falciparum undergoes a complex life cycle and requires both human and mosquito hosts to 
complete transmission (Figure 2) [7]. The infection begins when female Anopheles 
mosquitoes inoculate a small number of sporozoites (10-100) into the human’s dermis and 
blood stream while taking a blood meal (Figure 2A) [7]. A proportion of these sporozoites 
start to penetrate blood vessels, a process relying on gliding motility, in order to enter the 
bloodstream. Sporozoites remaining in the skin are destroyed and drained to regional lymph 
nodes [8]. Those that reach the circulation, quickly migrate to the liver tissue through a 
process called traversal. In the liver, the sporozoites first cross macrophage-like Kupffer cells 
and several hepatocytes before entering and taking residence in few hepatocytes (Figure 2B) 
[8, 9]. Inside the hepatocyte, the sporozoites start to replicate and differentiate for 
approximately 7 days until they give rise to tens of thousands of asexual blood-stage parasites 
called merozoites [10]. In each sporozoite-infected hepatocyte, around 40,000 merozoites are 
released into the blood-stream via the budding of parasite-filled vesicles called merosomes 
[10]. Throughout the whole pre-erythrocytic stage development in the liver, the infection 
remains clinically silent [9]. Clinical symptoms of malaria occur only during the asexual 
blood-stage infection (Figure 2C) and can develop as early as three days after merozoites are 
released from the liver. Once the merozoites are in the bloodstream, they start a 48 hour cycle 
of red blood cell (RBC) invasion, parasite replication and rupture, leading to the release of 
more merozoites that infect new RBC (Figure 2C), a process also known as asexual 
intraerythrocytic developmental cycle (IDC) [11]. The IDC includes four distinct stages: the 
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RBC-invasive merozoite stage; the ring-stage, which develops after RBC invasion and feeds 
on hemoglobin to form hemozoin crystal accumulations; the trophozoite stage, which is 
involved in the remodeling of the RBC architecture by the export of variant surface antigens 
(VSAs) such as PfEMP1 to the RBC surface; and the schizont stage, that is characterized by 
repetitive nuclear divisions in order to form new merozoites [9, 12]. VSAs act as receptors for 
endothelial cell surface expressed ligands, resulting in the binding (sequestration) of infected 
red blood cells (iRBCs) to the small blood vessels in various organs, which allows the parasite 
to avoid splenic clearance [9]. Sequestration of iRBCs is also associated with clinical 
syndromes of severe malaria like cerebral malaria where iRBC sequester in the brain or 
pregnancy-associated malaria, with iRBC sequestration in the placenta [9]. VSAs further 
contribute to disease by mediating rosetting of iRBCs to uninfected RBCs. Upon iRBC lysis, 
various parasite products are released that are thought to be responsible for the malaria 
symptoms like headaches, fever and lethargy [11]. A small number of blood-stage parasites 
will undergo gametocytogenesis and differentiate into male and female gametocytes (Figure 
2D), which can be taken up by mosquitoes during a blood meal. In the mosquito midgut 
(Figure 2E), micro- and macrogametes fuse to form the zygote, which further differentiates 
into ookinetes that pass the midgut epithelium and ultimately encyst to form new sporozoites, 
that enter the mosquito’s salivary glands - ready to be spread to the next human host [13]. 
Taken together, although the pathogenesis of malaria is not fully understood until today, the 
main effectors underlying this process are believed to be driven by both, parasite and host 
factors, which include the sequestration of iRBC in the blood vessels and the local and 
systemic inflammation [14]. 
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1.1.4 Malaria diagnosis and treatment 
According to WHO, every suspected malaria case should be confirmed by microscopy or a 
rapid diagnostic test (RDT) before treatment is initiated, unless there is no parasite-based 
diagnostic testing available [1]. Both techniques show higher limits of detection (LoD) in 
comparison to PCR-based detection methods [15]. As a result of this limited sensitivity, sub-
microscopic, low-density infections can be missed and a large proportion of transmission can 
be sustained [16]. These asymptomatic or chronic infections are particularly common in 
malaria pre-exposed individuals with naturally acquired immunity [17]. RDTs are immune 
chromatography-based assays that measure the presence of histidine-rich protein 2 (HRP2) 
for P. falciparum or lactate dehydrogenase for other Plasmodium species (pLDH) in 
peripheral blood [18]. In case of patient follow-up visits after treatment, these tests are not 
convenient, since they may lead to false positive results as the antigens can circulate up to 28 
days after parasite death [18, 19]. Most importantly, malaria parasites with gene deletions of 
pfhrp2/hrp3 begin to emerge in several South American countries, in the China-Myanmar 
 
Figure 2 Life cycle of Plasmodium falciparum [9]. 
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border, Ghana, the Democratic Republic of Congo, Eritrea, India, Uganda and Rwanda [1]. 
Consequently, new or better RDTs that target non-HRP2 antigens are needed [1]. 
Regarding treatment of uncomplicated P. falciparum malaria, WHO recommends for the 
treatment of children and adults (except pregnant women in their first trimester) an 
artemisinin-based combination therapy (ACT) [1]. To date, resistance to artemisinin has 
emerged in five countries in the Greater Mekong sub-region [1].  
 
1.1.5 Current malaria control strategies 
Current malaria prevention interventions include vector control, chemoprevention and 
potentially vaccination [1]. Among vector control, the use of insecticide-treated bed-nets 
(ITN) and indoor residual spraying (IRS) belong to the most frequently used methods in 
preventing mosquito bites [1]. Both strategies fundamentally contributed to the global decline 
in malaria burden since 2000 [2, 20, 21]. Chemoprevention consists of intermittent preventive 
treatment (IPT) of malaria in pregnant women (IPTp) and infants (IPTi) with sulfadoxine-
pyrimethamine (SP) [1]. During IPT, antimalarial drugs are administered at specified time 
points without prior screening for parasites [22, 23]. IPTp and IPTi have demonstrated 
efficient reduction of placental malaria, low birth weight, clinical malaria in infants and 
anemia [24, 25]. Nevertheless, the remarkable gains of malaria prevention and control in the 
past 15 years are currently threatened by emerging resistance to anti-malarial drugs and 
insecticides [26]. Hence, there is an urgent need in taking action by the global malaria 
community in order to prevent any further spread of drug resistant vectors and parasites, and 
in maintaining the effectiveness of existing control interventions [26]. An alternative 
prevention strategy could be achieved through vaccination. To date, the most advanced 
malaria vaccine RTS,S/AS01 showed 39% efficacy against clinical malaria and 31.5% 
efficacy against severe malaria in infants aged 5-17 months at first vaccination in a large 
phase 3 clinical trial conducted in sub-Saharan Africa [27]. At present, the RTS,S/AS01 is 
considered a complementary malaria control tool to the core package of proven malaria 
interventions [1]. So far, the only immunogens that have ever induced high level protection 
(>90%) against controlled human malaria infection (CHMI) is the immunization with whole 
attenuated sporozoites [28–32]. This vaccination approach will be discussed more in detail in 
section 1.3. 
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1.2 The human immune response to P. falciparum infection 
1.2.1 Humoral and cellular immune responses against P. falciparum 
Powerful clinical research models such as CHMI studies, animal models of malaria and the 
study of immune responses to natural infection in malaria endemic settings with different 
transmission intensities, have led to an improved understanding of the immunobiology of 
Plasmodium infection in the past years [9]. Nevertheless, many open questions remain to be 
elucidated in terms of cellular and molecular mechanisms invovled in malaria immunity [9]. 
A summary of the main humoral and cellular immune responses controlling the different 
stages of the P. falciparum parasite are shown in Figure 3. In the skin, antibodies are known 
to be the main immune effectors that are capable of blocking or reducing sporozoite migration 
to the liver [9]. The proportion of sporozoites drained in lymph-nodes start to prime specific B 
and T cell responses while the live sporozoites that enter the blood stream and migrate to the 
liver travers Kupffer cells and invade hepatocytes [33]. During this clinically silent stage, no 
sterilizing immunity is known to be naturally acquired and the cellular and molecular 
mechanisms underlying lack of sterilizing immunity remains to be investigated [34]. In 
contrast, experimental infection of humans and mice with attenuated sporozoites have 
revealed that sterilizing immunity can be induced at this stage [9, 31, 35–37], and IFN-γ-
producing CD8+ and CD4+ T cells, Natural killer (NK) cells and γδ T cells and inducible 
nitric oxidase synthase (iNOS) and nitric oxide (NO) secreted by macrophages are likely to be 
essential for this protection [9]. During blood stage infection, antibodies play a crucial role in 
the immune response against the asexual parasites [38]. The antibody-mediated protection 
involves the blocking of merozoites from RBC invasion [39, 40], opsonization of iRBC for 
phagocytic clearance [41, 42], monocyte-mediated antibody-dependent cellular killing [43], 
as well as complement-mediated lysis [44] and interference with the sequestration of iRBCs 
within the microvasculary blood vessels [45]. In addition, cytokine producing CD4+ T-cells, 
NK, NKT, γδ T cells, NO and iNOS-producing macrophages likely contribute to control of 
asexual blood-stage parasites [9]. Immune responses against the sexual stages (gametocytes, 
gametes, and ookinetes) are mainly driven by humoral immune effectors like complement-
fixing antibodies that are taken up by the mosquito during the blood meal [9, 33, 46]. 
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The complex life cycle and the high degree of genetic variability of P. falciparum pose 
several obstacles for the immune system [47]. Among the different parasite stages, asexual 
blood-stage parasites express the antigens with the highest variability, whereas surface 
proteins on sporozoites and sexual parasites are less or little polymorphic (Figure 3) [48]. As a 
result of antigenic polymorphism and genetic recombination, every new malaria infection can 
be genetically different and presents a new antigenic display to the immune system [33, 49]. 
Hence, during a natural infection, the induced immune responses may be highly stage- and 
genotype-specific [50]. Other challenges for the immune system are the obligate intracellular 
nature of the different parasite stages, which protects the parasite from antibody-mediated 
killing and the fast transition time of merozoites from one RBC to the next, as well as the 
short duration of each phase during the life cycle, which might be too short for the immune 
system to induce an effective antigen-specific immune response [51, 52]. 
 
 
Figure 3 Humoral and cellular immune responses induced against the different stages of P. falciparum 
infection [33]. 
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1.2.2 Naturally acquired immunity 
Naturally acquired immunity (NAI) to malaria is defined as the cumulative product of 
exposure to repeated infections over time, resulting in a sufficiently diverse repertoire of 
strain-specific immune responses in endemic populations [53]. NAI can be divided into 
clinical immunity and parasitological immunity [54]. Clinical immunity protects the 
individual from life-threatening disease and death and is normally obtained in children aged 
5-10 years, who live in endemic areas with moderate to intense transmission [54]. 
Parasitological immunity is associated with the control and an incomplete clearance of the 
parasite, which can result in asymptomatic parasitemia that is commonly observed in adults 
living in endemic regions [54]. Importantly, NAI is slowly developed, non-sterile, and 
relatively short-lived [54, 55]. Albeit not yet fully understood, NAI is mainly antibody-driven 
and directed against the asexual blood stage parasite and it remains unclear whether NAI has 
an effect on pre-erythrocytic immune responses or against sexual parasite stages [13]. NAI 
depends on cell-mediated and humoral immune responses while the relative contributions of 
these immune mechanisms is incompletely understood and might differ between different 
human populations [56]. 
 
1.2.3 Inefficient acquisition of humoral immune memory to malaria in exposed people 
living in endemic countries 
Humoral immune memory is composed of high-affinity memory B cells (MBCs) and long-
lived antibody-producing plasma cells (LLPCs) [57]. Upon re-infection, MBCs are 
reactivated and rapidly start to proliferate and differentiate either into plasma cells that secrete 
high-affinity antibodies at high rates or re-enter germinal center reactions in order to acquire 
more affinity maturation to adapt to modified pathogens [58]. LLPCs reside in the bone 
marrow for long periods of time and constantly secrete protective antibodies which serve as a 
first line of defense against re-exposure to foreign proteins or pathogens [59, 60]. 
In contrast to other viral or bacterial pathogens (tetanus, smallpox, measles) which can induce 
long-lived protective antibodies for decades after a single exposure or vaccination [61–63], 
antibodies to Plasmodium antigens are slowly and inefficiently generated and rapidly lost in 
the absence of ongoing exposure in semi-immune individuals who live in malaria-endemic 
regions [64]. Likewise, a defective acquisition and maintenance of MBCs specific for malaria 
antigens compared to childhood vaccination-induced MBC has been reported in such endemic 
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populations [65]. In contrast, individuals living in areas of infrequent malaria exposure, stable 
malaria-specific MBC populations are described [66–69], suggesting that different levels of 
transmission might have an impact on the development and maintenance of MBCs. Despite a 
largely incomplete understanding of the immunological processes leading to this impaired and 
insufficient acquisition of LLPCs and MBCs in malaria, several mechanisms responsible for 
these defects in B cell immunological memory have been described in the past years [64]. The 
following paragraphs will summarize these main findings:  
 
Clonal antigenic variation and the expression of highly polymorphic antigens on the surface 
of asexual blood stage parasites and iRBCs might be partially responsible for the sub-optimal 
acquisition of humoral immunity to malaria [64]. 
 
An expansion of a phenotypically similar memory B cell subset, so called atypical memory B 
cells, has been identified in various P. falciparum-exposed children and adults [68, 70]. The 
frequencies of these atypical MBCs seem to be positively correlated with the parasite’s 
transmission intensity [70]. The immunological processes driving the development of atypical 
MBCs and whether these cells are detrimental or beneficial in humoral malaria immunity 
remains unclear. Different investigators have published contrary results in terms of the 
functional relevance of this MBC subset [71, 72]; Muellenbeck et al. 2013, reported a positive 
contribution of atypical MBC in malaria immunity by demonstrating that VH and VL genes 
cloned from atypical MBC from malaria-exposed individuals encoded broadly P. falciparum 
neutralizing antibodies [71]. However, further investigations are required on this finding, 
since direct antibody secretion by atypical MBCs could not be demonstrated. In contrast, 
according to studies published by Portugal et al. 2015, atypical MBCs express several 
inhibitory receptors and B cell receptor (BCR) signaling seems to be defective, which leads to 
an impaired B cell response including proliferation, cytokine production and antibody 
secretion [72]. Next-generation sequencing of the expressed VH genes of atypical and classical 
MBCs revealed that VH gene usage and the rates of somatic hypermutation (SHM) are similar, 
indicating that classical and atypical MBCs share a common precursor [72]. 
 
Another explanation for the functionally impaired B cell memory and the mechanisms driving 
expansion of atypical MBCs could be the direct modulation of B cell function by the parasite 
itself [65]. In vitro studies proved that the malaria parasite can directly interact with human B 
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cells through the cysteine-rich interdomain region 1α (CIDR1α), an extracellular domain of 
the variant surface antigen PfEMP1 expressed on the surface of iRBCs. CD27+ B cells were 
the main responding population in these experiments, suggesting that MBC are particularly 
affected by CIDR1α. This interaction leads to T-cell-independent polyclonal B cell activation 
(PBA), resulting in MBC cell activation, proliferation and cytokine production [73, 74] and 
might induce altered Toll-like receptor (TLR) responsiveness and potentially lead to B cell 
exhaustion by reducing the B cell receptor activation threshold [75]. However, to confirm 
these findings further investigations are needed and it remains unclear whether the PfEMP1-
CIDR1α-MBC interaction results in activation, exhaustion, or deletion of malaria-specific B 
cell memory responses [64].  
 
It has also been discussed that systemic mediators responsible for B cell activation and 
survival, become modulated during a P. falciparum infection and thus, could potentially 
contribute to MBC dysfunction. One example of these mediators are the B cell activation 
factor BAFF and BAFF receptor [65, 76]. BAFF is a cytokine produced by mononuclear cells 
(monocytes, T cells, DCs) [77] and its production is mediated by the cytokines IL-10 and 
IFN-γ [78, 79], which are also up-regulated during an acute P. falciparum infection [76]. 
Increased plasma BAFF levels have been detected in children with acute P. falciparum 
infection [76] and in placental tissue from pregnant women infected with Pf malaria [80]. 
Parasite-induced BAFF secretion has been hypothesized to impair humoral B cell memory 
and B cell survival rates [65]. However, these findings are purely observational and the actual 
mechanisms and consequences underlying these modulations remain to be established [65]. 
 
The relatively insufficient acquisition of P. falciparum-specific humoral memory responses 
could also be linked to deficient immunological T cell help during a malaria infection [81]. 
CD4+ T cells isolated from children of high-transmission settings for P. falciparum, have 
shown to express up-regulated levels of phenotypic markers for exhaustion, such as 
programmed cell death-1 (PD-1) and lymphocyte activation gene-3 (LAG-3) [82–84]. The 
expression of these inhibitory receptors appears to correlate with decreased proportion of 
MBCs in children with ongoing P. falciparum exposure [83] and up-regulated levels of PD-1 
result in increased parasite burden during infection [84]. In vivo studies in mice further 
revealed that CD4+ T cell exhaustion induced by P. yoelii infection can be restored through 
the blockade of PD-1 ligand and PD-L1 and the inhibitory receptors LAG-3 [82]. 
Nevertheless, whether these findings also count for humans remains unknown and further 
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investigations are needed in order to determine if the above described CD4+ T cell phenotype 
is a reflection of exhaustion or of a compromised Tfh compartment during human malaria 
infection [64]. 
 
Studies in humans [85] and mice [86–88] indicated that severe malaria infection can 
dramatically affect the spleen’s architecture by dissolution of the marginal zone, loss of B and 
T cells and reduced GC formation. These findings could partially explain the defective 
acquisition of MBCs and LLPCs in patients suffering from a fatal malaria infection [64].  
 
In past years, great efforts in research on potential mechanisms responsible for this slow and 
inefficient acquisition of humoral immunity to malaria have provided important insights into 
this field. Nevertheless, many outstanding questions remain and thus, it is important to 
conduct further investigations on data collected from immune-epidemiological studies and as 
well from volunteers enrolled in vaccine trials and controlled human malaria infections to 
finally arrive at a better understanding of factors driving naturally acquired immunity to 
clinical malaria infection.  
1.3 Malaria vaccine development 
An effective malaria vaccine would be the ideal tool to reduce risk of contracting malaria in 
endemic populations, especially in areas where health-care delivery systems and vector 
control strategies are difficult to maintain due to political conflicts or natural disasters [89]. 
However, malaria vaccine development has been extremely hampered by the parasite’s 
complex life cycle [33]. Several malaria vaccine candidates are currently tested in clinical 
trials and these are summarized in the global malaria vaccine pipeline shown in Figure 4. To 
date, the most clinically advanced malaria vaccine candidate is the subunit vaccine 
RTS,S/AS01, also known as Mosquirix [90]. The RTS,S/AS01 vaccine formulation is 
composed of the C-terminal portion of the P. falciparum circumsporozoite protein that is 
physically linked to the hepatitis B virus S antigen and an immune adjuvant (AS01) [91]. 
Results from phase 3 efficacy trial in seven different sub-Saharan African countries showed 
26% reduction of clinical malaria in young infants aged 6-12 weeks, and 36% reduction in 
children aged 5-17 months at first vaccination, after a booster dose administration of 18 
months after the primary series [27]. In 2015, the RTS,S/AS01 vaccine obtained positive 
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approval from the European Medicines Agency (EMA), followed by a WHO recommendation 
in 2016 to further evaluate RTS,S/AS01 vaccine in a larger scale pilot implementation study 
in children aged 5 to 9 months in sub-Saharan African settings of moderate to high parasite 
transmission [92]. The protective efficacy of the RTS,S/AS01 subunit vaccine demonstrated 
in the phase 3 clinical trial [27] are below the goal of 75% efficacy against clinical malaria set 
by the WHO Malaria Vaccine Technology Roadmap [93]. Thus, alternative vaccine 
approaches are needed in order to fulfill these goals.  
So far, the only immunogens that have ever induced high-level protection against CHMI in 
humans is the immunization with live, whole sporozoites [28–30, 30, 32]. These vaccination 
approaches are discussed in detail in the paragraph below. 
 
 
1.3.1 Whole sporozoite immunization 
Sterilizing immunity in humans and mice against experimental malaria infection after 
immunization by the bites of mosquitoes with radiation-attenuated sporozoites (RAS) has 
already been demonstrated in the late 1960’s and early 1970’s [28, 35]. During irradiation of 
infectious mosquitoes, the sporozoites’ DNA becomes randomly damaged, resulting in 
 
Figure 4 Global malaria vaccine pipeline (WHO rainbow table of global malaria vaccine projects). 
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sporozoites that retain their capacity to invade hepatocytes, but are no longer capable of 
developing into mature liver-stage parasites and into disease-causing blood-stage parasites 
[35]. Besides radiation, other sporozoite attenuation approaches include genetic engineering 
of Plasmodium in order to generate live-attenuated parasites that cannot develop into asexual 
blood stage infections [94], or a combination of chemoprophylaxis and fully infectious 
sporozoites (CPS) [31]. However, this thesis will focus on RAS, since all the data generated 
in these studies come from RAS-immunized volunteers. 
In earlier studies, where humans were exposed to infected irradiated mosquitoes, the 
mosquito-bite immunization approach was reasonably tolerable with mostly mild and 
moderate local and systemic adverse events. These studies also revealed that in order to 
achieve sterile immunity in humans, over 1,000 bites of irradiated mosquitoes during five or 
more immunization sessions are required [37]. Despite these promising findings, the 
development of an effective whole sporozoite based vaccine stalled because it was believed to 
be clinically and logistically impractical to generate such large numbers of irradiated 
mosquitoes for vaccinations of larger human populations. Moreover, it was also perceived to 
be impossible to produce, purify and preserve aseptic live sporozoites that meet regulatory 
standards [95]. Following the discovery and sequencing of the circumsporozoite protein 
(CSP) [96], efforts rather moved towards the development of a malaria subunit vaccine. 
 
1.3.2 The SanariaTM PfSPZ Vaccine 
In 2003, scientists from the biotechnology company Sanaria Inc. re-started the efforts of 
developing an effective, aseptic, purified and potent irradiated whole sporozoite malaria 
vaccine suitable for injection to humans [95]. Six years later, Sanaria Inc. successfully 
managed to manufacture and release a metabolically active, non-replicating P. falciparum 
sporozoite (PfSPZ) Vaccine, the SanariaTM PfSPZ Vaccine (PfSPZ Vaccine), that is 
biologically active and can be preserved in liquid nitrogen vapor phase (LNVP) [95]. The 
PfSPZ Vaccine is produced by raising adult Anopheles stephensi mosquitoes under aseptic 
conditions and feed them on human blood cultures that consist of aseptic P. falciparum 
gametocytes. Within the mosquitoes, the gametocytes develop into sporozoites in 
approximately two weeks. At this stage, the mosquitoes are exposed to radiation for 
attenuation. Immediately after radiation, the attenuated PfSPZ are isolated from the salivary 
glands by dissection under aseptic conditions, purified, vialed and cryopreserved into LNVP 
[95]. 
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After the completion of pre-clinical studies, the first human clinical trial of the SanariaTM 
PfSPZ Vaccine was conducted at the Naval Medical Research Center and University of 
Maryland at the Center for Vaccine Development in Maryland, U.S.; in 2009-2010 [97]. In 
this study, the vaccine was tested through the intradermal (ID) and subcutaneous (SC) 
administration route in 80 malaria-naïve adults. The results demonstrated that the vaccine was 
safe and well-tolerated, but protective efficacy and immunogenicity were low [97]. 
Thereafter, the administration route was changed from ID/SC to intravenous (IV) injection 
and first tested in animal models of non-human primates, rabbits and mice [29, 98]. The 
outcome of these experiments revealed that the vaccine was highly potent when administered 
IV. Following these promising results, the next goal was to test the safety, immunogenicity 
and protective efficacy of the IV-administered SanariaTM PfSPZ Vaccine in humans. This was 
done in a phase 1 clinical trial at the Vaccine Research Center, National Institute of Allergy 
and Infectious Diseases, NIH, Maryland, U.S. in 2012 [29]. The IV injection was safe and 
well-tolerated in all the tested volunteers and most importantly, 100% protection against 
homologous CHMI was achieved when the vaccine was administered at 5 doses of 1.35 x 105 
PfSPZ. Strikingly, there was a dose response in terms of antibody- and T-cell responses 
observed [29]. Animal studies further showed that the IV administration route was critical for 
the induction of hepatic PfSPZ-specific CD8+, IFN-γ producing T cells, which are known to 
play an important role in the protective immune response against CHMI [97]. 
The next critical step was to assess the safety, immunogenicity and protective efficacy of the 
SanariaTM PfSPZ Vaccine in malaria pre-exposed populations. These first safety and efficacy 
trials took place in Mali (NCT01988636), Tanzania (NCT02132299) (Chapter 2) and 
Equatorial Guinea (NCT02418962) between 2014 and 2015. In contrast to the high level, 
durable protection against homologous CHMI seen in malaria-naïve volunteers after IV 
administered PfSPZ immunization [29], the immune responses in P. falciparum pre-exposed 
African adults were sub-optimal and the efficacy was much lower. The Mali trial showed 
28.5% protection against natural, field strain P. falciparum infection [99]. In the BSPZV1 
trial in Tanzania (Chapter 2), 6% of volunteers in the low-dose group (5 x 1.35 x 105 PfSPZ) 
and 20% of volunteers in the high-dose group (5 x 2.7 x 105 PfSPZ) were protected against 
homologous controlled human malaria infection (CHMI) conducted 3 weeks post last 
vaccination (Jongo et al., manuscript submitted). 
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1.3.3 Controlled human malaria infection (CHMI) 
The PfSPZ vaccine trials described above used the homologous CHMI model to assess the 
protective efficacy of the vaccine. CHMI is carried out under strictly controlled laboratory 
and clinical conditions, in which human volunteers are challenged with fully infectious 
sporozoites or blood-stage parasites using a defined dosing and malaria strain [100]. The 
experimental blood-stage infection approach is less established [101] than the sporozoite-
induced challenge model and here we will focus on the CHMI studies using experimental 
sporozoite infection. CHMI has proven to be a powerful tool to determine the protective 
efficacy of malaria vaccines and antimalarial drugs [100]. And moreover, CHMI studies can 
accelerate the clinical malaria vaccine development in providing important preliminary 
information between phase I and phase II trials, and thus, substantial costs can be saved [100]. 
 
The first CHMI studies, using infectious mosquito bites or the IV or SC inoculation of 
dissected sporozoites suspended in media were already carried out in 1917 by Wagner von 
Jauregg as a treatment for patients with neurosyphilis, also known as “malariotherapy” [102]. 
With the advent of protocols for routine cultivation of P. falciparum and for the generation of 
gametocytes in vitro, CHMI studies using infected anopheles bites were practiced more 
routinely in the beginning of the 1980s [100]. The successful manufacture of aseptic, vialed, 
purified, cryopreserved, infectious PfSPZ by Sanaria Inc., made it possible to administer 
CHMI via needle and syringe inoculation. The first human trial using CHMI with infectious 
sporozoites via needle and syringe inoculation was carried out at the Radboud University 
Medical Center (RUNMC) in Nijmegen, in the Netherlands between 2010 and 2011 [103], 
followed by another trial in Tanzania [104]. In both studies, the volunteers were intradermally 
injected with the infectious PfSPZ. Importantly, the ID administration of the infectious PfSPZ 
challenge was safe and well-tolerated in all the participants, but the pre-patent period was 
longer than after mosquito-bite challenge and a 100% infection rate could not be achieved in 
neither of the two independent studies. To overcome these obstacles, the administration route 
was changed to IV or direct venous inoculation (DVI) and tested in a dose-finding trial in two 
centers, namely in Tübingen, Germany and Barcelona, Spain [105]. The two study sites found 
that 100% infection can be achieved when the infectious PfSPZ are intravenously 
administered at a dose of 3.2 x 103 sporozoites. The same CHMI dose regimen has also been 
used in Tanzanian adults and proved to be 100% infective in malaria pre-exposed volunteers 
(Jongo et al., manuscript submitted). 
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1.4 Aims of the thesis 
As described in section 1.3.2, after the promising outcome of the vaccine trial in U.S. non-
immune volunteers after intravenous administration of the SanariaTM PfSPZ Vaccine with 100 
% protection against homologous CHMI [29], the next indispensable step was to assess the 
safety, immunogenicity and protective efficacy of DVI administered PfSPZ Vaccine in 
endemic African populations. This includes the aim of the first part of this thesis. Between 
April 2014 and August 2015, we have conducted a phase 1, dose escalation, randomized 
controlled clinical trial to evaluate the safety, immunogenicity and protective efficacy against 
homologous CHMI of the PfSPZ Vaccine in Tanzanian male adults, in Bagamoyo, Tanzania 
(Chapter 2). The safety was determined by observation of adverse events including follow-up 
visits with clinical examination and laboratory tests. The immunogenicity was assessed by 
measurements of vaccine-induced antibody and T cell responses as described in Chapter 2. 
The vaccine efficacy was measured by CHMI via direct venous inoculation of 3,200 PfSPZ 
conducted 3 and 24 weeks after the last vaccination. 
The aim of the second part of this thesis (Chapter 3) was to explore the impact of malaria pre-
exposure on the humoral immune responses induced in Tanzanian adults after receiving active 
immunization with the PfSPZ Vaccine. Our primary objectives in Chapter 3 were i) to 
determine the ex vivo induction of Pf sporozoite invasion inhibitory activity upon PfSPZ 
vaccination and ii) to investigate if antibodies of the non-IgG isotype, such as sporozoite-
specific IgM antibodies are induced after vaccination and can potentially contribute to 
protection by preventing sporozoite invasion in vitro. In vitro inhibition of sporozoites 
invasion (ISI) assays were performed to assess the functional capacity of the vaccine-induced 
antibodies. PfSPZ-Vaccine-induced IgG and IgM antibodies were detected by enzyme-linked 
immunosorbent assasys (ELISA) using full length PfCSP. Plasma from a subset of volunteers 
was depleted from IgG and IgA antibodies in order to obtain IgM antibody fractions, which 
were tested in in vitro ISI assays to determine sporozoite-blocking activity and in 
immunofluorescence assays (IFA) to confirm binding against whole sporozoites. 
The isolation and characterization of monoclonal antibodies has proven to be a powerful tool 
in diagnostics, therapeutics [106] and the identification of target antigens and conserved 
epitopes that can be formulated as a vaccine (“analytic vaccinology”) [107]. As an example 
for malaria, monoclonal antibodies to CSP, AMA-1 and MSP-1 have been useful to explore 
the of process of sporozoite and merozoite invasion and for the identification of target 
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antigens of invasion inhibitory antibodies [108, 109]. Moreover, human monoclonal 
antibodies for MSP2, p27 and VAR2CSA, which is a PfEMP1 variant involved in placental 
malaria, have been isolated and functionally characterized [110–113]. The aim of the third 
part of this thesis (Chapter 4) was to isolate sporozoite-specific human monoclonal antibodies 
from Tanzanian adults, who have been experimentally infected with P. falciparum 
sporozoites. The PBMC samples for the isolation of memory B cells were obtained from the 
volunteers of the clinical trial described in Chapter 2, and memory B cells were immortalized 
with EBV and CpG in clonal conditions in 384-well plates. The culture supernatants of the B 
cell clones, containing the monoclonal antibodies, were screened for their capacity to bind to 
whole sporozoites using a high-throughput flow cytometer (IntelliCyte). Positive B cell clones 
were expanded and the produced antibodies were purified from the culture. cDNA was used 
to sequence the VH and VL genes and to produce recombinant antibodies in HEK293 cells 
transfected with appropriate human Ig vectors. Recombinant monoclonal antibodies were 
purified from the culture supernatants and produced in sufficient amounts to assess their 
biological function using in vitro and in vivo sporozoite blocking assays [32].
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2.1 Abstract 
Background: We are using controlled human malaria infection (CHMI) by direct venous 
inoculation (DVI) of cryopreserved, infectious Plasmodium falciparum (Pf) sporozoites (SPZ) 
(PfSPZ Challenge) to reduce time and costs of developing PfSPZ Vaccine to prevent malaria 
in Africa. PfSPZ Vaccine gave 65% vaccine efficacy (VE) at 24 weeks against mosquito bite 
CHMI in US adults and 52% (time-to-event) or 29% (proportional) VE over 24 weeks against 
naturally transmitted Pf in Mali. We assessed the identical regimen in Tanzanians for VE 
against PfSPZ Challenge. 
 
Methods: 20 to 30 year old men were randomized to DVI of 5 doses normal saline or 1.35 x 
105 or 2.7 x 105 (US/Mali dose) PfSPZ of PfSPZ Vaccine in a double blind clinical trial. VE 
was tested 3 and 24, or 24, weeks later. 
 
Findings: Adverse events were similar in vaccinees and controls. Antibody responses to Pf 
circumsporozoite protein were 4.3-fold lower than in US, but higher than in Malians. 1/18 
(6%) and 4/20 (20%) vaccinees were protected (1.35 x 105, 2.7 x 105 groups, respectively) at 
3 week CHMI. Four protected volunteers were protected again at 24 weeks, compared to 0/5 
undergoing first CHMI at 24 weeks. All 18 controls developed Pf parasitemia. 
 
Interpretation: PfSPZ Vaccine was safe, well tolerated, and induced durable immunity in 4 
subjects. CHMI by DVI of PfSPZ Challenge appeared more stringent over 24 weeks (VE 0-
20%) than mosquito bite CHMI (VE 65%) or natural exposure (VE 52%/29%), providing a 
rigorous test of VE in Africa. 
 
Funding: Swiss TPH, Ifakara Health Institute, Tanzanian Commission for Science and 
Technology, U.S., NIAID, NIH, Sanaria. 
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2.2 Introduction 
In 2015 >$2.5 billion were invested in malaria control. Yet, in 2015 there were an estimated 
438,000-730,000 deaths caused by malaria.1-3 Plasmodium falciparum (Pf) is the cause of > 
98% of malaria deaths and >80% of malaria cases in sub-Saharan Africa. Our goal is to field a 
vaccine that will prevent infection with Pf and thereby prevent all manifestations of Pf 
malaria and parasite transmission from humans to mosquitoes.4 When used in mass 
vaccination program campaigns such a vaccine could eliminate Pf from geographically 
defined areas. Pf sporozoites (SPZ) are the only immunogens that have ever prevented Pf 
infection in >90% of recipients. This was initially done by mosquito bite administration of 
radiation attenuated PfSPZ.5-7 Sanaria® PfSPZ Vaccine, radiation attenuated, aseptic, purified, 
cryopreserved PfSPZ, was then developed.8,9 When administered by rapid intravenous 
injection, PfSPZ Vaccine protected 100% (6/6) of subjects against controlled human malaria 
infection (CHMI) with Pf parasites similar to those in the vaccine (homologous) 3 weeks after 
last immunization.10 PfSPZ Vaccine protected against, 1) homologous CHMI for at least 59 
weeks,11 2) heterologous (parasites different than in vaccine) CHMI for 3 weeks12 and then 
for at least 33 weeks.13 PfSPZ Vaccine also prevented naturally transmitted heterogeneous Pf 
in adults in Mali for at least 24 weeks.14 We used the same dosage regimen as in the U.S. and 
Mali to evaluate the tolerability, safety, immunogenicity, and vaccine efficacy (VE) of PfSPZ 
Vaccine in young adult Tanzanians. Previously, we had conducted the first modern CHMI in 
Africa and showed that injection of aseptic, purified, cryopreserved PfSPZ, Sanaria® PfSPZ 
Challenge, consistently infected Tanzanian volunteers.15-20 In this study we took advantage of 
this capability to assess the VE of PfSPZ Vaccine by CHMI with PfSPZ Challenge. To our 
knowledge this was the first time CHMI has ever been used to assess a malaria vaccine in 
Africa. The results showed the same dosage regimen of PfSPZ Vaccine was less 
immunogenic and protective against CHMI in Tanzanians than in non-malaria exposed US 
Americans,12 and VE against homologous CHMI in Tanzania was lower (or similar) to VE 
against intense field exposure to heterogeneous Pf parasites in Mali.14 
Chapter 2 
23 
 
2.3 Materials and Methods 
2.3.1 Study design and population 
This double blind, randomized, controlled trial was conducted in Bagamoyo, Tanzania 
between April 2014 and August 2015. 67 healthy male volunteers 18 to 35 years of age were 
recruited from higher learning institutions in Dar es Salaam through sensitization meetings. 
After initial screening, prospective volunteers were invited to the Bagamoyo Clinical Trial 
Unit (BCTU) of the Ifakara Health Institute (IHI) to complete informed consent and 
screening. All had to complete a 20-question assessment of trial understanding with a 100% 
correct response rate on the first or second attempt (Table S1) to be eligible. Volunteers were 
screened using predetermined inclusion and exclusion criteria based on medical history, 
clinical examinations and laboratory tests (Tables S2, S3). History of malaria in the previous 
5 years was an exclusion criterion; antibodies to PfEXP1 by ELISA above a pre-specified 
level (see below) 5 were considered evidence of recent or substantial past malaria infection 
and an exclusion criterion. Hematology, biochemistry, and parasitology testing, including 
malaria thick blood smear (TBS), stool and urine by microscopy was done. Tests for HIV, 
hepatitis B and C were performed after counseling; volunteers were excluded if positive and 
referred for evaluation and management. Volunteers were excluded if they had significant 
abnormalities on electrocardiograms. 
The trial was performed in accordance with Good Clinical Practices. The protocol was 
approved by institutional review boards (IRBs) of the Ifakara Health Institute (Ref. No. 
IHI/IRB/ No:02-2014), the National Institute for Medical Research Tanzania (NIMR/ 
HQ/R.8a/Vol.IX/1691) and the Ethikkommission Basel (EKNZ), Basel, Switzerland 
(reference number 261/13). The protocol was approved by the Tanzania Food and Drug 
Authority (TFDA) (Ref. No. TFDA 13/CTR/0003), registered at Clinical Trials.gov 
(NCT02132299) and conducted under U.S. FDA IND 14826. 
 
2.3.2 Investigational products  
The investigational products (IPs) were Sanaria® PfSPZ Vaccine 8-14 and Sanaria® PfSPZ 
Challenge,15-20 both comprised of the NF54 strain of Pf. PfSPZ Vaccine consists of aseptic, 
purified, vialed, metabolically active, non-replicating (radiation attenuated) cryopreserved 
PfSPZ. It was stored, thawed, diluted and administered by direct venous inoculation (DVI) in 
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0·5 mL through a 25 gauge needle.12,14,18,20 PfSPZ Challenge is identical to PfSPZ Vaccine 
except it is not radiation attenuated. It was handled and administered like PfSPZ Vaccine. 
Preparation of IPs was supervised by the study pharmacist. After labeling the syringe, the 
pharmacist handed it to the nurse through a window. 
 
2.3.3 Allocation and randomization 
Volunteers were allocated to 5 groups (Table 1, Figure 1). Forty-nine received PfSPZ 
Vaccine, 8 were normal saline (NS) controls, and 10 were additional infectivity controls. The 
clinical team and volunteers were blinded to assignment to vaccine or NS until study end. 
 
Group 1. 3 volunteers received consecutive doses of 3 x 104, 1·35 x 105, and 2·7 x 105 PfSPZ 
of PfSPZ Vaccine at 4-week intervals to assess safety. 
 
Group 2. Volunteers were randomized to receive 1·35 x 105 PfSPZ of PfSPZ Vaccine (N=20) 
or NS (N=4) at 0, 4, 8, 12 and 20 weeks. 
 
Group 3. Volunteers were randomized to receive 2·7 x 105 PfSPZ of PfSPZ Vaccine (N=20) 
or NS (N=4) at 0, 4, 8, 12 and 20 weeks. 
 
Group 4. 6 volunteers were immunized with 2·7 x 105 PfSPZ of PfSPZ Vaccine on the same 
schedule as Group 3. 
 
Group 5. 10 volunteers served as unblinded infectivity controls during CHMIs (see below); 
two with CHMI #1, two with CHMI #2 and six with CHMI #3. 
 
2.3.4 Vaccine efficacy (VE) 
CHMI: VE was assessed by CHMI by DVI of 3·2 x 103 PfSPZ of PfSPZ Challenge. CHMI #1 
was 3 weeks after last immunization in Group 2. CHMI #2 was 3 weeks after last 
immunization in Group 3. CHMI #3 was 24 weeks after last immunization in Group 4 and 
included the 4 volunteers in Group 3 who did not develop parasitemia after CHMI #2. 
Volunteers were inpatients from day 9 after PfSPZ Challenge injection for observation until 
diagnosed and treated for malaria or until day 21; daily outpatient monitoring for TBS 
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negative volunteers continued until day 28. TBSs were obtained every 12 hours on days 9-14 
after CHMI and daily on days 15-21 until positive or until day 21. TBSs could be performed 
more frequently, if volunteers had symptoms/signs consistent with malaria. After initiation of 
treatment, TBSs were assessed until two consecutive daily TBSs were negative, and on day 
28. 
Diagnosis: Slide preparation and reading for TBSs were performed following a standard 
procedure.19 Sensitivity was 2 parasites/μL blood unless the volunteer was symptomatic, in 
which case twice as many fields were read. Parasitemia was also determined by quantitative 
polymerase chain reaction (qPCR) using two previously published qPCR assays. All samples 
were measured using a multiplex assay, detecting Plasmodium spp. 18S genes and the human 
RNaseP gene as endogenous control.21 Following first qPCR assays, negative samples were 
analyzed using the Pf specific telomere-associated repetitive element 2 (TARE-2).22 The 
WHO International Standard for Pf DNA Nucleic Acid Amplification Techniques (NIBSC, 
Hertfordshire, UK) was used as standard for calculation of parasite densities. DNA was 
extracted from 100μL whole blood and eluted with 50μL Elution Buffer using Quick-gDNA 
Blood MicroPrep Kit (Zymo Research, Irvine, USA). Blood samples collected during CHMI 
#1 were analyzed retrospectively after storing at –80 °C. During CHMI #2 and CHMI #3 
qPCR results were provided to physicians within 12 hours of blood collection. To exclude 
field strain infections, parasite genotyping was performed on 10% of samples randomly 
chosen as described.23 
 
2.3.5 Adverse events (AE)  
Volunteers were observed as inpatients for 48 hours after administration of IP and discharged 
home with diaries and thermometers for recording AEs and temperatures and followed with 
daily telephone calls. Symptoms and signs (solicited and unsolicited) were recorded and 
graded by physicians: mild (easily tolerated), moderate (interfere with normal activity), severe 
(prevents normal activity) or life threatening. Axillary temperature was grade 1 (> 37·5–38·0 
°C), grade 2 (> 38·0–39·0°C), grade 3 (39·1-40·0°C) or grade 4 (>40·0°C). Hematological 
and biochemical abnormalities were also assessed. 
 
During the first 7 days after injection of IP pre-specified local (site of injection) and systemic 
AEs were solicited. Open-ended questioning was used to identify unsolicited AEs through 
day 28 (Table S4). All AEs were assessed for severity and relatedness to IP administration. 
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For CHMIs, volunteers returned on day 9 for admission to the ward for assessment of safety 
and diagnosis and treatment of malaria. Events during the 8 to 28 day period were assessed 
for relationship to Pf infection, and considered related if the event was within 3 days prior to 
and 7 days after TBS was first positive. 
 
2.3.6 Antibody assays 
Sera were assessed for antibodies by enzyme-linked immunosorbent assay (ELISA), 
immunofluorescence assay (aIFA), and inhibition of sporozoite invasion (aISI) assay as 
described (see Table S5).24 ELISA for PfEXP1 was used to screen volunteers for possible 
malaria exposure (Table S6). Any subject with an OD 1·0 of >600 was excluded. 
 
2.3.7 T cell assays 
T cell responses in cryopreserved PBMCs were measured by flow cytometry in a single batch 
after the study as described.11 After stimulation, cells were stained as described.25 The staining 
panels are shown in Table S7 and the antibody clones and manufacturers are shown in Table 
S8. All antigen-specific frequencies are reported after background subtraction of identical 
gates from the same sample incubated with control antigen. Data were analyzed with FlowJo 
v9·9·3 (TreeStar) and graphed in Prism v7·0a (GraphPad). 
 
2.3.8 Statistical analysis 
Comparisons of categorical variables between groups were analyzed using 2-tailed Fisher’s 
exact test. Comparisons of continuous variables between groups were analyzed by 2-tailed 
non-parametric tests. For multiple group comparisons Kruskal-Wallis test was used. Time to 
event was assessed by Kaplan Meier curves and log rank test. Analysis of variance was 
utilized to analyze differences in trends between groups. Analyses of immunological data are 
described with the data. 
 
2.3.9 Role of the funding source 
The funders were involved in the study design, study management, data collection, data 
analysis, data interpretation and writing the report. SA and SLH had full access to all the data 
in the study and had final responsibility for the decision to submit for publication. 
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2.4 Results 
2.4.1 Study population and experience with DVI 
57 Tanzanian men (Table 1, Figure 1) met criteria (Table S2, S3), and received PfSPZ 
Vaccine (n=49) or NS (n=8). All volunteers had AA hemoglobin and normal G6PD activity. 
31 volunteers (46%) were heterozygous for D-thalassemia; 21 had evidence of latent 
tuberculosis infection by Quantiferon testing, but showed no evidence of active tuberculosis. 
One volunteer (group 2, NS) had a Strongyloides stercoralis on screening and was 
successfully treated prior to vaccination (Table 1). 
 
Of 237 immunizations with PfSPZ Vaccine, 234 were completed with a single injection 
(98·7%). 230 injections (97·0%) were considered painless by the volunteer. For NS subjects, 
39 of 40 immunizations (97·5%) were completed in a single injection and 39 of 40 (97·5%) 
considered painless by the volunteers. The nurse performing immunizations considered the 
procedure to be simple in 265 of 273 single injections (97·1%). 
 
One subject in Group 2 received four immunizations. The third immunization was withheld 
while the subject was evaluated for what was diagnosed as benign ethnic neutropenia. One 
subject in Group 4 missed his second immunization when he left town. All other subjects 
received 5 immunizations. 
 
2.4.2 Safety 
Among 49 volunteers who received 237 doses of PfSPZ Vaccine, there were 17 solicited AEs 
possibly related to IP (17/237=7·2%) in 10 of the 49 vaccinees (20·4%) (Table 2a). Among 8 
volunteers who received 40 doses of NS, there were two solicited AEs (2/40=5·0%) in one 
volunteer (12·5%) possibly related to IP (Table 2a). There were no local or serious AEs. 
Systemic AEs included headache (10), abdominal pain (3), chills (1), fever (2) and atypical 
chest pain (1). One episode each of headache and fever were grade 2; all other solicited AEs 
were grade 1. Seven episodes of headache were observed in Group 2 volunteers who received 
1·35 x 105 PfSPZ; 4/7 episodes occurred after the 3rd vaccine dose and did not recur with 4th 
or 5th doses. No factor was identified to account for this apparent clustering of headache. 
None of the comparisons of AEs between vaccinees and controls or between Group 2 (1·35 x 
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105 PfSPZ) with Groups 3 and 4 (2·7 x 105 PfSPZ) was significant (Table 2a). 26 of 49 
vaccinees (53·1%) experienced 43 unsolicited AEs (0·88/individual) in the 28 days following 
injections #1-#4, and the 21 days before CHMI after injection #5. Seven of 8 controls 
(87·5%) experienced 14 unsolicited AEs (2/individual) during this period. No vaccinee or 
control experienced an unsolicited, related AE within 28 days of an immunization. 
 
No significant laboratory abnormalities were attributed to PfSPZ (Table 2b). Three 
abnormalities during immunization were deemed clinically significant or grade 3. One was 
diagnosed as benign ethnic neutropenia. One was lymphopenia associated with an infected 
foot laceration, and one was eosinophilia associated with Fasciolopsis buski and S. stercoralis 
infection. Lymphopenia and eosinophilia resolved with treatment. Two Group 4 volunteers 
had asymptomatic hookworm infections diagnosed prior to CHMI; one was co-infected with 
Enterobius vermicularis. No volunteer had malaria during screening or during the trial other 
than from CHMI. A cyclic variation in total bilirubin following each immunization was 
observed in volunteers receiving vaccine or NS (see Figure S1). 
 
2.4.3 Tolerability, Safety and VE during CHMI 
46 vaccinees, 8 NS controls, and 10 infectivity controls underwent homologous CHMI. All 
subjects were negative by TBS and qPCR for Pf infection on day of CHMI. Two volunteers 
were excluded from primary analysis - a Group 2 volunteer who left the area two days after 
administration of PfSPZ Challenge and a Group 4 volunteer who left 9 days after. Both 
volunteers were located and treated pre-emptively. 
 
Tolerability and safety of administration of PfSPZ Challenge: CHMI was well tolerated with 
no local solicited AEs and 3 systemic solicited AEs (grade 1 headache in Group 3, grade 2 
headache in Group 4 and grade 1 arthralgia in an infectivity control) in the 7 days post 
administration of PfSPZ Challenge. 
 
Parasitemia: 
Controls: The 18 NS and infectivity controls developed Pf infection after CHMI (16 TBS and 
qPCR positive, 2 TBS negative and qPCR positive) (Figure 2a-d and Table S9). These 
included, four NS and 2 infectivity controls in CHMI #1 and CHMI #2, and six infectivity 
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controls in CHMI #3. All received the same lot of PfSPZ Challenge. Thus, results from all 18 
were pooled for assessment of statistical significance. 
 
Group 2 (1.35 x 105 PfSPZ): 17/18 volunteers who received five doses and 1/1 volunteer who 
received 4 doses developed parasitemia (Figure 2a), 15 positive by TBS and qPCR and 3 by 
qPCR only (CHMI #1). One volunteer (5·3%) was negative through day 28 by TBS and 
qPCR (p=1, Fisher’s exact test, 2-tailed as compared to 18 controls). 
 
Group 3 (2.7 x 105 PfSPZ):  
1st CHMI at 3 weeks (CHMI#2): 16/20 volunteers who received five doses developed 
parasitemia (Figure 2b), all positive by TBS and qPCR. Four volunteers (20%) were negative 
through day (p=0.11). 
2nd CHMI at 24 weeks (CHMI #3): The four protected volunteers from the first CHMI 
underwent a second CHMI 24 weeks after last vaccine dose (Figure 2c). Three were 
asymptomatic and negative by TBS and qPCR through day 28 day. The 4th volunteer, also 
asymptomatic, was reported to have a positive TBS on day 12 and treated. The sample with 
positive TBS was negative by retrospective qPCR. Re-evaluation of the TBS indicated an 
error in slide reading (false positive). P values for all 18/18 positive controls (CHMIs #1, #2, 
#3) vs. 0/3 or 0/4 vaccinees positive were 0·0008 (95% CI: 43·85%, 100%) and 0·0001 (95% 
CI: 51·01%, 100%), respectively. If only the six control volunteers at CHMI #3 are used, p 
values were 0·0119 (95% CI: 43·85%, 100%) and 0·0048 (95% CI: 51·01%, 100%), 
respectively. 
 
Group 4 (2·7 x 105 PfSPZ):  
1st CHMI at 24 weeks after last vaccine dose (CHMI #3): 4/5 vaccinees developed 
parasitemia by TBS and qPCR. The fifth was negative by TBS, but positive by qPCR. There 
was one excluded volunteer (see above) (Figure 2c). 
 
Volunteers heterozygous for D-thalassemia were no more likely to be TBS negative and 
qPCR positive than volunteers without D-thalassemia (3 of 27 vs. 3 of 34, p=1·0). Protection 
from CHMI did not correlate with D-thalassemia status; 3/37 with normal hemoglobin and 
2/29 heterozygous for D-thalassemia protected. 
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Prepatent periods and parasite densities: The median pre-patent period in the 16 TBS 
positive NS and infectivity controls was 12·2 days. In the vaccinees in Groups 2-4 
respectively they were 14·0, 14·0, and 15·3 days (p=0·1066) (Table S9). The parasite 
densities by qPCR and TBS at time of diagnosis for each individual are in Table S10. The 
median parasite density in controls vs. vaccinees at time of first positivity were 0·5 vs. 0·4 
parasites/PL for qPCR (p=0·5714) and 11·2 vs 15·0 parasites/PL for TBS (p=0·1492). All 
parasites tested were PfNF54. 
 
Tolerability and Safety of Parasitemia During CHMI: 
Controls: 16 controls developed parasitemia by TBS; 9 (56%) never had symptoms (Table 
S11). Headache occurred in 7/7 symptomatic individuals. One of two control volunteers only 
positive by qPCR did not have any symptoms; the second had headache 8 days after qPCR 
spontaneously reverted to negative. No volunteer had symptoms at time of first positive 
qPCR. 
 
Vaccinees: 35 immunized volunteers developed parasitemia by TBS; 20 (57%) never had 
symptoms. Three volunteers had temperature > 39·0ºC; all other clinical manifestations were 
grade 1 or 2. Fever (28·6%) and headache (31·4%) were most common. Compared with 
controls, elevated temperature was more common in vaccinees with positive TBSs (9/35 vs. 
0/16, p=0·043). There was no significant difference in frequency of headache between 
controls and vaccinees. In the 3 volunteers in Group 2 who were qPCR positive and TBS 
negative, one developed headache 3 days after qPCR positivity. No volunteer had symptoms 
at time of first positive qPCR. 
 
Clinical labs: No unexpected changes in clinical values were observed following CHMI. 
Declines in lymphocyte counts were observed in TBS positive controls and vaccinees (mean 
decline 1110 ± 720 cells/μl and 1180 ± 680 cells/μl, respectively) on day of first positive 
TBS. Absolute lymphocyte counts less than 1000 cells/μl were observed in 8/16 and 16/35 
TBS positive controls and vaccinees. All lymphocyte counts returned to baseline by day 28. 
There were mild decreases in platelet counts in TBS positive subjects, but all platelet counts 
were > 100 x 103 cells/μl. 
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Treatment: Volunteers with positive TBS were treated with either atovaquone/proguanil 
(n=43) or artemether/lumefantrine (n=8) within 24 hours of first positive TBS. NS and 
infectivity controls who were TBS negative (n=2) were treated at day 28. 
 
2.4.4 Immunogenicity 
 
Antibody Responses: 
PfCSP and PfSPZ: Antibodies against PfCSP by ELISA (a), PfSPZ by aIFA (b), and PfSPZ 
by ISI (c) in sera taken 2 weeks after last vaccine dose and just prior to CHMI (20-23 days 
after last dose) for Groups 2 (CHMI #1) and 3 (CHMI #2) are in Figure 3a-c. The median 
response and those uninfected and infected by qPCR are shown. 
 
For all three assays median antibody responses prior to first CHMI were higher in uninfected 
than in infected vaccinees. There was a significant difference in median net aIFA responses 
between infected and uninfected volunteers in Group 3 prior to CHMI #1 (p = 0·0499, 
Wilcoxon Rank Sum Test). For Group 3 the p value for PfCSP ELISA results in uninfected 
(N=4) and infected (N=16) volunteers was 0·2902 and for ISI was 0·2485. 
 
In sera collected prior to CHMI #3 (170-171 days after last vaccine dose), antibodies by the 3 
assays for Group 4 and for the 4 volunteers in Group 3 uninfected in CHMI #1 who 
underwent CHMI#2 are in Figure 3d-f. All data appear in Table S12. 
 
After the 5th dose, in the PfCSP ELISA, volunteers were considered to have seroconverted if 
their net OD 1·0 and OD 1·0 ratio, calculated, respectively, by subtracting or dividing by the 
pre-vaccination antibody OD 1·0, were ≥ 50 and ≥ 3·0. By these criteria, 15/18 volunteers 
(83%) in Group 2, 20/20 (100%) in Group 3, and 5/5 (100%) in Group 4 seroconverted, 
median net OD 1·0 of positives of 1189, 2685, and 961, and median OD 1·0 ratio of positives 
of 11·50, 21·15, and 37·83, respectively (Table S13). In the aIFA, volunteers with a net AFU 
2 x 105 of ≥150 and a ratio of post to pre AFU 2 x 105 of ≥ 3·0 were considered positive 
(Table S13). By these criteria, 17/18 volunteers (94%) in Group 2, 18/20 (90%) in Group 3, 
and 5/5 (100%) in Group 4 seroconverted, median net OD 1·0 of positives of 2844, 1165, and 
1820, and median OD 1·0 ratio of positives of 1193·00, 552·88, and 224·86, respectively 
(Table S13). For the ISI, volunteers with a net ISI activity of ≥10% and ratio of post to pre ISI 
activity of ≥ 3·0 were considered positive. By these criteria, 3/18 volunteers (17%) in Group 
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2, 8/20 (40%) in Group 3, and 3/5 (60%) in Group 4 were positive, median net OD 1·0 of 
positives of 22·05, 38·92, and 12·44, and median OD 1·0 ratio of positives of 19·79, 12·53, 
and 13·44, respectively (Table S13). 
 
Other Antigens: Two weeks after 5th dose in Groups 2 (1·35 x 105 PfSPZ) and Groups 3 and 4 
(2·7 x 105 PfSPZ), there were antibodies to: 1) PfCSP in 15/18 and 25/25 subjects; 2) 
PfCelTOS in 1/18 and 1/25; 2) PfMSP5 in 2/18 and 3/25; 4) PfAMA1 in 2/18 and 10/25; 5) 
PfEXP1 in 0/18 and 0/25; 6) PfLSA1 in 0/18 and 1/25; 7) PfMSP1 in 1/18 and 4/25; and 8) 
PfEBA175 in 1/18 and 1/25, respectively (Table S14). The presence of antibodies against 
proteins first expressed in late liver stages (PfMSP1 and PfEBA175) was unexpected; results 
were confirmed. No antibody responses were associated with protection. 
 
T cell responses: T cells against liver-stage malaria parasites in mice and non-human primates 
immunized with radiation-attenuated sporozoites mediate protection,9,26-28 and likely in 
humans.11 T cell responses were measured prior to immunization, two weeks after first and 
two weeks after final immunization in Group 2 (1·35 x 105 PfSPZ). For technical reasons the 
other groups could not be studied. CD8 and CD4 T cell responses generally peak after first 
vaccination with PfSPZ Vaccine.13 
 
After the first vaccination, the percent of PfRBC-specific and PfSPZ-specific cytokine 
producing memory CD4 T cell responses increased by 0·25 ± 0·06 (mean ± s.e.m.) and 0·24 ± 
0·04 respectively (Figure 4a,b). After final vaccination, at week 22, the CD4 T cell responses 
were above pre-vaccine responses by 0·17 ± 0·05 and 0·18 ± 0·05 percentage points, 
respectively. These responses were significantly lower than after the same immunization 
regimen in malaria- nnaïve U.S. adults.10 
 
PfRBC-specific CD8 T cells were not significantly above pre-vaccine levels, and PfSPZ-
specific CD8 T cells were slightly above background (Figure 4c,d). These responses were 
lower than in U.S. adults. 
 
In contrast to other PfSPZ Vaccine trials,10,11,13,14 there was negligible change in frequency of 
circulating γδ T cells (Figure 4e), or activation as measured by change in expression of the 
activation markers HLA-DR and CD38 following immunization (Figure 4f). To identify 
potential explanations for lower cellular immune responses in Tanzanians, we examined 
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frequency of T regulatory cells (Treg) (CD4+Foxp3+CD25+CD127–) expressing the activation 
marker CD137 (also known as 4-1BB) 29 after stimulation with PfRBC. There was no 
difference in pre-vaccine frequency of PfRBC-specific Tregs in the Tanzanians as compared 
to Americans10 (Figure 4g). Consistent with CD4 and CD8 T cell responses, PfRBC-specific 
Tregs were highest after first immunization in Tanzanians (Figure 4h). Last, the pre-vaccine 
frequency of total memory T cells relative to total naïve T cells was significantly higher in 
Tanzanians compared to Americans (Figure 4i). 
2.5 Discussion 
To our knowledge this is the first assessment of the VE of a malaria vaccine in Africa by 
CHMI; the first CHMI in Africa with Sanaria® PfSPZ Challenge was conducted by the 
Tanzanian/SwissTPH team.19 PfSPZ Vaccine was well tolerated and safe, but less 
immunogenic and protective in Tanzanian men than in U.S. volunteers. 4/20 (20%) recipients 
of 5 doses of 2·7 x 105 PfSPZ were protected against homologous CHMI by DVI 3 weeks 
after last immunization. In contrast, 12/13 (92·3%) volunteers in the U.S. who received 5 
doses of 2·7 x 105 PfSPZ were protected against homologous CHMI by mosquito bite 3 
weeks after last vaccine dose.12 When the four protected Tanzanian volunteers underwent 
repeat homologous CHMI at 24 weeks after last dose, all four (100%) were protected. In the 
U.S. 7/10 previously protected volunteers were protected when they underwent homologous 
CHMI at 24 weeks12 and all 5 volunteers in the U.S. who were protected at 21 weeks after last 
immunization (4 doses of 2·7 x 105 PfSPZ) were protected against repeat mosquito 
administered CHMI at 59 weeks.11 However, none of the volunteers in this Tanzanian study 
who only underwent CHMI at 24 weeks were protected.  
The same regimen (5 doses of 2·7 x 105 PfSPZ) was assessed for VE against intense field 
transmission of heterogeneous Pf in Mali. VE against infection with Pf on TBS was 52·1% by 
time to event and 28·5% by proportional analysis during 24 weeks after last vaccine dose.14 
This was higher than the 20% VE against homologous CHMI in Tanzania. This suggests that 
CHMI by DVI of PfSPZ Challenge may provide a potentially more rigorous test of VE than 
field transmission. 
Vaccine-induced antibody responses and T cell responses in the Tanzanians were 
significantly lower than in malaria naïve Americans. Two weeks after last dose, the median 
antibody responses to PfCSP, the major protein on the surface of PfSPZ, were 4.3 times lower 
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in the Tanzanians than in Americans,12 but higher than in Malians who received the same 
immunization regimen14 (Figure 3g). The T cell responses were also lower than in 
Americans.10,11 (Figure 4). The Tanzanians had a significantly higher proportion of total 
memory T cells compared to total naïve T cells at baseline than did the Americans. This 
higher frequency of memory cells compared to naïve cells may explain the lower 
immunogenicity due to less available naïve cells for expansion during the vaccinations. 
Moreover, the greater frequency of non-Pf-specific memory T cells may compete for infected 
cell contacts during pathogen surveillance.30 These data suggest that PfSPZ Vaccine 
immunogenicity may be dependent on cumulative history of Pf exposure. Another 
explanation is that an activated immune microenvironment in the Tanzanians as compared to 
the Americans reduced immune responses.31 Helminth infections have been associated with 
reduced immune responses to malaria,32 the paucity of helminth infections in this population 
does not support helminth infection as a cause of the reduced immune responses.  
There were no differences between vaccine and NS placebo recipients in regard to vaccine 
tolerability or AEs. 97.1% of the DVI administrations were rated painless and no volunteer 
experienced any local AE. Systemic AEs, most commonly headache, were mild, infrequent 
and of short duration, with a similar frequency in NS controls as in vaccinees.  
Among the controls, 16 of 18 were positive for Pf by TBS after CHMI. However, all 18 were 
positive by qPCR. This is consistent with findings in Gabon after CHMI (B. Lell, submitted). 
It is likely that pre-existing asexual blood stage immunity limits Pf replication in some 
individuals. Thus, they never reach the threshold for detection by TBS. In our CHMI studies 
in Bagamoyo we now use qPCR to confirm positive TBS, and retrospectively or in real time 
assess parasitemia in all volunteers by qPCR. 
We propose that increasing the numbers of PfSPZ per dose and altering intervals between 
doses will lead to overcoming the down regulation of humoral and cell-mediated immunity 
most likely due to previous exposure to Pf and thereby increase immune responses to PfSPZ 
Vaccine and VE. Based on work in the U.S., we are also reducing to three doses of PfSPZ 
Vaccine and conducting CHMI with heterologous as well as homologous Pf strains.12,13 
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2.6 Figure legends 
Figure 1: Volunteer participation (CONSORT 2010 diagram). 
 
Figure 2: Kaplan-Meier survival curves in immunized volunteers vs. controls as assessed 
by qPCR. Kaplan-Meier curves in volunteers undergoing CHMI 3 weeks after the last of 5 
doses with 1.35 x 105 (Group 2) (a) or 2.7 x 105 (Group 3) (b) PfSPZ of PfSPZ Vaccine. Panel 
(c) volunteers undergoing either first (Group 4) or second (Group 3) CHMI 24 weeks after the 
5th immunization with 2.7 x 105 PfSPZ of PfSPZ Vaccine. (d) Protective efficacy and pre-
patent period results. 
 
Figure 3: Antibody responses to PfSPZ and PfCSP prior to CHMI. For all assays, 
uninfected subjects are shown as filled (black) circles and infected subjects are open circles. 
For each of the defined subject groups, the interquartile ranges and the median values of 
response of subjects in each group are shown. Assessment of antibodies was performed in 
sera from subjects before immunization and prior to CHMI #1 (~2 weeks after last dose of 
PfSPZ Vaccine or NS) and/or CHMI #2 (~24 weeks after last dose of PfSPZ or NS) (a, d). 
Antibodies to PfCSP by ELISA are reported as net OD 1.0 (the difference in OD 1.0 between 
pre-CHMI and pre-immunization sera). (b, e) Antibodies to PfSPZ by aIFA are reported as 
net AFU 2 x 105, the reciprocal serum dilution at which the fluorescent units were 2 x 105 
(AFU 2 x 105) in pre-CHMI minus pre-immunization sera. (c, f) Results of inhibition of 
sporozoite invasion (ISI) assay are reported as serum dilution at which there was 80% 
reduction of the number of PfSPZ that invaded a human hepatocyte line (HC-04) in the 
presence of pre-CHMI as compared to pre-immunization sera from the same subject. Panels 
a-c show Groups 2 (5 doses of 1.35 x 105 PfSPZ) and 3 (5 doses of 2.7 x 105 PfSPZ) prior to 
short-term CHMI (2 weeks after last dose of PfSPZ or NS); panels d-f show those volunteers 
in Groups 3 (5 doses of 2.7 x 105 PfSPZ) and 4 (5 doses of 2.7 x 105 PfSPZ) who underwent 
long-term CHMI (24 weeks after last dose of PfSPZ). Panel g shows net OD 1.0 anti-PfCSP 
antibodies by ELISA comparing vaccinated Tanzanian volunteers to volunteers in other trials 
receiving the same regimen. After 5 doses of 2.7 x 105 PfSPZ/dose, volunteers in BSPZV1 (N 
= 25) had a 4.3-fold lower median net OD 1.0 than those in the U.S.-based clinical trial 
WRAIR 2080 (N = 26) but a 6.6-fold higher median OD 1.0 than volunteers in 14-I-N010 in 
Bamako, Mali (N = 42), where malaria transmission rates are higher. 
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Figure 4: PfSPZ-specific T cell responses in vaccine recipients receiving 1.35 × 105 
PfSPZ. (a–d) PfSPZ-specific T cell responses. Frequency of cytokine-producing memory 
CD4 T cells responding to (a) PfRBC or (b) PfSPZ. Frequency of cytokine producing 
memory CD8 T cells responding to (c) PfRBC or (d) PfSPZ. Results are the percentage of 
memory T cells producing IFN-γ, IL-2, and/or TNF-α following stimulation minus the 
percentage of cells following control stimulation. (e) Frequency of the Vδ2+ sub-family of γδ 
T cells out of total lymphocytes. Results are expressed as fold-change from the pre-vaccine 
frequency. (f) γδ T cell activation in vivo. Data are the percentage of memory γδ T cells 
expressing HLA-DR and CD38 as measured on PBMCs following incubation with control 
stimulation (vaccine diluent). (g) Pre-vaccine frequency of PfRBC-specific Tregs in Tanzania 
compared to malaria-naive U.S. subjects from the VRC 314 study. (h) Frequency of PfRBC-
specific Treg. Results are the percentage of CD4+Foxp3+CD25+CD127– T cells expressing 
CD137 (also known as 4-1BB) after stimulation with PfRBC minus the percentage of cells 
following stimulation with uninfected RBC. (i). Percentage of total CD4 (left) or CD8 (right) 
T cells that are naïve (gray bar; CCR7+CD45RA+) or memory (blue bar; not 
CCR7+CD45RA+) phenotype assessed pre-vaccination in all 48 subjects vaccinated in 
Tanzania or in 14 healthy U.S. subjects from the VRC 314 study13. For a–f and h, n = 24, and 
statistical difference was by Wilcoxon matched-pairs signed rank test. For g and i, statistical 
difference was by Mann-Whitney U test. P-values are reported as not significant (ns), <0.05 
(*), <0.01 (**) or <0.001 (***). Data are mean ± SEM. Time points are pre-vaccine, two 
weeks after the first vaccination, and two weeks after the final vaccination. Black arrowhead 
designates PfSPZ Vaccine administration. 
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2.7 Figures and Tables 
 
 
  
Table 1 Demographic characteristics of volunteers. 
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Table 2 a) Solicited adverse events (AEs) by group considered possibly related to administration of the 
investigational product during the first 7 days post immunization. b) Summary of abnormal laboratory values and 
severity grades. 
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3.1 Abstract 
Background 
To date, the assessment of vaccine-induced humoral immune responses upon whole 
sporozoite vaccination focuses largely on antibodies of the IgG isotype. Here, we aimed to 
investigate if sporozoite binding and invasion inhibitory IgM antibodies are induced 
following immunization with aseptic, purified, irradiated, non-replicating, metabolically 
active Plasmodium falciparum sporozoites (PfSPZ Vaccine) in malaria pre-exposed 
volunteers. 
Methods 
Serum and plasma samples were collected from malaria pre-exposed volunteers immunized 
by direct venous inoculation (DVI) of PfSPZ Vaccine. Functionality of serum antibodies was 
assessed by in vitro inhibition of sporozoite invasion (ISI) assay. Vaccine-induced IgG and 
IgM antibodies were determined by enzyme-linked immunosorbent assay (ELISA) against 
full length circumsporozoite protein (CSP). Plasma from a subset of volunteers was depleted 
from IgG and IgA antibodies to obtain antibody fractions containing only IgM antibodies and 
tested in an in vitro ISI assay to determine sporozoite-blocking activity. 
Results 
Malaria pre-exposed volunteers developed sporozoite-invasion inhibitory antibodies and anti-
CSP IgG and IgM antibodies upon DVI-administered PfSPZ vaccination. IgM plasma 
fractions of three volunteers mediated ISI in vitro. 
Conclusions 
We demonstrate for the first time that sporozoite binding IgM antibodies are induced 
following repeated PfSPZ vaccination in malaria pre-exposed individuals and that these IgM 
antibodies can inhibit sporozoite invasion in vitro. These findings suggest that the 
immunological assessment of PfSPZ Vaccine-induced humoral immune responses should 
include monitoring of parasite specific IgG and IgM antibodies. 
Keywords 
Malaria, PfSPZ Vaccine, malaria pre-exposed individuals, functional antibodies, IgM, 
vaccine-induced humoral immunity, ISI, IFA 
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3.2 Background 
Despite the global reduction in malaria incidence and mortality rates between the years 2000 
and 2015, malaria remains a major public health concern. In 2016, the World Health 
Organization (WHO) estimated 212 million new malaria cases globally, of which 429,000 
died from the disease, mostly due to Plasmodium falciparum (Pf) [1]. Most of these deaths 
(92%) occurred in the WHO African region with 70% of all deaths reported in children under 
5 years of age [1]. The most advanced malaria vaccine candidate, the CSP-based subunit 
vaccine RTS,S/AS01 (Mosquirix™), showed limited vaccine efficacy of 36.3% against 
clinical malaria among children aged 5 to 17 months and of 25.9% in young infants 6 to 12 
weeks of age in phase 3 clinical trials in several sub-Saharan countries [1, 2]. RTS, S/AS01 
mediated protection is short-lived and wanes after the first year of vaccination [2]. This is 
below the goal of 75% efficacy against clinical malaria set by the WHO Malaria Vaccine 
Technology Roadmap [1, 3].  
Sterile protection against CHMI has been achieved via mosquito bite administration of 
radiation-attenuated Pf sporozoites (RAS) [4] and by DVI of aseptic, purified, radiation-
attenuated, cryopreserved Pf sprozoites (PfSPZ Vaccine) [5]. Administration of fully 
infectious Pf sporozoites either via mosquito bite or DVI to volunteers taking simultaneously 
the anti-malarial drug Chloroquine (CVac) has been tested recently with promising results [6–
8]. Pf attenuation by genetic modification is under investigation, with no CHMI protection 
data yet reported [9]. So far, most of these experimental malaria vaccinations followed by 
CHMI have been performed in volunteers living in non-malaria endemic countries [4–8]. The 
slow and incremental acquisition of anti-malarial immunity during natural exposure [10, 11] 
and growing experimental evidence in mouse models suggest that prior exposure of malaria 
might hamper malaria vaccine-induced protection [12]. Better understanding of type, kinetics 
and maintenance of malaria-specific immune responses in malaria pre-exposed populations is 
an indispensable step for successful deployment of the PfSPZ Vaccine [13]. 
Serum samples used in this study were collected during a phase 1 clinical trial investigating 
the safety, immunogenicity and protective efficacy of DVI administered PfSPZ Vaccine in 
Tanzanian adults in Bagamoyo, Tanzania (NCT02132299) (Jongo et al., manuscript 
submitted). Briefly, two groups of volunteers (n=20) were vaccinated five times each with a 
dosage of 1.35 x 105 (low-dose) or 2.7 x 105 (high-dose) PfSPZ Vaccine. The first 
homologous CHMI (CHMI1) using fully infectious NF54 Pf sporozoites was conducted 21 
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days after last vaccination and was followed by a second homologous CHMI (CHMI2) 140 
days later in the subset of volunteers protected after CHMI1 (Jongo et al., manuscript 
submitted). Here, we aimed i) to determine the ex vivo induction of Pf sporozoite invasion 
inhibitory activity upon PfSPZ vaccination and ii) to investigate if sporozoite-specific IgM 
antibodies are induced after vaccination and can potentially contribute to protection by 
preventing sporozoite invasion of hepatocytes in vitro. The magnitude and longevity of these 
vaccine-induced responses were followed for 168 days after last vaccination in a subset of 
sterile protected volunteers. 
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3.3 Methods 
3.3.1 Ethics statement 
All volunteers gave written informed consent before screening. The clinical trial was 
performed in accordance with Good Clinical Practices. The protocol was approved by the 
institutional review boards (IRBs) of the Ifakara Health Institute (Ref. No. IHI/IRB/ No: 02-
2014), the National Institute for Medical Research Tanzania (NIMR/ HQ/R.8a/Vol.IX/1691) 
and the Ethikkommission Basel (EKNZ), Basel, Switzerland (reference number 261/13). The 
protocol was approved by the Tanzania Food and Drug Authority (TFDA) (Ref. No. TFDA 
13/CTR/0003) and the trial was registered at Clinical Trials.gov (NCT02132299) and 
conducted under U.S. FDA IND 14826. 
 
3.3.2 Clinical trial design and study population 
Details of the trial procedure and volunteers enrolled are given elsewhere (Jongo et al., 
manuscript submitted). In summary, healthy male volunteers aged 20 to 30 years were 
randomized to DVI of 5 doses of normal saline or 1.35 x 105 or 2.7 x 105 of PfSPZ Vaccine in 
a double blind clinical trial at the Bagamoyo Clinical Trial Unit (BCTU) of the Ifakara Health 
Intsitute (IHI) in Bagamoyo, Tanzania between 2014 and 2015. Vaccine efficacy was 
assessed by CHMI by DVI of 3,200 PfSPZ of PfSPZ Challenge at 3 and 24 weeks, or 24 
weeks after the last PfSPZ immunization. The PfSPZ Vaccine proved to be safe and well 
tolerated in all Tanzanian volunteers. In the low-dose group, 1 of 18 (6%) volunteer was 
protected against CHMI at 3 weeks and 4 of 20 (20%) volunteers were protected at 3 and 24 
weeks in the high-dose group. 
 
3.3.3 Sample collection 
Serum samples were collected at screening one week prior to the first immunization 
(baseline), on the day of each vaccination, followed at weeks 2, 4 and 8 after each 
immunization. In addition, serum was sampled one week before, and at weeks 2, 4 and 8 after 
each CHMI. Whole blood was collected in vacutainer tubes with clot activators (Becton 
Dickinson, 369032), allowed to stand at RT until a clot was formed and subsequently 
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centrifuged at 2000 g for 10 minutes at 22°C. Afterwards, the serum was collected, aliquoted 
and stored at -80°C for later antibody immunogenicity assessments.  
Plasma was obtained during isolation of peripheral blood mononuclear cells (PBMC) from 
whole blood using Ficoll density gradient centrifugation and stored at -80°C. 
 
3.3.4 Inhibition of sporozoite invasion assay (ISI) 
To determine the capacity of serum antibodies to inhibit sporozoite invasion in vitro, a 
previously described flow cytometry-based assay was performed [9, 14]. Briefly, 
immortalized HC04 human hepatocyte cells (MRA-975, MR4) were cultured in D10 Media 
(DMEM, Gibco) supplemented with 10% FBS, 2.5mM glutamine, 1% penicillin/streptomycin 
and fungizone (Life Technologies) at 37°C in 5% CO2. HC04 cells were split at 90% 
confluence and plated at 105 cells/well in a 96 well plate for the assay. Freshly dissected 
salivary gland NF54 P. falciparum sporozoites [15] were incubated with sera from volunteers 
at a 1:20 dilution of complete culture media for 15 minutes at 37°C. Sporozoites were then 
added to HC04 cells in triplicate in 96 well plates in a total volume of 100µL/well. To 
facilitate sporozoite contact with hepatoma cells, the plate was centrifuged at 400 x g for 3 
minutes and afterwards incubated at 37°C for 90 minutes. After incubation, cells were fixed 
and permeabilized (BD Cytofix/Cytoperm, BD Bioscience) and subsequently stained with an 
Alexa fluor-647-conjugated anti-CSP monoclonal antibody (clone 2A10). Invasion was 
analyzed by flow cytometry by first identifying live HC04 cells by forward and side scatter 
and then monitoring for CSP+ cells. Percent of inhibition of invasion for each volunteer was 
determined by normalizing to the CSP cells in triplicate wells containing volunteer matched 
pre-immune serum or a pooled serum sample from malaria-naïve individuals. Samples were 
excluded if invasion of cells in untreated wells was < 0.5%. The reported data indicates the 
average of at least two independent experiments. 
 
3.3.5 CSP enzyme-linked immunosorbent assay (ELISA) 
IgG and IgM antibodies were measured against full length Pf CSP protein. Pf CSP was 
produced in HEK293F cells as previously described [9]. High-binding 96-well plates 
(Corning) were coated with 0.1 µg Pf CSP/mL in sodium-carbonate/calcium-bicarbonate 
coating buffer and incubated overnight at 4°C, washed 4 times with 0.05 Tween-20 in PBS 
(Sigma, Life Technologies), and blocked for 2 hours 15 minutes at RT in dilution/blocking 
buffer (PBS containing 0.05% Tween-20 and 6% BSA). After washing 4 times, serum 
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samples were added in dilution/blocking buffer at a dilution of 1/800 for the IgG-CSP ELISA, 
and at 1/80 for the IgM-CSP ELISA, and incubated for 2 hours at RT. Samples were tested in 
duplicate. Each independent plate included a standard positive sample, which was used to 
create an 8-point 2-fold serial dilution series and additional negative controls at dilutions of 
1/400 for the IgG-CSP ELISA and 1/80 for the IgM-CSP ELISA. For analysis of IgM 
antibodies, serial dilutions of fractions were applied as indicated in Figure 4A and ELISA 
development was performed per manufacturer’s protocol (Bethyl Laboratories). After 
washing, the secondary antibody was applied. For detection of antibodies, a subclass-specific 
HRP-conjugated anti-human secondary antibody (Life Technologies) was applied at 1/5000 
(IgG, IgA) or 1/2000 (IgM). Secondary antibodies were incubated for 2 hours and 15 minutes 
at RT. After incubation, plates were washed 4 times, developed in SigmaFast OPD (Sigma) 
for 4 minutes for the IgG-CSP ELISA and for 16 minutes for the IgM-CSP ELISA, and 
immediately read for absorbance at 450 nm using a Spectramax M2 Molecular Devices 
Microplate reader. Arbitrary units (AU) were calculated by interpolating values based on the 
standard curve using nonlinear regression with Prism 6 software and multiplied by the 
dilution factor. Samples were defined as CSP binding when titers were above a pre-defined 
cutoff for positivity calculated by the mean of the negative control (pooled serum sample 
from malaria naïve people) plus 3 standard deviations to the mean. Sample data outside the 
standard curve range or with coefficient variation (CV) >30% between duplicates values were 
excluded for analysis. All ELISA values were repeated and are referred to as the mean of two 
independent runs. Not all volunteers were tested at all the time points due to sample 
availability.  
 
3.3.6 Generation of IgM antibody fractions 
In order to generate antibody fractions containing only IgM antibodies, plasma from a subset 
of volunteers was first depleted of IgG antibodies by use of protein G columns (GraviTrap 
Protein G columns, GE Healthcare Life Sciences). This was performed by diluting plasma 
from immunized volunteers and a pool of pre-immune sera from volunteers 1:2 in binding 
buffer (GE Healthcare Life Sciences) and applied to protein G column per manufacturer’s 
instructions. Flow-through was collected and columns were washed and eluted using elution 
buffer (GE Healthcare Life Sciences) per protocol. After column regeneration, this process 
was repeated for a total of 6 times. IgG recovery in eluate and depletion in flow-through was 
confirmed via human IgG ELISA (Bethyl Laboratories). IgG flow-through was then buffer-
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exchanged into PBS using PD-10 desalting columns and recovery of both IgM and IgA was 
confirmed via ELISA (Bethyl Laboratories). IgA was then removed from this fraction by 
application of a calculated 1mg of total IgA to 1mL of PBS-equilibrated Jacalin-sepharose 
(BioVision, Inc.) and all volumes brought to 12mL in PBS. Samples were incubated with 
Jacalin-sepharose for 2h at RT with rotation. IgA-depleted fraction (“IgM fraction”) was 
collected by centrifugation at 150 x g for 2 minutes and collection of supernatant. IgA was 
then eluted using 0.1M melibiose. Depletion of IgA in the IgM fraction and recovery in the 
eluate was then confirmed by IgA and IgM ELISA. All fractions were then concentrated 
using 10kD protein concentration filters (Amicon Ultra-15, EMD Millipore) and returned to 
original input volumes to maintain equivalent dilutions for ISTI analysis. Purity was assessed 
using total human IgM and IgA ELISAs (Bethyl Laboratories) according to manufacturer’s 
protocol.  
 
3.3.7 Sporozoite immunofluoresence assays (IFA) 
Sporozoite IFAs were performed as previously described [9]. Briefly, freshly-dissected Pf 
sporozoites were fixed in 10% PFA for 10 minutes at RT, washed and air-dried onto 12-well 
glass microscope slides. Sporozoites were permeabilized and blocked in 3% BSA in PBS with 
0.1% Triton-X100. IgM antibody fractions were applied at a 1:100 dilution in 3% BSA in 
PBS and incubated at RT for 1h. Anti-human IgM conjugated to AlexaFluor-594 (Southern 
Biotech) was then applied at a 1:6000 dilution and incubated in the dark at RT for 1h. 
Sporozoites were then stained with AlexaFluor-488-conjugated anti-CSP mAb 2A10 at 
2µg/mL in 3% BSA in PBS for 1h at RT followed by DAPI nuclear staining. Sporozoites 
were visualized using Deltavision microscopy. Images were captured using the same exact 
exposure conditions in the hIgM/Alexafluor-594 channel to allow comparisons of intensity 
across samples. Images were modified for clarity with the same exact parameters applied to 
each sample. 
 
3.3.8 Statistical analysis 
Statistical analyses were carried out using R (R Development Core Team (2011), R: A 
Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for 
Statistical Computing. Available online at http://www.R-project.org/.). The R package 
ggplot2 was used for data visualization (H. Wickham.ggplot2: Elegant Graphics for Data 
Analysis. Springer Verlag New York, 2009). 
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3.4 Results 
3.4.1 Immunization with PfSPZ Vaccine induces sporozoite inhibitory antibodies 
An overview of the vaccination schedule followed by two consecutive homologous CHMIs is 
given in Supplementary Figure 1.  
To explore the inhibitory capacity of PfSPZ Vaccine-induced antibodies, we used a 
previously described flow cytometry-based inhibition assay of Pf sporozoite invasion of 
HC04 cells (ISI) [9, 14]. For the low-dose (Figure 1A), serum samples collected at 14 days 
after 3rd and 5th immunization and 28 days past CHMI1 were assessed and likewise for the 
high-dose group (Figure 1B) except for two additional time-points at 140 days past CHMI1 
and 28 days post-CHMI2 included for immunized protected subjects. 
Vaccine-induced changes in serum reactivity were determined by normalizing each time point 
to the inhibitory activity of serum taken at baseline. After 3rd immunization, immunized 
volunteers in the low-dose group showed an average inhibition of 53.75 ± 10.81 % (Figure 
1A) while immunized volunteers from the high-dose group were inhibited by an average of 
52.73 ± 5.14 % (Figure 1B). Two volunteers from the low-dose group and one from the high-
dose group showed no ISI activity. After the 5th immunization, all volunteers in both groups 
developed functional antibodies with an average inhibition of 62.93 ± 6.36 % for the low-dose 
group and 61.47 ± 3.55 % for the high -group. ISI activity remained unchanged in both groups 
when compared before and after CHMI1. ISI in CHMI protected and unprotected subjects did 
not differ significantly at any time point (Figure 1A, B). When followed in the four CHMI1 
protected volunteers, ISI activity was sustained until day 140 after CHMI1, with an average 
inhibition of 75.60 ± 7.89 %. ISI results of serum samples collected from placebo controls are 
provided in Figure 1C. ISI remained undetectable during PfSPZ vaccinations and increased 
significantly only after CHMI1 (Figure 1C).  
Collectively, these results demonstrate that PfSPZ vaccination of malaria pre-exposed 
Tanzanian volunteers induced antibodies inhibiting Pf sporozoite invasion in vitro. No 
difference was observed between the low- and high-dose groups and in some volunteers, these 
inhibitory antibodies were detectable up to 140 days past CHMI1. 
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Figure 1 Evaluation of serum from PfSPZ-immunized malaria pre-exposed Tanzanian volunteers for functional 
inhibition of sporozoite invasion (ISI) in vitro. Percentage ISI of HC04 cells infected with Pf sporozoites obtained 
from post-immunization sera from malaria pre-exposed volunteers immunized with (A) 5 x 1.35 x 105 PfSPZ Vaccine 
(n = 10) and (B) 5 x 2.7 x 105 PfSPZ Vaccine (n = 20). Serum samples at d140post-CHMI1 (n=4) and d28post-CHMI2 
(n=3) were only available from protected subjects of the high-dose group. One sample at d14post-5th was missing for 
the high dose group. Each data point indicates a volunteer’s mean value across 2 independent experiments. The middle 
bar of each box plot represents the median and the whisker maximum length set to 1.5 IQR (interquartile range). 
Asterisks above box plots indicate a statistically significant difference of the group mean invasion relative to 0% 
inhibition of invasion, determined by one-sample t-test. Bars with asterisks show statistically significant changes of 
inhibition of invasion between visits determined by paired t-test. Immunized protected individuals are shown as empty 
triangles, immunized non-protected volunteers as solid circles and control subjects as crossed circles. (C) Percentage 
ISI from sera collected from control volunteers from low- and high-dose group (n = 8), who received normal saline 
instead of PfSPZ-immunization at 14 days after the 3rd and 5th immunization. On day 28post-CHMI1 all control 
volunteers were challenged with 3,200 non-irradiated PfSPZ of PfSPZ Challenge. 
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3.4.2 PfSPZ vaccination induced anti-CSP IgG and IgM antibodies 
The circumsporozoite protein is the major protein on the surface of Pf sporozoites and has 
been known to be immunodominant [16]. We assessed the IgG and IgM antibody titers 
specific for full length recombinant CSP [9] using ELISA (Figure 2A, B) at baseline, 14 days 
past 5th immunization and 140 days post-CHMI1 and 28 days post-CHMI2 for the high-dose 
group. 
We set the positivity cutoff for anti-CSP IgG antibody titers at 10.12 arbitrary units (AU) 
(Figure 2A). At baseline, four of 23 volunteers showed positive IgG titers (average of 18.89 ± 
1.84 AU) with a total group average of 7.94 ± 1.15 AU. The four positive subjects included 
one volunteer who was protected after CHMI1 and CHMI2. 14 days after the 5th 
immunization, all vaccinees had developed significantly higher anti-CSP IgG antibodies 
(average of 68.02 ± 8.63 AU). All placebo controls remained negative with an average of 9.89 
± 0.81 AU. Interestingly, the anti-CSP IgG titers remained unchanged before and after 
CHMI1 (average of 64.81 ± 9.16 AU for all volunteers). Placebo controls and non-protected 
vaccinees developed asexual blood stage parasitemia after CHM1. Anti-CSP IgG titers after 
CHMI1 were not boosted and were remained lower in placebos (29.32 ± 6.87 AU) compared 
to PfSPZ immunized volunteers (71.91 ± 10.23 AU) (Figure 2A). On follow-up visits at 140 
days post-CHMI1 and on 28 days post-CHMI2, the four protected volunteers remained 
positive for anti-CSP IgG.  
The positivity cutoff for anti-CSP IgM antibody titers was set at 9.21 AU. At baseline, CSP-
binding IgM antibodies (Figure 2B) were detected in four of 23 volunteers with an average of 
12.78 ± 1.83 AU while the total group average was 7.39 ± 0.71 AU. 14 days past 5th 
immunization, 18 of 23 volunteers showed anti-CSP IgM titers with an average of 89.61 ± 
27.30 AU. Three of four placebo controls remained negative at this time point as well as one 
vaccinee. 28 days post CHMI1, a significant increase in anti-CSP IgM titers (average of 
164.30 ± 33.79 AU) in all volunteers which experienced asexual blood stage infections was 
observed. Interestingly, anti-CSP IgM titers from placebo controls (average: 152.71± 54.50 
AU) and non-protected vaccinees (average: 157.88 ± 34.71 AU) did not differ significantly. 
28 days post CHMI1. Anti-CSP IgM titers remained unchanged in sterile protected volunteers 
after CHMI1. One protected volunteer did not develop anti-CSP IgM antibodies during 
vaccination and after CHMI1 and CHMI2. In serum samples collected 140 days after CHMI1 
(average: 134.65 ± 30.93 AU) and 28 days post CHMI2 (average: 168.21 ± 33.99 AU), 
sustained anti-CSP IgM titers were measured in two of four protected volunteers. 
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Figure 2 Induction of IgG (A) and IgM antibody (B) responses to full length Pf CSP from malaria pre-
exposed volunteers immunized with 5 x 2.7 x 105 PfSPZ Vaccine, quantified by ELISA at the time-points: 
baseline, day 14 post-5th-immunization, day 28 post-CHMI1, day 140 post-CHMI1 and day 28-post-CHMI2. 
Antibody titers are specified as arbitrary units (AU) with a positivity cutoff shown by a dashed line. Each data 
point represents the mean of the duplicate ELISA titers for one volunteer. Asterisks indicate statistically 
significant difference of the mean antibody titer compared to the mean titer measured at the pre-immunization 
time-point as determined by paired t-test. Bars with asterisks indicate statistically significant difference of the 
mean antibody titer between visits determined by paired t-test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Control 
volunteers are shown as crossed circles (n=4), immunized non-protected volunteers as solid circles (n=16) and 
immunized protected (n=4) as empty triangles. Serum samples of two volunteers were not available, one at 
baseline and one at visit of d14post-5th. The two volunteers were not considered for statistical analysis. 
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Overall these results revealed that malaria pre-exposed Tanzanian adults developed anti-CSP 
IgG and IgM antibody titers that persisted for more than 6 months after PfSPZ immunization 
and CHMI. We next tried to correlate level of in vitro Pf sporozoite inhibition with anti-CSP 
IgG and IgM antibody titers from the high-dose group. No significant correlation became 
apparent between invasion inhibition and anti-CSP IgG (Figure 3A) and IgM titers (Figure 
3B). 
3.4.3 IgM antibodies contribute to inhibition of sporozoite invasion 
Next, we wanted to understand better the potential contribution of vaccine-induced anti-CSP 
IgM antibodies to in vitro sporozoite invasion inhibition. Here, we selected plasma samples 
collected from five volunteers with high anti-CSP IgM titers 14 days after 5th immunization. 
Plasma samples were depleted of IgG and IgA antibodies and the IgM enriched fractions were 
used to test for binding against full length PfCSP in ELISA (Figure 4A) and whole 
sporozoites in IFA (Figure 4B) and subsequently in ISI assay to determine inhibition of 
sporozoite invasion in vitro (Figure 4C). The resulting fractions after IgG and IgA depletion 
contained IgM antibodies with higher than 90% purity as measured by total IgM and IgA 
ELISA and all bound to full length CSP by ELISA (Figure 4A). At a 1:20 dilution in 
 
Figure 3 No statistically significant correlation between anti-CSP titers and percentage ISI of HC04 cells 
assessed from malaria pre-exposed people immunized with 5 x 2.7 x 105 PfSPZ Vaccine measured at time-
points of baseline, post-immunization and post-CHMI1. (A) Correlation between percentage of ISI and anti-
CSP IgG titers and (B) anti-CSP IgM titers determined by Spearman correlation. Immunized non-protected 
volunteers are shown as solid circles (n = 31) and immunized protected as empty triangles (n = 15). 
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complete medium the IgM enriched preparation inhibited sporozoite invasion in 3 out of 5 
volunteers, ranging between 28 to 43 % (Figure 4C). Before enrichment of IgM fractions, the 
three ISI positive volunteers had the highest anti-CSP IgM titers with an average AU of 304, 
while the two ISI negative volunteers had an average of 104 AU. IgM enriched plasma 
preparations of these three positive volunteers also recognized strongly whole sporozoites in 
IFA (Figure 4B). IgM fractions from plasma samples of the four high-dose protected 
volunteers collected 140 days after the first CHMI were tested as well. One volunteer with 
high anti-CSP IgM titers showed strong binding to purified sporozoites by IFA and showed 
invasion inhibition at 31% (data not shown).  
In summary, PfSPZ Vaccine-induced anti-CSP IgM antibodies in malaria pre-exposed 
volunteers inhibit in vitro sporozoite invasion and persisted in one volunteer for at least 140 
days after CHMI1. 
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Figure 4 Vacine-induced anti-CSP IgM antibodies bind to whole sporozoites and inhibit sporozoite 
invasion in vitro. Plasma from a subset of volunteers (n=5) collected at 14 days post-5th immunization was 
depleted of IgG and IgA antibodies to generate IgM antibody fractions. Each individual volunteer is indicated 
with a different letter (T, V, W, Y, Z). IgM fraction of volunteers which were inhibitory in ISI are indicated in 
blue while those which were not are in orange. IgM fraction from a pre-immune pool was used as a negative 
control and is indicated as NC. A) IgM fractions were used in ELISA with full length PfCSP at indicated 
dilutions. Anti-human IgM secondary was used to detect anti-CSP IgM with indicated OD at 405nm. B) IgM 
fractions were applied to fixed, permeabilized whole sporozites and IgM binding detected in IFA by staining with 
anti-human IgM AlexaFluor594 (red) and anti-CSP monoclonal antibody 2A10 conjugated to AlexaFluor488 
(green). Each panel represents an individual volunteer indicated in different letters (n = 5) with each image 
captured under the same exposure conditions with identical modifications. C) IgM fractions were tested in ISI at 
a ~1:20 dilution from original plasma. Percent ISI as normalized to pre-immune pooled IgM fractions are 
displayed at time-point 14 days post-5th immunization. Each data point and letter represents a volunteer’s mean 
value across 2 independent experiments. IgM fractions from volunteers W, Y and V showed ISI activity between 
28% to 43%. 
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3.5  Discussion 
We demonstrate here that malaria pre-exposed adult volunteers develop antibodies that ex 
vivo inhibit sporozoite invasion following intravenous immunization with PfSPZ Vaccine 
(Figure 1). At baseline (Supplementary Figure 2) and in placebo controls (Figure 1C), 
inhibitory antibody activity was not observed strongly supporting the conclusion that we 
measured PfSPZ Vaccine-induced parasite inhibitory antibodies. Lack of ISI activity at 
baseline is in concordance with previous field studies demonstrating inefficient acquisition of 
pre-erythrocytic stage specific humoral immune responses [10, 11]. From our data, the 
invasion inhibition activity of serum samples does not seem to correlate with PfSPZ Vaccine 
dosing as similar results were obtained from the low and high-dose group (Figure 1). 
CSP is the most immunodominant antigen expressed on the sporozoite surface [16] and 
therefore we analyzed if anti-CSP IgG and IgM isotypes are detected in serum after PfSPZ 
vaccination. Two weeks past 5th vaccination, in 17 of 19 immunized volunteers anti-CSP IgM 
antibodies were observed with all immunized volunteers mounted anti-CSP IgG antibodies 
(Figure 2A, 2B). Most importantly, we demonstrate that in three volunteers, these anti-CSP 
IgM antibodies mediate ISI activity in plasma fractions after IgG and IgA depletion. To our 
knowledge, this is the first demonstration of PfSPZ Vaccine-induced in vitro liver cell 
sporozoite inhibition mediated by enriched IgM preparations. We did not find correlations 
between anti-CSP IgG or IgM titers and ISI activities (Figure 3A, 3B). One possible 
explanation could be that antibodies targeting antigens other than CSP are involved in ISI 
outcomes [17].  
Vaccine-induced IgM antibodies have been regarded in the past as short-lived and less 
affinity-matured compared to IgG antibodies [18]. Therefore, investigation of whole 
sporozoite vaccine-induced humoral immunity focused on IgG isotypes in malaria-exposed 
and malaria-naïve populations [5, 9, 19]. Sporozoite binding IgG antibodies have been 
proposed as correlate of protection in whole irradiation-attenuated sporozoite immunized 
volunteers [5, 20] and in GAP vaccinated volunteers using passive transfer experiments in 
FRG mice (Sack et al., npj Vaccines in press). 
In RAS immunized mice, IgM antibodies were described as binding to live sporozoites and 
limiting parasite liver infection by 74% in passive transfer experiments [21]. IgM antibodies 
cross-reacting with glycoproteins on the sporozoite surface were shown to inhibit parasite 
infection of hepatocytes in vivo and in vitro [22]. In the latter example, these antibodies 
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appeared to function largely through FC-dependent effectors and complement fixation with 
recruitment of polymorph nuclear cells [22]. Long-lived, somatically hyper-mutated IgM 
memory B cells can contribute to protection from asexual blood stage infection in mice [23]. 
Plasma cells secreting IgM antibodies that are somatically hyper-mutated and that reside in 
the spleen have been detected during vaccination and influenza virus and lymphocytic 
choriomeningitis virus infections [24].  
The PfSPZ Vaccine is given intravenously using exceedingly high sporozoite dosing when 
compared to natural infection by mosquito bites. It could be assumed that a considerable 
fraction of injected sporozoites are drained into the spleen and get into contact with 
macrophages, dendritic cells, neutrophiles and marginal zone (MZ) B cells [25]. MZ B cells 
are a human B cell subset located in the marginal zones of human spleens [25]. They are 
defined based on their IgMhiIgDlowCD1c+CD21hiCD23-CD27+ marker expression [26–28]. 
MZ B cells have been commonly regarded as front-line sentinels involved in induction of 
rapid, T cell independent innate-like antibody responses at the host-environmental interface. 
However, some MZ B cells express somatically mutated V(D)J genes, are dependent on T cell 
interaction, toll-like receptor co-stimulation and some show past germinal center experience. 
These B cells could be regarded as memory B cells that have retained IgM and IgD 
expression [25]. We hypothesize that a subset of MZ B cells could constitute the source of 
PfSPZ Vaccine-induced long-lived and functionally active anti-CSP IgM antibodies.  
Our data suggest that sporozoite binding and invasion inhibitory IgM could contribute to 
protection against malaria infection. IgM antibodies are excellent in fixing complement which 
could either eliminate circulating sporozoites by formation of the membrane attack complex 
leading to parasite lysis, or by C3a formation and recruitment of mononuclear cells 
(phagocytosis). Complement-mediated lysis has been demonstrated for asexual blood stage 
merozoite in humans [29, 30]. However, similar evidence is yet lacking for sporozoites but is 
conceivable as sporozoites could encounter IgM and complement during their journey from 
the skin to the liver parenchym. It will be interesting to determine if IgM antibodies such as 
those elicited in our vaccine trial are capable of fixing complement upon sporozoite binding in 
vitro. 
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3.6 Conclusions 
In conclusion, our data show that immunization of malaria pre-exposed volunteers with 
PfSPZ Vaccine elicits functional, sporozoite invasion inhibitory antibodies. In volunteers that 
mounted higher titers of anti-CSP IgM antibodies, this sporozoite inhibition could be partially 
attributed to IgM. Immunological assessment of mode of action of PfSPZ vaccine-induced 
humoral effector mechanisms should therefore include monitoring of parasite-specific IgG 
and IgM antibodies. Future studies need to expand on our findings and address if (i) parasite-
inhibitory IgM production is related to PfSPZ vaccine delivery route and dosing, (ii) PfSPZ 
vaccine-induced IgM responses are unique to malaria pre-exposed individuals and (iii) the 
sporozoite binding IgM antibody repertoire undergoes affinity maturation resulting in 
improved effector function over repeated vaccinations. 
3.7 Abbreviations 
AU: Arbitrary units BCTU: Bagamoyo Clinical Trial Unit BSA: Bovine serum albumin 
CHMI: Controlled human malaria infection CSP: Circumsporozoite protein CV: Coefficient 
of variation CVac: Chemoprophylaxis Vaccination DVI: Direct venous inoculation ELISA: 
Enzyme-linked immunosorbent assay EKNZ: Ethikkommission Basel FBS: Fetal bovine 
serum HRP: Horseradish peroxidase IFA: Immunofluoresence Assay IHI: Ifakara Health 
Institute IRBs: Institutional review boards ISI Inhibition of sporozoite invasion assay IQR: 
Interquartile range mAB: Monoclonal antibody MZ B cells: Marginal zone B cells NIMR: 
National Institute for Medical Research Tanzania PBMCs: Peripheral blood mononuclear 
cells: PBS: Phosphate buffer saline PFA: Paraformaldehyde Pf: Plasmodium falciparum 
PfSPZ: Plasmodium falciparum sporozoites RAS: Radiation attenuation sporozoites RT: 
Room temperature TFDA: Tanzania Food and Drug Authority WHO: World Health 
Organization 
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3.8 Supplementary Figures 
 
Supplementary Figure 1 Vaccination schedule. Volunteers were immunized with the PfSPZ Vaccine at 
monthly intervals between the 1st and 4th immunization and 56 days between the 4th and 5th immunization. 21 
days after the last immunization, volunteers were challenged for the first time with non-irradiated PfSPZ of 
PfSPZ challenge (CHMI1). Protected volunteers after the first challenge, were re-challenged (CHMI2) at 140 
days post-CHMI1. D indicates the number of days between the vaccination- and CHMI visits. 
 
 
 
Supplementary Figure 2 No pre-existing inhibitory antibodies in the majority of malaria pre-exposed 
Tanzanian volunteers prior to immunization with the PfSPZ Vaccine. Percentage ISI of HC04 cells by Pf 
sporozoites obtained from serum collected from volunteers from the low- and high-dose group measured at 
baseline visit, before active immunization with the PfSPZ Vaccine. Control volunteers are shown as crossed 
circles, immunized unprotected as solid circles and immunized protected as empty triangles. 
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4.1 Abstract 
The immunization with radiation-attenuated whole Plasmodium falciparum (Pf) sporozoites 
mediates sterilizing immunity in malaria-naïve volunteers, but the protective role of 
antibodies induced by this vaccination approach remains to be elucidated. To investigate this, 
we isolated a panel of monoclonal antibodies from individuals living in malaria-endemic 
Tanzania, who received active immunization with whole, radiation-attenuated sporozoites 
(Sanaria® PfSPZ Vaccine), and who were subsequently found to be protected against 
homologous sporozoite challenge. Using an antigen-agnostic approach to identify any 
antibodies that can bind to the surface of intact sporozoites, we found that all of the isolated 
antibodies targeted the circumsporozoite protein, confirming its known immunodominance. 
Characterization of these antibodies using epitope mapping and in vitro and in vivo functional 
assays revealed a few antibodies with distinct binding properties that were very potent in 
reducing liver burden in an in vivo human-liver chimeric mouse model of Pf sporozoite 
invasion. Overall, these findings identified and characterized human monoclonal antibodies 
that show potent inhibition of sporozoite invasion in an in vivo model and reveal an epitope 
that is not in the current leading malaria vaccine canidate of RTS, S but that appears to be a 
target of antibodies in protected individuals immunized with the PfSPZ Vaccine. 
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4.2 Introduction 
Malaria is a mosquito-borne disease caused by Plasmodium parasites. In 2016, the World 
Health Organization (WHO) estimated approximately 212 million malaria cases and 429,000 
malaria-related deaths globally [1]. The life cycle of Plasmodium falciparum (P. falciparum) 
is complex and starts with the injection of sporozoites by infected mosquito in the skin, which 
then progress through the blood circulation to the liver, where the sporozoites begin to 
traverse and infect hepatocytes [2]. Inside the hepatocyte, the sporozoites start to replicate and 
further develop into merozoites, which are released in the blood initiating the development of 
disease-causing asexual blood-stage parasites [2]. There is currently no protective malaria 
vaccine available [3]. The most clinically advanced malaria vaccine candidate, the 
circumsporozoite (CSP) protein-based RTS, S subunit vaccine, showed only partial and short-
term efficacy in malaria-endemic populations [4]. To date, the only experimental vaccination 
approach which has ever achieved complete sterile protection in humans is the immunization 
with whole-attenuated sporozoites [5–9]. Immunologic correlates of protection against pre-
erythrocytic stage infection in humans remain to be investigated [10, 11]. Findings from 
animal studies in mice and non-human primates (NHPs) suggest that sterile protection relies 
on a combination of cellular and humoral immune responses. Hepatic alpha beta CD8+ T 
cells that secrete interferon-γ upon recognition of infected liver cells result in killing of the 
parasite inside the hepatocytes. Antibodies bind and block sporozoites in the skin and inhibit 
their traversal and inhibition in the liver [4, 9, 10, 12–14]. It has been demonstrated that 
immunization with whole-attenuated sporozoites can induce functional antibodies that inhibit 
sporozoite invasion in vitro and in in vivo models in mice [11, 15–17]. Nonetheless, 
contribution to protection in vaccinated humans is unclear and antigens recognized by 
sporozoite inhibiting antibodies are incompletely known [18]. To better understand the 
repertoire and targets of sporozoite binding antibodies in humans inoculated intravenously 
with high numbers of purified sporozoites, we have isolated a panel of sporozoite-specific 
human monoclonal antibodies in this study. The donors were residing in a malaria-endemic 
area of Tanzania and received active immunization of 5 doses of 1.35 x 105 or 2.7 x 105 
aseptic, purified, radiation-attenuated, whole P. falciparum sporozoites (PfSPZ Vaccine). 
Three weeks and after last vaccination, these volunteers underwent homologous controlled 
human malaria infection (CHMI) and were found to be sterile protected (Jongo et al., 
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manuscript submitted). We characterized the biological function of these antibodies by using 
in vitro and in vivo sporozoite infection models of Pf in human liver cells [16]. 
4.3 Results 
4.3.1 Serological screen of IgG and IgM antibodies against whole sporozoites 
We developed a flow cytometry-based screening assay that allows detection of serum 
antibodies binding to whole intact sporozoites in vaccinees and placebo controls. IgG and 
IgM titers against whole sporozoites were measured at time-points before immunization 
(baseline), two weeks after last vaccination (2w post-vaccination) and 4 and 20 weeks after 
homologous CHMI Challenge (Supplementary Figure 1). The results of immunized donors 
showed that IgG and IgM titers are low at baseline and increase significantly after 
vaccination. There is no boost of IgG and IgM antibodies induced at 4 weeks after CHMI 
compared to titers measured at 2 weeks after last vaccination (Supplementary Figure 1). 
Antibody titers, especially IgG, of immunized volunteers measured at 20 weeks after CHMI, 
remain sustained above baseline level. No clear differences between protected and non-
protected volunteers were observed. In contrast, antibody titers of placebo controls were low 
at all time-points, except for titers measured at 4 weeks after challenge, where titers increased. 
In conclusion, these results indicate that immunization with the PfSPZ Vaccine boosts 
sporozoite-specific IgG and IgM antibodies in Tanzanian adults after vaccination and IgG and 
IgM antibody titers remain sustained above background levels at 20 weeks after CHMI. 
Furthermore, there was no boost in the antibody responses observed in the vaccine recipients 
4 weeks after challenge compared to the titers measured 2 weeks after the vaccination. 
 
4.3.2 Isolation of anti-sporozoite monoclonal antibodies 
Next, we immortalized IgG+ memory B cells [19] from five CHMI protected donors (U, G, V, 
H and W). IgG+ memory B cells were isolated from PBMC, sorted by flow cytometry and 
subsequently immortalized with Epstein-Barr virus and a TLR agonist using established 
protocols [19, 20] (Figure 1). Two weeks after immortalization, B cell supernatants from 
immortalized IgG+ memory cells were screened for their capacity to bind intact sporozoites by 
flow cytometry. Positive B cell clones were selected for isolation of mRNA, sequencing of 
heavy and light chain variable regions (VH and VL), and recombinant IgG+ monoclonal 
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antibody production [21]. Staining of whole intact sporozoites of a subset of produced 
recombinant IgG+ monoclonal antibodies (mABs) by flow cytometry are shown in 
Supplementary Figure 2. Using this approach, we have isolated a panel of sporozoite-specific 
IgG+ mABs from five Tanzanian donors who have been immunized with the PfSPZ Vaccine 
and were protected against homologous CHMI. 
 
 
4.3.3 All monoclonal antibodies target the circumsporozoite protein 
After successful production of IgG+ mABs, we wanted to test if the mABs target the P. 
falciparum circumsporozoite protein (PfCSP). PfCSP is the predominant sporozoite surface 
antigen [22]. Therefore an enzyme-linked immunosorbent assay (ELISA) against full length 
recombinant PfCSP protein was performed (data not shown). A schematic representation of 
the full length PfCSP protein is given in Figure 3A. The ELISA results revealed that all 
isolated monoclonal antibodies target the PfCSP protein. 
 
4.3.4 In vitro sporozoite-blocking activity of monoclonal antibodies 
To assess the functional capacity of the anti-CSP mABs in relation to inhibition of sporozoite 
infection of human hepatocytes (HC-04 cells) in vitro, a flow cytometry-based inhibition of 
sporozoite traversal and invasion assay (ISTI) was performed [17, 23]. Each anti-CSP 
 
Figure 1 Workflow of sporozoite-specific monoclonal antibody isolation from protected PfSPZ Vaccine-
immunized Tanzanian donors using a high-throughput screening system. 
 
 
Chapter 4 
77 
 
antibody was mixed with P. falciparum sporozoites in the presence of FITC-dextran and then 
used for infection of HC-04 cells. Monoclonal antibody 2A10 served as positive control in 
our ISTI assays [23]. This antibody targets the NANP repeats of CSP and is known to inhibit 
sporozoite invasion and traversal at approximately 80% and 50%, respectively. Traversed 
HC-04 cells, wounded by sporozoite invasion and egress and therefore allowing dextran 
uptake, were identified as dextran-positive cells. Sporozoite invasion of HC-04 cells was 
monitored by gating CSP- positive hepatocytes using a fluorescently-conjugated anti-CSP 
mAb [17, 23]. 
ISTI activity of a panel of anti-CSP antibodies from donors G, H, U and V were tested and are 
presented in Figure 2A. All anti-CSP antibodies showed ISTI activity with mAB MGG4, 
MGH1, MGH2 and MGH3 displaying the strongest sporozoite inhibition in both assays 
(Figure 2A).  
 
4.3.5 In vivo functional activity of anti-CSP monoclonal antibodies 
To investigate the in vivo blocking activity of the monoclonal antibodies, MGG4, MGG8, 
MGG3, MGH1, MGH2 and MGH3, we used a human liver-chimeric mouse model (FRG 
huHep) in combination with luciferase-expressing P. falciparum sporozoites [16, 24, 25]. 
FRG huHep mice consist of engrafted human hepatocytes and lack mouse B cells, T cells and 
natural killer cells. This mouse model has proven to allow complete liver-stage development 
of P. falciparum parasites and to distinguish in vivo antibody function [25]. Our collection of 
mABs were passively transferred into four FRG mice per antibody at a concentration of 
150µg/mouse. P. falciparum liver stage burden of mice was measured by an in vivo imaging 
system at the peak of liver burden six days after mosquito-bite challenge with malaria 
parasites [16, 26]. The anti-CSP repeat monoclonal antibody 2A10 was used as a positive 
control and as a negative control non-specific IgG was used. Reduction of the liver stage 
burden induced by anti-CSP mAB is summarized in Figure 2B. Out of the six antibodies 
tested, mAB MGG4, MGH2 and MGG3 showed the strongest reduction of liver burden to 
less than 6% (Figure 2B). 
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4.3.6 Potent parasite inhibitory monoclonal antibodies target a distinct peptide at the 
N-terminal end and the NANP repeat, which is not included in the RTS, S 
vaccine 
To identify further the target structure of our collection of mABs, we performed ELISA with 
three synthetic peptides representing different parts of CSP and full length recombinant CSP 
protein (Figure 3A). Peptide 22-110 encompasses the N-terminal region and Region I of CSP, 
Peptide NANP10 consists of 10 consecutive NANP repeat sequences and the 18-mer peptide 
with the sequence KQPADGNPDPNANPNKNN covers the junction between the N-terminal 
end and the NANP repeat region of PfCSP. The ELISA results demonstrated that all mABs 
bound to full length CSP. Monoclonal antibodies MGG4, MGH2 and MGG3, which were 
 
Figure 2 Functional assessment of sporozoite-blocking activity of isolated anti-CSP monoclonal 
antibodies. A) Anti-CSP monoclonal antibodies isolated from four protected immunized donors (G, H, U, V) 
were evaluated for in vitro inhibition of sporozoite traversal and invasion (ISTI) of HC04 hepatocytes. The 
ISTI activity of each anti-CSP antibody was normalized to a negative control of non-specific human IgG. 
Percent of inhibition of invasion are indicated in empty bars and percent of inhibition of traversal are shown 
in gray bars. The anti-CSP repeat antibody 2A10 was used as a positive control. B) Anti-CSP antibodies 
MGG3, MGG4, MGG8, MGH1, MGH2 and MGH3 were selected for passive transfer into FRG huHep mice 
to assess in vivo reduction of liver-stage Pf parasites. Liver-stage burden was assessed by bioluminescent 
imaging six days after mosquito bite challenge with infected luciferase-expressing P. falciparum sporozoites. 
Each data point in the graph represents one mouse. The y-axis shows the parasite liver burden as a percent of 
the average of control mice given non-specific IgG. Each anti-CSP antibody tested is indicated on the x-axis. 
Anti-CSP antibodies MGG4, MGH2 and MGG3 reduced liver burden to less than 6%. 
 
 
Chapter 4 
79 
 
most potent in the in vivo model, showed strong binding to the 18-mer peptide and the NANP 
repeats (Figure 3B). 
 
 
Figure 3: The most potent anti-CSP antibodies show strong binding to the 18-mer peptide. A) 
Schematic representation of the PfCSP protein showing the different peptides used in the ELISA screen of 
the monoclonal antibodies. B) EC50 values of different monolconal antibodies from 4 donors (G, H, U, V) to 
full length PfCSP and to peptides shown in different symbols on the legend to the right of the plot. The 
monoclonal antibodies that were most potent in the in vivo model, MGG3, MGG4 and MGH2 are marked by 
black asterisks and show strong binding to the 18-mer peptide (KQPADGNPDPNANPNKNN) and the 
NANP repeats. 
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4.4 Discussion 
We have isolated a panel of sporozoite binding mABs from five Tanzanian adults who were 
immunized with aseptic, purified, radiation-attenuated, whole P. falciparum sporozoites 
(Sanaria® PfSPZ Vaccine) and showed sterile protection against homologous challenge three 
weeks post last vaccination. All mABs target the PfCSP protein, the major surface antigen 
expressed on sporozoites. Strikingly, the anti-CSP monoclonal antibodies which were most 
potent in reducing the liver stage burden in vivo (Figure 2B) showed strong binding to an 18-
mer peptide sequence (KQPADGNPDPNANPNKNN) located at the junction between the N-
terminal end and the NANP repeat region (Figure 3B). Interestingly, this peptide is not 
included in the most advanced malaria subunit vaccine, RTS, S vaccine, which consists of a 
fusion protein of hepatitis B and 16 NANP repeats and the entire C-terminus [27]. The N-
terminus of PfCSP has been described as functionally relevant in the process of sporozoite 
attachment and invasion into liver cells [22, 27–29]. Moreover, the 18-mer peptide also 
includes three amino acids of the highly conserved region I (RI) (Figure 3A), which has been 
reported to contain the CSP cleavage site essential for rapid CSP processing shown to be 
critical for sporozoite entry into hepatocytes [22, 29]. Our functional data strongly suggest 
that antibodies targeting a region between a CSP-N-terminal peptide 
(KQPADGNPDPNANPNKNN) and NANP could be highly potent in blocking sporozoite 
infection. Previous studies in mice have shown that immunization with peptides located at the 
PfCSP N-terminus can induce invasion-inhibiting antibodies [30]. In field studies conducted 
in children living in malaria-endemic regions of Tanzania, a correlation between the presence 
of antibodies targeting the PfCSP N-terminus with protection from clinical malaria was 
observed [31]. Our approach of studying vaccine-induced sporozoite binding humoral 
immunity at the single cell level from Tanzanian donors has the power to identify rare B cell 
clones that produce highly effective parasite inhibitory antibodies.  
Taken together, we developed for the first time PfCSP-specific mABs from African donors, 
who received active immunization of the PfSPZ Vaccine. The mAbs with strongest parasite 
growth inhibition in a humanized mouse model target a distinct peptide located at the N-
terminal end of PfCSP and the first NANP repeat. The target recognized by these mABs 
might support a second generation of PfCSP subunit vaccines against the most deadly malaria 
species [20].  
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4.7 Material and Methods 
4.7.1 Clinical trial and donors 
All samples used in this study were collected from malaria pre-exposed volunteers during a 
clinical phase I trial on the safety, immunogenicity and protective efficacy of the Sanaria® 
PfSPZ Vaccine in Bagamoyo, Tanzania between 2014 and 2015. The protocol was approved 
by the Tanzanian Food and Drug Authority (TFDA) (Ref. No TFDA 13/CTR/0003) and the 
trial was registered at Clinical Trial.gov (NCT02132299) and conducted under U.S. FDA IND 
14826. Detailed information on the study procedures and the volunteers enrolled are 
described elsewhere (Jongo et al., manuscript submitted). Briefly, healthy male volunteers 
aged 20 to 30 years were randomized to direct venous inoculation of 5 doses of normal saline 
or 1.35 x 105 or 2.7 x 105 of the Sanaria® PfSPZ Vaccine. Vaccine efficacy was evaluated by 
homologous controlled human malaria infection (CHMI) by direct venous inoculation of 
3,200 infectious P. falciparum sporozoites at 3 and 24 weeks after the last immunization. The 
PfSPZ Vaccine proved to be safe and well tolerated in all Tanzanian volunteers. In the low-
dose group,1 of 18 (6%) volunteer was protected against CHMI at 3 weeks and in the high-
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dose group, 4 of 20 (20%) volunteers were protected at 3 and 24 weeks after the last 
vaccination. 
 
4.7.2 Sample collection and preparation 
For serum preparation, whole blood was collected in vacutainer tubes containing clot 
activators (Becton, Dickison, 369032) and kept at RT until a clot was formed. Then the tube 
was centrifuged at 2000g for 10 minutes at 22°C and the serum fraction was collected in 
cryogenic vials and stored at -80°C. 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll 
density gradient centrifugation. Whole blood was collected with a syringe containing EDTA-
Na2 as anti-coagulant and subsequently diluted with the same volume of 1 X PBS in order to 
facilitate the separation process. The anti-coagulated blood was poured into LeucosepTM 
tubes (227 789 or 227 290) prefilled with Ficoll Paque separation medium (Ficoll Paque 
Premium GE17-5442-03) and centrifuged at 800 x g for 15 minutes at RT (20-22°C) with 
acceleration and brake set to 0. After centrifugation, the layer of PBMCs was collected and 
transferred to a separate tube containing wash buffer (1X PBS/2% FCS). The PBMC fraction 
was washed twice at 250 x g for 10 minutes at RT (20-22°C). After washing, the PBMC cell 
pellet was resuspended in freezing medium (10%DMSO/90%FCS) and stored in Mr. Frosties 
at -80°C overnight and on the day after transferred to liquid nitrogen for long-term storage. 
 
4.7.3 Evaluation of serum IgG and IgM antibodies against whole intact sporozoites by 
flow cytometry 
Binding of IgG and IgM serum antibodies to intact sporozoites was analyzed by flow 
cytometry. Aseptic, purified, cryopreserved PfSPZ from Sanaria were labeled with 6.7× 
SYBR Green I (ThermoFisher Scientific) and incubated with each of the serum samples at a 
12-point 2-fold serial dilution (6000PfSPZ per sample) for 20 minutes at RT. The PfSPZ were 
washed twice by centrifugation at 4,000 rpm for 5 minutes, split into two, and then stained 
with 2.5 µg/mL of Alexa Fluor 647-conjugated goat anti-human IgG or Alexa Fluor 647-
conjugated goat anti-human IgM (Jackson ImmunoResearch) for 1 h at 4°C. After incubation, 
the sporozoites were washed twice and the samples were analyzed by flow cytometry. The 
PfSPZ were gated based on high SYBR Green I and low forward scatter, and binding of IgG 
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or IgM antibodies was calculated based on the mean fluorescence intensity (MFI) of the 
PfSPZ in the Alexa Fluor 647 channel. 
 
4.7.4 B cell immortalization and isolation of monoclonal antibodies 
IgG+ memory B cells were isolated from PBMCs by flow cytometry-based cell sorting. The 
sorted memory B cells were used for immortalization with Epstein-Barr virus (EBV) in the 
presence of CpG-DNA (2.5 µg ml-1) and irradiated feeder cells, as previously described [19]. 
Two weeks after immortalization, culture supernatants were screened for their capacity to 
stain to the surface of whole intact sporozoites using a high-throughput flow cytometer. 
PfSPZ were thawed and stained with 6.7 x SYBR Green I (ThermoFisher Scientific) and 
incubated with the B cell supernatants for 30 minutes at RT. To detect IgG-antibody binding 
to whole sporozoites, 2.5 µg/mL of Alexa Fluor 647-conjugated goat anti-human IgG was 
added and incubated for 1 hour at 4°C. 
 
4.7.5 Sequence analysis of antibody cDNA and production of recombinant antibodies 
Antibody sequences were obtained by amplifying cDNA using primers specific for IgG heavy 
or light chains. Antibody heavy and light chains were cloned into human IgG expression 
vectors and expressed by transient transfection of Expi293F Cells using polyethylenimine 
(PEI). 
 
4.7.6 ELISA with full length CSP and CSP peptides 
All recombinant monoclonal antibodies were measured in an ELISA against full length 
recombinant CSP (rCSP) and peptides 22-110, NANP(10) and 18-mer peptide. High-binding 
surface 96-well plates (Costar 3690) were coated with 1µg full length rCSP and 22-110 
peptide/mL or 2µg NANP(10)/ml in PBS and incubated overnight at 4°C. Plates were washed 
4 times before blocking with PBS/1%BSA for 1 hour at RT. Plates were washed twice before 
purified recombinant monoclonal antibodies were applied to the coated wells in a 1:3 serial 
dilution and incubated for 1 hour at RT. Afterwards, plates were washed 4 times and the 
substrate was added, developed and plates were read at 30 minutes and 1 hour. 
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4.7.7 In vitro assay of inhibition of sporozoite traversal and invasion (ISTI) 
A previously described inhibition of sporozoite traversal and invasion assay (ISTI) [17, 23] 
was used to assess the in vitro sporozoite blocking activity of the monoclonal antibodies. In 
brief, freshly dissected salivary gland NF54 P. falciparum sporozoites were incubated 
together with each monoclonal antibody at a concentration of 10µg/ml in DMEM medium 
supplemented with 10%FBS, 2.5mM glutamine, penicillin/streptomycin, fungizone and 
10mg/mL FITC dextran for 15 minutes at 37°C. Afterwards the sporozoite-antibody mixture 
was added to HC-04 cells at an MOI of 0.3:1 (30,000 sporozoites: 100,000 HC-04 cells) in 
triplicate in a 96 well plate in a total volume of 100µl/ml. The plate was centrifuged at 400 x g 
for 3 minutes to enhance interaction of sporozoites with HC-04 cells and then incubated for 
90 minutes at 37°C. After incubation was completed, cells were fixed, permeabilized (BD 
Cytofix/Cytoperm, BD Bioscience) and stained with an Alexa fluor-647-conjugated anti-CSP 
monoclonal antibody (clone 2A10). Sporozoite invasion (CSP+) and traversal (dextran+) of 
HC-04 cells was analyzed by flow cytometry by first gating live HC-04 cells by forward and 
side scatter and then gating for CSP+ and dextran+ cells. Percent of inhibition of invasion and 
traversal for each monoclonal antibody was determined by normalizing it to a negative 
control consisting of non-specific human IgG at 10µg/ml. Triplicate samples which had a 
coefficient of variation (CV) > 30% were rejected for data analysis. The reported data shows 
the average of three independent experiments. 
 
4.7.8 In vivo functional assay in FRG humanized mice (huHep) 
To assess the sporozoite blocking activity of the monoclonal antibodies in vivo, a previously 
described human liver-chimeric mouse model (FRG huHep) was used in combination with 
luciferase expressing P. falciparum sporozoites (Sack et al, manuscript submitted) [16, 24, 
25]. Each monoclonal antibody was injected intraperitoneally into FRG huHep mice at a 
concentration of 150µg/mouse and 24 hours later, the mice were challenged by the bites of 50 
mosquitoes infected with luciferase-expressing P. falciparum sporozoites [24]. Six days post-
challenge, the liver-stage burden was determined by measuring the luciferase activity in 
anesthetized mice through imaging of whole bodies with an in vivo imaging system (IVIS) 
[26]. Percent of mock (% of mock) parasite liver burden was calculated by dividing the total 
flux (pixels per second) of each individual mouse by the average of mice receiving non-
specific IgG. 
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4.8 Supplementary Material 
4.8.1 Figure Legends 
 
Supplementary Figure 1: IgG and IgM antibody titers to whole intact sporozoites 
obtained from serum samples of Tanzanian adults who received active immunization 
with the PfSPZ Vaccine. Antibody titers against whole intact sporozoites were quantified by 
flow cytometry at time-points before vaccination (baseline), 2 weeks after last vaccination 
(2w post-vaccination), 4 and 20 weeks after the first CHMI challenge. IgM antibody titers are 
shown in red and IgG antibody titers in black. The y-axis indicates the antibody binding to 
sporozoites expressed by the median fluorescence intensity (MFI) and the serum dilution is 
shown on the x-axis. Donor U, G, V and H were protected against CHMI at 3 and 24 weeks. 
Placebo controls were injected with normal saline instead of PfSPZ Vaccination and 
challenged with PfSPZ Challenge at 3 and 24 weeks. Antibody titers of protected donor W are 
not shown. 
 
Supplementary Figure 2: Staining of whole sporozoites with recombinant IgG+ 
monoclonal antibodies by flow cytometry: Flow plots showing the binding of a subset of 
recombinant IgG+ monoclonal antibodies to whole sporozoites. The SYBR-green stained 
DNA of the sporozoites is shown on the vertical axis versus the IgG binding of the mABs on 
the horizontal axis. BKC3 (last plot) is an antibody of irrelevant specificity and was used as a 
negative control. 
  
Chapter 4 
86 
 
4.8.2 Supplementary Figures 
 
 
Supplementary Figure S1-1 
 
 
Chapter 4 
87 
 
 
Supplementary Figure S1-2 
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Supplementary Figure S1-3 
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Supplementary Figure S2 
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In Chapter 2 we demonstrated that direct venous inoculation of PfSPZ Vaccine following two 
homologous CHMI studies in Tanzanian adults was safe and well tolerated. This was the first 
study using CHMI as an assessment tool for malaria vaccine efficacy in Africa and the results 
demonstrated the potential to introduce it into malaria-endemic settings. This is of great value 
since experimental human challenge infection models can accelerate clinical malaria vaccine 
development through rapid screening of candidate malaria vaccines and providing preliminary 
information on efficacy compared to more costly and time consuming field trials [100]. 
Immunogenicity and protective efficacy were significantly lower in the Tanzanian vaccine 
recipients when compared to malaria-naïve people from the U.S., who received the same 
vaccination regimen [29]. Lower antibody and T cells responses compared to malaria-naïve 
vaccine recipients were also seen in volunteers of a study in Mali, at which the safety and 
efficacy of the PfSPZ Vaccine was tested in similar immunization regimens as in the 
Tanzanian trial, but here, vaccine efficacy was assessed through natural field exposure to P. 
falciparum parasites [99]. Such population-based differences in response to vaccination have 
been described in other vaccines against BCG, hepatitis B, tetanus, diphtheria, pertussis, 
measles, influenza, oral cholera vaccine and yellow fever [114–116], all of which performed 
less well in populations from developing countries compared to populations living in 
industrialized countries [117]. The immunogenetics behind these variations in immune 
responses to vaccines observed in different human populations remain largely unknown [118]. 
Antigenic variation of P. falciparum, immunoregulation due to lifelong exposure 
(summarized in section 1.2.3) to the parasite and sub-optimal immunization regimen could 
have an influence on the poor immunogenicity seen in the malaria pre-exposed individuals of 
the studies in Tanzania and Mali [99]. It is hypothesized that higher individual doses of the 
PfSPZ Vaccine might be required in these main target populations to achieve high-level 
protection lasting for at least six months [99]. Studies testing this hypothesis are currently 
ongoing in Africa, the U.S. and Europe [99]. Furthermore, it could be possible that previous 
or frequent exposure to blood stage parasites diminish humoral immune responses to pre-
erythrocytic stage parasites in malaria pre-exposed people. This finding has been recently 
reported from studies in mice where CSP-specific humoral memory formation was found to 
be impaired after blood stage infection [119]. Other factors possibly affecting vaccine-
induced immune responses differing between human populations could be differences in 
genetic background environment, diet, gut microbiota, co-infections or an activated immune 
microenvironment as described in Ugandan volunteers who participated in a yellow fever 
vaccine study [114, 116]. In the latter study, the vaccine-induced immune responses of a 
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licensed, live attenuated yellow fever vaccine were compared between volunteers residing in 
Entebbe, Uganda, and volunteers living in Lausanne, Switzerland. The study revealed that the 
vaccine-induced CD8+ T cell and B cell responses were significantly lower in the Ugandan 
volunteers as a result of high frequencies of exhausted and activated NK cells, differentiated T 
and B lymphocytes and pro-inflammatory monocytes measured before vaccination. This 
immune activation negatively correlated with the vaccine-induced neutralizing antibody titers 
and was probably associated to higher exposure frequency to infectious diseases in Entebbe 
compared to Lausanne [116]. Higher immune activation status at baseline could also be 
present in the Tanzanian volunteers compared to U.S. resident volunteers enrolled into the 
PfSPZ vaccination studies. To confirm this hypothesis, similar immunological measurements 
between the two cohorts would need to be conducted.  
To gain a better understanding of potential immunological correlates against malaria induced 
in malaria-endemic populations after PfSPZ vaccination, measures of vaccine-induced 
immune responses need to be greatly expanded. This could be done at a single-cell level as 
described in Chapter 4, whereby B cell clones producing highly effective anti-parasite 
inhibitory antibodies are identified from the total memory B cell pool of immunized donors 
protected after CHMI [107]. Approaches including antibody repertoire sequencing [120], 
analysis of immune cells, cytokines and whole-genome tanscriptomics might also support the 
identification of correlates or markers of protection [121].  
In conclusion, the manuscript in Chapter 2 demonstrates that the immunization regimen of the 
PfSPZ Vaccine tested in volunteers of malaria-endemic Tanzania needs further optimization 
if the target of an efficacious vaccine > 75 % efficacy, lasting for at least six months is to be 
met. More research is required to understand the immunological mechanisms underlying the 
insufficient protective efficacy and immunogenicity observed in malaria-endemic target 
populations. Despite low protective efficacy, the trial did show protection in a few volunteers 
and consequently there are valuable samples available to study potential immune correlates of 
host protection. Overall, these results also highlight the importance of conducting early stage 
malaria vaccine trials in the relevant target population e.g. in sub-Saharan Africa, and the 
potential of CHMI as an assessment tool to measure vaccine efficacy. 
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In Chapter 3, we reported for the first time that anti-sporozoite IgM antibodies are induced in 
malaria pre-exposed Tanzanian adults after immunization with PfSPZ Vaccine, and most 
importantly that these IgM antibodies can mediate inhibition of sporozoite infection in vitro. 
To our knowledge this is the first demonstration of anti-sporozoite IgM antibody function 
reported in humans. So far, little has been published about the functional relevance of IgM 
antibodies in human malaria infection [56]. “Natural” or “non-immune” IgM antibodies, 
which are the first antibodies produced during a primary antibody response, are polyreactive 
and of low antigen-binding affinity [122]. They have been reported to bind to the surface of P. 
falciparum-infected erythrocytes and thereby contribute to RBC rosetting, as well to 
syndromes of severe malaria, such as placental malaria [123–126]. In contrast, Plasmodium-
specific or “immune” IgM antibodies proved to be protective against murine asexual blood 
stage parasites of P. chabaudi [127]. Furthermore, elevated levels of IgM antibodies specific 
for α-Gal, a glycoprotein expressed on the surface of Plasmodium sporozoites and of the 
human gut pathobiont E. coli, were detected in children with no P. falciparum infection 
versus children who became infected with P. falciparum during a 6-month malaria season 
[128]. In the same study, anti-α-Gal IgM antibodies inhibited parasite infection of hepatocytes 
in vivo and in vitro. In addition, Arama et al., 2015, reported a protein microarray study of 
profiling in total 1087 P. falciparum antigens and demonstrated that plasma samples collected 
from the Fulani ethnic showed higher breadth and magnitude of IgM antibody responses 
towards Plasmodium antigens compared to the Dogon ethnic group, who live in the same 
geographic area in Mali [56]. The Fulani and Dogon groups differ in their resistance against 
clinical malaria with the Fulani having a higher resistance. These findings could further 
support a potential protective role of malaria specific IgM antibodies during human malaria 
infection.  
To date, vaccine-induced IgM antibody responses have not been investigated in great detail 
during experimental malaria vaccine trials [27, 29, 32, 99]. This is not surprising, since IgM 
antibodies are traditionally believed to be short-lived and not affinity-matured and thereby do 
not contribute to memory and long-term immunity like antibodies of the switched isotype 
[129, 130]. It is commonly accepted that humoral immune memory is formed during a 
primary antibody response to foreign antigens. During this process, antigen-activated naïve B 
cells receive stimulating signals from T helper cells, which results in the proliferation of the 
activated B cells [131]. The majority of the proliferating cells differentiates into short-lived, 
mostly IgM, antibody-secreting plasmablasts, which act as a first line of defense while some 
B cell clones begin to form germinal center (GC) reactions through the interaction with 
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follicular helper T cells and dendritic cells in secondary lymphoid organs [132]. Germinal 
center B cells undergo T cell-dependent class-switching and somatic hypermutation (SHM) in 
their variable regions, which results in the generation of long lived-memory B cells (MBCs) 
and long-lived plasma cells (LLPCs) producing high-affinity antibodies of switched isotype 
[133, 134]. Upon re-challenge with the same antigen, these classical memory B cells become 
re-activated and rapidly begin to proliferate and differentiate into either plasmablasts that 
secrete high-affinity antibodies or re-enter germinal center reactions to undergo further 
affinity maturation [58]. In recent years, this view of humoral memory has been scrutinized in 
various studies with growing evidence demonstrating the existence of a higher diversity of the 
memory B cell (MBC) subset including germinal-center-independent memory B cells [135–
137], T cell-independent MBCs [138–140] and unswitched, somatically hypermutated IgM 
memory B cells [58, 141, 142] as well long-lived antigen-induced IgM plasma cells with 
somatic mutations [143]. In malaria, such phenotypically distinct MBC populations have been 
identified in murine malaria infection models, where somatically hypermutated, high-affinity 
Plasmodium-specific IgM MBCs targeting asexual blood stage parasites dominated the early 
response upon malaria re-infection [144]. In the same study, switched and unswitched 
Plasmodium-specific MBCs were also detected in PBMCs from malaria pre-exposed Malian 
subjects. Nevertheless, these findings so far describe asexual blood-stage-specific MBCs, 
since B cell tetramers specific for MSP1 were used for tracking Plasmodium-specific B cells 
[144]. Referring to our results of the PfCSP-specific IgM antibodies induced in malaria pre-
exposed volunteers after PfSPZ vaccination, the cellular source of these antibodies remains to 
be investigated.  
One limitation of our study in Chapter 3 was the low number of samples tested on day 140 
after the first CHMI. A sample size of two out of four does not allow for meaningful 
statistical analyses of the proportion of volunteers generating such vaccine-induced CSP-
binding IgM antibodies up to 140 days post-CHMI1. Results presented in Chapter 4 
(Supplementary Figure 1) clearly demonstrate elevated and sustained serum IgM antibody 
titers binding to whole sporozoites when measured by flow cytometry on day 140 post-
CHMI1. With their pentameric structure, IgM antibodies can bind to antigens with higher 
affinity compared to other immunoglobulins, allowing them to efficiently neutralize and 
agglutinate pathogens [145, 146]. In addition, IgM antibodies can activate the classical 
complement cascade with 1000-fold increased binding affinity than IgG [147]. Moreover, 
long-term production protective IgM antibodies have also been described under natural 
conditions against viral (Influenza, West Nile virus) and intracellular bacterial infections 
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[129, 138, 148–152]. There are many childhood vaccines that induced low but persistent 
protective IgM antibodies against infection [153–156]. Furthermore, sustained and long-term 
IgM production was also found in human volunteers in a phase I clinical trial of a Francisella 
tularensis vaccine [157] as well after immunization with the HIV envelope glycoprotein 
gp120 [158]. Overall, our data suggest that IgG and IgM antibody responses should both be 
assessed in future malaria vaccine trials.  
Taken together, the manuscript in Chapter 3 demonstrated that malaria pre-exposed 
individuals induce PfCSP-specific IgM antibodies following intravenous inoculation of 2.7 x 
105 purified sporozoites. It can be assumed that a large portion of these intravenously applied 
sporozoites are reaching the marginal zone of the spleen, an organ with important function in 
host defense against blood-borne pathogens and which receives large amounts of blood of 
about 5 % from the general circulation [159]. In these splenic marginal zones, so called 
marginal zone B cells (MZ B cells) are present in order to capture incoming antigens with the 
help of B cell-helper neutrophils, macrophages and DCs and subsequently differentiate into 
plasmasblasts producing large amounts of IgM or antibodies of switched isotype [160]. With 
the release of IL-21 from B cell helper-neutrophils, human MZ B cell undergo SHM and class 
switch recombination (CSR) [160]. B cells identical to splenic MZ B cells have been 
identified in human peripheral blood, suggesting that these cells recirculate [161, 162]. It 
could be possible that splenic MZ B cells are the source of the induced PfCSP-IgM antibodies 
observed in our study from Chapter 3. 
 
In Chapter 4 we reported for the first time the successful isolation and establishment of 
PfCSP-specific human monoclonal antibodies (mABs) from Tanzanian adults who received 
PfSPZ Vaccine and were protected against homologous CHMI three weeks past last 
vaccination. To our knowledge, this is the first time sporozoite-specific human mAbs were 
generated from African donors living in malaria-endemic regions. We found that the mAbs 
with the strongest capacity to inhibit parasite growth in vitro and in vivo target a distinct 
peptide located at the junction between the N-terminus and the first NANP repeat of the CS 
protein (KQPADGNPDPNANPNKNN). The N-terminus of PfCSP is known to be critical for 
sporozoite attachment and invasion of hepatocytes, and antibodies targeting this part of 
PfCSP were associated with protection from clinical malaria in children living in malaria-
endemic regions [163, 164]. However, the latter study tested serum samples in an ELISA 
against several PfCSP N-terminal peptides differing in length. ELISA measures the presence 
of the total antibody response in serum, but does not dissect the response at the clonal B cell 
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level. In contrast, our study investigated the efficacy of specific antibodies produced by single 
B cell clones from protected donors and identified the most inhibitory antibodies as those able 
to bind to a narrow region between the N-terminus and the repeat region of PfCSP. 
Overall, our data presented in Chapter 4 suggest that we have identified a promising epitope 
that appears to be a target of antibodies in individuals protected from malaria. However, the 
key question, whether this epitope when delivered as synthetic peptide in combination with a 
strong adjuvant is immunogenic and induces protective humoral immunity in humans, 
remains to be investigated. This could be analyzed further through direct testing of one of the 
highly effective mAbs in humans, e.g. via passive transfer experiments followed by controlled 
human malaria infection. Production of GMP conform mAB that could be tested in humans 
requires a long process of extensive pre-clinical safety studies evaluating immunotoxicity, 
pharmacokinetics and pharmacodynamics of mAbs, which may take several years before 
entering human clinical trials [165, 166]. Foremost, based on our current findings, the next 
critical step is to test if the epitope is immunogenic in mice and to test the functional capacity 
of the induced antibodies to block sporozoite invasion in vitro and in vivo similar to the 
experiments described in Chapter 4. Structural analysis of epitope – antibody interactions are 
currently carried out in collaboration with Ian Wilson (unpublished data). 
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Clinical trials on the safety and efficacy of the PfSPZ Vaccine are ongoing in Africa, the U.S. 
and Europe and new studies are planned. All of these studies are testing higher doses and 
fewer immunizations of the PfSPZ Vaccine than used in the BSPZV1 study described in 
Chapter 2. The aim is to finally arrive at an effective dosing and vaccination regimen for 
malaria-endemic populations to achieve high-level protection. These studies include follow-
up trials in Equatorial Guinea, Mali, Tanzania, Burkina Faso and Kenya in adult volunteers 
but also in adolescents, children and infants (Tanzania and Kenya). All of these trials are 
testing the safety, tolerability and protective efficacy of 3 dose regimens of 4.5 x 105, 9 x 105 
and 1.8 x 106 radiation-attenuated PfSPZ. Besides of increasing the doses of radiation-
attenuated PfSPZ Vaccine, it will also be important to investigate if improved 
immunogenicity and protective efficacy in malaria pre-exposed populations can be achieved 
through other whole sporozoite vaccination approaches using chemoprophylaxis vaccination 
(CVac) or genetically attenuated parasites (GAP). In CVac, the Sanaria PfSPZ are 
administered as non-irradiated sporozoites under anti-malaria drug coverage [30]. This 
vaccination approach conferred sterile protection (100%) against homologous CHMI in 
malaria-naïve volunteers in Germany when administered at 3 doses of 5.12 x 104 non-
irradiated PfSPZ at 28-day intervals under choloroquine chemoprophylaxis coverage [167]. In 
contrast to radiation-attenuated PfSPZ used in the PfSPZ Vaccine, the non-attenuated PfSPZ 
in CVac develop into mature liver stages and give rise to schizonts that are released as 
merozoites into the blood, where the parasites are killed by the antimalarial-drug chloroquine. 
CVac exposes the immune system to an increased breath and quantity of malaria antigens 
compared to radiation-attenuated PfSPZ [30]. To induce complete protection, CVac requires 
approximately 20-fold fewer PfSPZ than immunization with radiation-attenuated PfSPZ 
(PfSPZ Vaccine), but is limited by the need of continuous taking of anti-malarial drugs during 
immunization [31]. The CVac approach is currently tested in malaria-endemic adults in 
Equatorial Guinea using a dosage of 1 x 105 PfSPZ in each vaccination (unpublished data). 
Alternatively, GAPs are attenuated via genetic engineering of P. falciparum through targeted 
deletions of genes that are essential to complete pre-erythrocytic infection and transition into 
blood-stage parasites [32]. As a result, homogeneous populations of parasites with a defined 
attenuation phenotype can be generated and used for immunization. This has the advantage of 
preventing over-attenuation and batch-to-batch variation [32]. Recently, Kublin et al., 
reported complete attenuation of genetically-attenuated P. falciparum sporozoites from a first-
in-human phase 1 safety and immunogenicity trial in malaria-naïve people from the U.S. [32]. 
Another promising GAP malaria vaccine candidate [168] is currently tested in humans in the 
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Netherlands (unpublished data) and it will be interesting to explore the efficacy of GAP 
malaria vaccine candidates in malaria-endemic target populations. 
 
Based on our findings in Chapter 3, the next important step will be to confirm the functional 
capacity of sporozoite-inhibiting IgM antibodies in vivo in mice studies. This can be done 
with the same human liver-chimeric mouse model as described in Chapter 4, except of 
passively transferring monoclonal antibodies into FRG-mice, IgM-purified sera will be used 
for the the passive transfer. Alternatively, generation and testing of sporozoite binding IgM 
human monoclonal antibodies from African donors as described in Chapter 4 could support 
this research. Furthermore, it will be interesting to investigate if the IgM antibodies elicited by 
the PfSPZ Vaccine are capable of fixing complement upon sporozoite binding in vitro. It 
would be important to compare our findings with serum samples collected from malaria-naïve 
volunteers who have been immunized with the same dosing and regimen to see if induction of 
sporozoite-specific IgM antibodies after PfSPZ immunization is restricted to individuals 
residing in malaria-endemic areas. In order to get a better understanding of the cellular source 
of these sporozoite –specific IgM antibodies, one could use the PBMC samples collected at 
the same time-points and sort for plasmablasts and MBCs using specific markers for MZ B 
cells by flow cytometry. MZ B cells are defined based on their 
IgMhiIgDlowCD1c+CD21hiCD23-CD27+ marker expression [169–171]. Future studies should 
also address if the sporozoite binding IgM antibody repertoire undergoes affinity maturation 
resulting in improved effector function upon repeated vaccinations. 
 
Considering our findings in Chapter 4, the next step would be to test whether the target 
epitope of the highly functional antibodies is immunogenic in mice. Therefore, BALB/C mice 
could be immunized with the peptide conjugated to a carrier protein such as KLH. 
Afterwards, the serum will be collected to analyze the induced IgG and IgM antibody 
responses against the 18-mer peptide by ELISA and against whole sporozoites by our newly 
developed flow cytometry screening assay. If the epitope is immunogenic in mice, the next 
step will be to collect sera from the immunized mice and test for functional antibodies capable 
of inhibiting sporozoite development in vitro (ISTI). In parallel, production of mouse 
monoclonal antibodies targeting the 18-mer peptide could be tested similarly in vitro and in 
vivo. In addition, resolution of a crystal structure of a highly functional human mAb with its 
corresponding target peptide could provide insight into antibody affinity maturation steps and 
peptide structure essential for providing functionally highly active humoral immunity. Three-
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dimensional structural analysis of antibody-epitope specificity through high-resolution X-ray 
crystallography is necessary in order to understand the mechanism of immune recognition and 
for the rational design of synthetic vaccines [172]. 
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In two previously described donors, the extracellular domain 
of LAIR1, a collagen-binding inhibitory receptor encoded on 
chromosome 19 (ref. 1), was inserted between the V and DJ 
segments of an antibody. This insertion generated, through 
somatic mutations, broadly reactive antibodies against RIFINs, 
a type of variant antigen expressed on the surface of Plasmodium 
falciparum-infected erythrocytes2. To investigate how frequently 
such antibodies are produced in response to malaria infection, we 
screened plasma from two large cohorts of individuals living in 
malaria-endemic regions. Here we report that 5–10% of malaria-
exposed individuals, but none of the European blood donors tested, 
have high levels of LAIR1-containing antibodies that dominate the 
response to infected erythrocytes without conferring enhanced 
protection against febrile malaria. By analysing the antibody-
producing B cell clones at the protein, cDNA and gDNA levels, we 
characterized additional LAIR1 insertions between the V and DJ 
segments and discovered a second insertion modality whereby the 
LAIR1 exon encoding the extracellular domain and flanking intronic 
sequences are inserted into the switch region. By exon shuffling, this 
mechanism leads to the production of bispecific antibodies in which 
the LAIR1 domain is precisely positioned at the elbow between the 
VH and CH1 domains. Additionally, in one donor the genomic 
DNA encoding the VH and CH1 domains was deleted, leading to the 
production of a camel-like LAIR1-containing antibody. Sequencing 
of the switch regions of memory B cells from European blood donors 
revealed frequent templated inserts originating from transcribed 
genes that, in rare cases, comprised exons with orientations and 
frames compatible with expression. These results reveal different 
modalities of LAIR1 insertion that lead to public and dominant 
antibodies against infected erythrocytes and suggest that insertion 
of templated DNA represents an additional mechanism of antibody 
diversification that can be selected in the immune response against 
pathogens and exploited for B cell engineering.
LAIR1-containing antibodies were initially isolated from two 
Kenyan donors who were selected from a large cohort of more than 
500 individuals for their capacity to produce broadly reactive antibodies 
to P. falciparum-infected erythrocytes2. To establish the prevalence 
of LAIR1-containing antibodies in malaria-exposed individuals, we 
screened plasma samples from two large cohorts in Tanzania3 and Mali4. 
To identify LAIR1-containing antibodies irrespective of their  specificity 
for parasite isolates, we developed a two-determinant immuno-
assay using beads coated with anti-LAIR1 or control antibodies. 
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Figure 1 | Prevalence and dominance of  
LAIR1-containing antibodies in malaria-
endemic regions. a, b, Prevalence of LAIR1-
containing IgG and IgM in African individuals 
living in malaria-endemic regions and in 
European blood donors. Donors from whom 
LAIR1-containing antibodies were isolated are 
highlighted in red. c, Comparison between LAIR1-
containing IgG and IgM values. MFI, median 
fluorescence intensity. Data points with a ∆ MFI 
value below − 2,000 are not shown. d, Staining of 
infected erythrocytes by LAIR1-containing IgG 
and conventional IgG from three representative 
donors. e, Dominance of LAIR1-containing B cell 
clones among memory B cells specific for infected 
erythrocytes. Monoclonal antibodies isolated 
from immortalized memory B cells were classified 
according to their ability to bind to infected 
erythrocytes and the presence of a LAIR1 insert. 
Bars show number of IgG or IgM monoclonal 
antibodies isolated from each donor. For gating 
strategy, see Supplementary Fig. 1. ND, not 
determined.
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Six out of 112 Tanzanian donors (5.4%) and 57 out of 656 Malian 
donors (8.7%) had detectable levels of LAIR1-containing IgG (Fig. 1a). 
In addition, 2–4% of African donors had LAIR1-containing IgM, with 
no or variable levels of LAIR1-containing IgG (Fig. 1b, c). By  contrast, 
only 3 and 4 out of 1,043 European blood donors showed a low  positive 
result in the assays for LAIR1-containing IgG and IgM, respectively. 
The presence of LAIR1-containing antibodies was confirmed by the 
isolation of 52 immortalized B cell clones from seven East and West 
African donors (Extended Data Table 1 and Supplementary Table 1), 
whereas we were not able to isolate LAIR1-containing monoclonal anti-
bodies from four European donors that showed serum reactivity. The 
finding that 5–10% of individuals living in malaria-endemic regions 
produce LAIR1-containing antibodies is suggestive of a public antibody 
response.
To investigate the contribution of LAIR1-containing antibodies to 
the response to infected erythrocytes, we dissected this response at 
the polyclonal and monoclonal levels. Staining of infected erythro-
cytes with plasma from selected individuals with LAIR1-containing 
antibodies revealed that most infected erythrocytes were recognized 
by the LAIR1-containing antibodies, whereas only a minority of 
infected erythrocytes was recognized by conventional IgG (Fig. 1d). 
Furthermore, when immortalized memory B cell clones from four 
donors were analysed for reactivity to infected erythrocytes and for 
the presence of LAIR1, all of the infected erythrocyte-recognizing mon-
oclonal antibodies from three donors and most of such antibodies from 
the fourth donor contained the LAIR1 insert (Fig. 1e). These findings 
suggest that, in certain individuals, circulating antibody and memory 
B cell responses are dominated by LAIR1-containing antibodies, a 
finding that may be explained both by the breadth of these antibodies’ 
reactivities and by clonal expansion of the B cells that produce these 
antibodies.
To investigate the nature of the LAIR1 insertion, we sequenced cDNA 
and gDNA from B cell clones isolated from different individuals. As 
reported for the first two Kenyan donors2, the B cell clones isolated 
from four Malian and Tanzanian donors (E, F, O and Q) contained 
an insertion of the LAIR1 exon with flanking intronic sequences 
between the V and DJ segments, positioning the LAIR1 domain in 
the CDR3 loop (Fig. 2a and Extended Data Fig. 1). The size of the 
insert and the partial splicing of the upstream intronic region differed 
between donors, but were identical in the sister clones isolated from 
each  individual, indicating that in each donor the LAIR1-containing 
antibody response is monoclonal.
Strikingly, B cell clones from three additional donors showed a 
 different insertion modality (Fig. 2b–d). The cDNA of clones isolated 
from donors M (Malian) and J (Tanzanian) contained only the LAIR1 
exon, which was precisely located between the JH and CH1 domains. 
In both cases, gDNA analysis revealed that a DNA fragment comprising 
the LAIR1 exon flanked by intronic sequences was inserted into the 
switch-µ region (Extended Data Fig. 2) and, by alternative  splicing, 
gave rise to two mRNA variants with or without the LAIR1 insert. 
This was confirmed by the production of antibodies with or without 
LAIR1 in similar proportions by a single B cell clone (Fig. 2e). Another 
example of LAIR1 insertion into the switch region was observed in 
donor B (Kenyan), from whom we isolated a B cell clone (MGB47) 
producing a truncated LAIR1-containing IgG3 heavy chain without an 
attached light chain (Fig. 2f, g). In this clone, the gDNA carried multiple 
 deletions that removed most of the VDJ and the entire CH1 region, 
leading to the production of a camel-like antibody5 (Fig. 2d). Together, 
these findings highlight a new modality of exon insertion in the switch 
region that can add an extra domain to an antibody.
The two insertion modalities result in the production of antibodies 
with non-conventional structures in which an additional domain is 
inserted into the CDR3 region or into the elbow between VH and 
CH1 (Fig. 3a). To investigate the effect of the insert position on anti-
body specificity, we designed different constructs in which unmutated 
LAIR1, mutated LAIR1 or other Ig-like domains were inserted into 
the CDR3 or elbow regions of an antibody of known specificity that 
was used as a scaffold (Fig. 3b). Antibody constructs carrying LAIR1 
stained infected erythrocytes and were recognized by an anti-LAIR1 
antibody, independent of the position of LAIR1 in the scaffold. While 
insertion of LAIR1 into the CDR3 region of an antibody specific 
for granulocyte–macrophage colony-stimulating factor (GM-CSF)6 
abolished binding to GM-CSF, insertion of LAIR1, programmed cell 
death-1 (PD-1), or signalling lymphocytic activation molecule family 
member (SLAM) Ig-like domains into the elbow region did not affect 
binding to GM-CSF. This indicates that the VH–CH1 elbow is permis-
sive for insertions of different domains without affecting the original 
antibody specificity and may therefore be suitable for the generation 
of bispecific antibodies.
To analyse the role of somatic mutations, we aligned and compared 
the LAIR1 sequences of 52 antibodies (Extended Data Fig. 3 and 
Extended Data Table 1). LAIR1 inserts between the V and DJ  segments 
carried several amino acid substitutions clustering at hot spots around 
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Figure 2 | LAIR1-containing antibodies produced by two insertion 
modalities. a–d, cDNA and gDNA organization in representative  
B cell clones from different donors. Donors E and J are Tanzanian, donor 
M is Malian and donor B is Kenyan. e, Western blot analysis of culture 
supernatants of B cell clones with LAIR1 insertion in the VDJ (MME2, 
donor E) or in the switch region (MMJ5, donor J) or a conventional 
antibody (MME17) (n = 4). f, Surface staining of clone MGB47 showing  
co-expression of LAIR1 and IgG and lack of light chain (n = 3).  
A positive control and a LAIR1-negative clone (MGB21) are shown  
for comparison. For gating strategy, see Supplementary Fig. 1.  
g, Western blot analysis of culture supernatant of the camel-like clone 
MGB47 (n = 4). Also shown are supernatants from clones MGO3  
(LAIR1 insertion in VDJ region), MGB21 (IgG3 control) and MGB4  
(IgG1 control). For gel source data, see Supplementary Fig. 2.
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positions 67, 77 and 102 that determined distinct patterns of reactivity 
with parasite isolates, as well as loss of collagen binding (Fig. 3c). By 
contrast, LAIR1 inserted into the switch region carried only a few sub-
stitutions, which were, however, sufficient to abolish collagen binding. 
In particular, the camel-like antibody MGB47, which had the highest 
level of amino acid substitutions among those with inserts in the switch 
region, showed considerable breadth, staining eight out of the nine 
parasites tested. Notably, unmutated LAIR1 bound to a few isolates 
when tested at 1 µ g ml−1 and to all parasites when tested at a 100-fold 
higher concentration (Fig. 3c). We conclude that the unmutated LAIR1 
domain binds with low affinity to most parasite isolates and that muta-
tions can increase affinity and modify the spectrum of cross-reactivity. 
Furthermore, the finding that collagen binding is lost even in cases 
where the somatic mutation mechanism is less effective, as in the case of 
insertions into the switch region, suggests that there is strong pressure 
to ‘redeem’ this B cell receptor from autoreactivity7.
The insertion of an extra exon into the switch region represents a new 
modality of antibody diversification, analogous to exon shuffling8,9, that 
has the potential to generate a panoply of bispecific antibodies. To inves-
tigate how generally and how frequently templated DNA sequences 
are inserted into the switch region, we isolated gDNA from switched 
 memory B cells of European blood donors, amplified the switch regions 
and sequenced them using the Illumina platform (Extended Data Fig. 4). 
Using a bioinformatics pipeline, we identified templated inserts at a 
 frequency of approximately one in more than 1,000 B cells, with the 
length of the inserts ranging from below 100 to over 1,000  nucleotides 
(Fig. 4a, Extended Data Fig. 5 and Supplementary Tables 2–4). 
Switch region inserts could also be detected using long-read MinION 
 sequencing of intact amplicons, which provided a suitable platform for 
insert identification, in spite of its high error rate10. Using MinION, we 
confirmed the identity of several inserts using biological replicates and 
estimated a higher frequency of templated inserts, in the region of one 
in a few hundred switched memory B cells (Fig. 4a and Extended Data 
Fig. 6). By contrast, no insert was detected in the switch region of naive 
B cells (Fig. 4c). Most of the inserts were derived from genic regions 
from all chromosomes and in particular from genes expressed in 
B cells, such as PAX5 and EBF1 (Fig. 4b, e, f and Extended Data Fig. 7). 
The genic inserts, which account for 75% of all inserts, were derived 
from introns and exons, and in some cases comprised an entire exon 
with preserved splice sites (Fig. 4d). A fraction of the latter had the 
correct frame and orientation for the potential expression of an extra 
protein sequence in the immunoglobulin elbow (Extended Data Fig. 8). 
Together, the above findings indicate that templated inserts derived 
from transcribed genes are found frequently in the switch regions of 
memory B cells.
We have shown that LAIR1-containing antibodies are produced by 
two insertion modalities and have a prevalence of 5–10% of individuals 
exposed to malaria infection, suggesting that they may contribute to 
acquired immunity to blood-stage parasites. However, in spite of their 
breadth and opsonizing activity2, the presence of LAIR1-containing 
antibodies did not confer improved protection against febrile malaria 
(Extended Data Fig. 9), a finding that may be explained by the fact that 
the LAIR1-containing antibodies recognize only a fraction of cultured 
parasites and may allow the selection of escape mutants. A thorough 
investigation of the role of the LAIR1-containing antibodies in vivo will 
require the isolation of autologous parasites from the individuals who 
possess these antibodies.
It is unusual that, in all cases observed so far, the LAIR1-containing 
antibodies are produced by a single expanded B cell clone that domi-
nates the antibody response to infected erythrocytes in these  individuals. 
The finding that unmutated LAIR1 has the inherent  ability to bind to 
infected erythrocytes explains how the insertion of this domain results 
in the generation of public antibodies with a common specificity. 
Furthermore, the fact that this domain binds to all  parasite isolates 
tested, albeit with low affinity, suggests a mechanism for the extraordi-
nary clonal expansion and selection of mutated  antibody  variants with 
improved affinity and breadth by repeated  infections with different 
P. falciparum parasites. These findings illustrate, in a  biologically relevant 
system, the power of clonal selection driven by both antigen binding 
and loss of self-reactivity. Furthermore, the binding of infected erythro-
cytes to LAIR1 suggests the possibility that the parasite might target this 
inhibitory receptor to modulate the host immune response.
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Figure 3 | The influence of insert position and somatic mutations on 
antibody specificity. a, Schematic representation of LAIR1-containing 
antibodies produced by different insertion modalities. b, Scheme of 
constructs (C1–C10) containing LAIR1 or other Ig-like domains in 
different positions that were tested for binding to a set of antigens or  
anti-domain antibodies by enzyme-linked immunosorbent assay  
(ELISA) or flow cytometry. The construct domains and their binding 
values to the cognate ligands are colour coded as depicted in the figure. 
The V and J segments that do not contribute to any binding are not 
coloured. BKC3 (grey) is a negative control. LAIR1D21, LAIR1M1 and 
LAIR1J5 are the exons from MGD21, MGM1 and MGJ5 antibodies, 
respectively. LAIR1gen is the unmutated genomic sequence of LAIR1 
encoded on chromosome 19. MGDUCA, unmutated common ancestor 
of donor D antibodies; GL, germline; IEs, infected erythrocytes. Data 
are from one experiment out of two. EC50, half-maximum effective 
concentration. c, Binding of LAIR1-containing antibodies to erythrocytes 
infected with nine parasite isolates and to human collagen (n = 1).  
Values refer to binding at a concentration of 1 µ g ml−1. The MGDUCA 
was also tested at 100 µ g ml−1. The number of amino acid substitutions is 
shown in brackets next to the antibody names. OD, optical density.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
6 0 0  |  N A T U R E  |  V O L  5 4 8  |  3 1  A U G U S T  2 0 1 7
LETTERRESEARCH
The insertion of LAIR1 into the switch region, resulting in the 
expression of a new domain in the elbow between the VH and CH1 
domains, represents a new and possibly general example of protein 
engineering by exon shuffling8,9, as suggested by the frequent occur-
rence of templated inserts. Although insertions in the CDR3 loop result 
in monospecific antibodies, insertions in the switch region do not affect 
the specificity of the original antibody but rather add a second speci-
ficity that is found in approximately half of the antibodies produced by 
alternative splicing. We are not aware of deliberate attempts to engineer 
the antibody elbow, and in this context, nature has shown considerable 
ingenuity by taking advantage of the exon shuffling principle.
It has been reported that, in mice, chronic Plasmodium chabaudi 
infection promotes genomic instability that leads to chromosomal 
translocations involving the switch region11. Although we cannot 
exclude the possibility that the LAIR1 insertions in the switch region 
observed in African donors may have been promoted by malaria 
infection, the frequent templated insertions found in European blood 
donors would be consistent with a general mechanism that does not 
necessarily rely on malaria infection. Nevertheless, the data suggest 
that it is the exposure to the malaria parasite that selects the rare B cells 
with a LAIR1 insertion in the VDJ or switch region. Finally, it remains 
to be established whether chromosomal translocations and templated 
insertions share a common mechanism.
The finding of templated inserts in the switch region of switched 
memory B cells, but not naive B cells, suggests that the insertions occur 
in germinal centres as a consequence of unconventional repair of 
activation-induced cytidine deaminase (AID)-induced double-strand 
DNA breaks. Similarly, repair of recombination activating gene (RAG)-
induced double-strand breaks during B cell development in the bone 
marrow may give rise to insertions in the CDR3 region. Our finding 
that switch region inserts are derived from transcribed genes suggests 
the involvement of nascent RNA as an insert template, and recent 
publications have shown that both nascent12,13 and foreign RNA14,15 
can be used to repair double-strand DNA breaks. Furthermore, 
multiple templated inserts from transcribed genes have been observed 
in engineered double-strand breaks in a human cell line and mouse 
pro-B cells14,16. However, we cannot exclude the possibility that acces-
sible DNA is a primary substrate. The possibility of inducing naive 
human B cells to switch in vitro offers the opportunity to study the 
mechanism of templated insertions and to engineer B cells by manipu-
lating the factors involved in DNA repair and by offering different 
substrates.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Figure 4 | Frequent occurrence of templated inserts in the switch 
region. a, Inserts in the switch region were detected by amplification and 
Illumina MiSeq sequencing (left) of six polyclonal samples of primary  
B cells from European donors and of the MGB47 monoclonal cell line as 
a control. Biological replicates were analysed with MinION technology 
(right). Shown are the size distribution of all detected inserts and the 
estimated number of B cells that need to be analysed to detect one insert. 
For each technology, two independent experiments with 2–3 donors 
were performed. Red lines show mean values. b, Circos plot showing the 
origin of the inserts from different chromosomes. c, Insert frequencies 
in switch-µ (Sµ ) regions of naive B cells and in µ –γ joint regions of IgG 
memory B cells. d, Frequency of intergenic and different types of genic 
inserts. The red bar shows the number of exon-containing inserts with 
preserved splice sites in anti-sense and sense orientation. Inserts with 
the correct orientation and frame of the coding sequence (CDS) are 
highlighted in pink. e, EnrichR analysis on the Human Gene Atlas reveals 
significant enrichment for B cell-associated genes. f, List of B cell-specific 
genes donating inserts.
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METHODS
No statistical methods were used to predetermine sample size. The experiments 
were not randomized and the investigators were not blinded to allocation during 
experiments and outcome assessment.
Serum and plasma samples. Kenyan plasma samples were obtained from adults 
living in a malaria-endemic region within Kilifi County. Tanzanian serum and 
plasma samples were obtained from healthy male volunteers, malaria negative 
at study enrolment and during peripheral blood mononuclear cell (PBMC) 
 collection, HIV and hepatitis B and C negative, age 25.4 ± 2.8 years (mean ± s.d.)3. 
The Mali study was conducted in the rural village of Kalifabougou where intense 
P.  falciparum transmission occurs from June to December each year. Six hundred 
and ten individuals (310 males and 300 females) were enrolled, ranging in age from 
1 to 26 years (mean 9 years). The cohort has been described in detail elsewhere4. 
A smaller number of serum samples was also obtained from adults in the Fulani 
and Dogon ethnic groups in Mantéourou, Mali. Forty-eight individuals (28 males 
and 20 females) were enrolled, ranging in age from 21 to 57 years (mean 39.7 years).
Ethics approval. In all cases, written informed consent was obtained from the 
participants (or guardians of participating children) before inclusion in the study. 
The acquisition and use of the Kenyan plasma samples were approved by the Kenya 
Medical Research Institute Scientific and Ethics Review Unit (protocol number: 
KEMRI-SERU 3149), as well as the Oxford Tropical Research Ethics Committee. 
The Tanzanian samples were obtained with informed consent from the trial 
 participants. The clinical trial was conducted according to good  clinical practice 
and with authorization from the Institutional Review Boards of the Ifakara Health 
Institute, the National Institute for Medical Research Tanzania, the Tanzanian Food 
and Drugs Authority and the Commission cantonale d'éthique de la recherche 
sur l'être humain du canton de Vaud, Switzerland. The trial is registered at https://
clinicaltrials.gov/ with identifier: NCT01949909. The Mali study was approved by 
The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the 
University of Sciences, Technique and Technology of Bamako, and the Institutional 
Review Board of the National Institute of Allergy and Infectious Diseases, National 
Institutes of Health. Written informed consent was obtained from participants or 
parents or guardians of participating children before inclusion in the Mali study.
Parasite culture. P. falciparum parasites were initially obtained from children who 
were diagnosed with malaria in Kilifi County, Kenya. The parasites were adapted 
to in vitro culture and cultivated using standard protocols17. The P. falciparum 
laboratory line 3D7 was also cultured under the same conditions. 3D7D21 was 
derived by enrichment of 3D7 parasites reactive with the LAIR1-containing 
 monoclonal antibody MGD21. Parasites were cryopreserved at the late trophozoite 
stage in small aliquots for subsequent use in assays.
Screening of serum or plasma with bead-based immunoassay. Serum and 
plasma were tested for the presence of LAIR1-containing antibodies using a two- 
determinant bead-based immunoassay. Anti-goat IgG microbeads (Spherotech) 
were coated with goat anti-human LAIR1 (R&D Systems, AF2664) and 40 × SYBR 
Green I (ThermoFisher Scientific) or with goat anti-human EGF (R&D Systems, 
AF-259-NA) without SYBR Green I for 20 min at room  temperature. The beads 
were washed, mixed, and incubated with the serum at a 1/30 dilution for 1 h at 
room temperature under shaking conditions. Beads coated with anti-LAIR1 
were differentiated from control beads coated with anti-EGF based on SYBR 
green  staining. Serum antibody binding was detected using 2.5 µ g ml−1 Alexa 
Fluor 647-conjugated donkey anti-human IgG (Jackson ImmunoResearch, 
709-606-098) or Alexa Fluor 647-conjugated donkey anti-human IgM (Jackson 
ImmunoResearch, 709-606-073). FACS Diva (version 6.2) was used for acquisition 
of samples and Flow-Jo (version 10.1) was used for flow cytometry analysis. ∆ MFI 
was calculated by subtracting the MFI of the anti-EGF control beads from that of 
the anti-LAIR1 beads in the IgG or IgM channel.
B-cell immortalization and isolation of monoclonal antibodies. IgM or IgG 
memory B cells were isolated from frozen PBMCs by magnetic cell sorting with 
anti-CD19-PECy7 antibodies (BD, 341113) and mouse anti-PE  microbeads 
(Miltenyi Biotec, 130-048-081), followed by fluorescence-activated cell  sorting 
(FACS) using goat Alexa Fluor 647-conjugated anti-human IgG (Jackson 
ImmunoResearch, 109-606-170) or anti-human IgM (Jackson ImmunoResearch, 
109-606-129) and PE-labelled anti-human IgD (BD, 555779). As previously 
described18, sorted B cells were immortalized with Epstein-Barr virus (EBV) 
and plated in single cell cultures in the presence of CpG-DNA (2.5 µ g ml−1) 
and  irradiated PBMC-feeder cells. Two weeks after immortalization, the culture 
supernatants were tested (at a 2/3 dilution) for the presence of LAIR1-containing 
 antibodies using the bead-based immunoassay described above. For several 
donors, the culture supernatants were also tested for the ability to bind to infected 
erythrocytes from a mixture of four parasite isolates (3D7-MGD21+, 9106, 9605 
and 11019) by flow cytometry. In brief, cryopreserved infected erythrocytes were 
thawed, stained with 10 × SYBR Green I for 30 min at room temperature, and 
 incubated with the B-cell supernatants for 1 h at 4 °C. Detection of antibody  binding 
was done with 2.5 µ g ml−1 Alexa Fluor 647-conjugated goat anti-human IgG.
Sequence analysis of antibody cDNA. cDNA was synthesized from selected 
B cell cultures and both heavy chain and light chain variable regions (VH and VL) 
were sequenced as previously described19. The usage of VH and VL genes and 
the  number of somatic mutations were determined by analysing the homology 
of VH and VL sequences of monoclonal antibodies to known human V, D and 
J genes in the IMGT database20. Antibody-encoding sequences were amplified 
and sequenced with primers specific for the V and J regions of the given antibody. 
Sequences were aligned with Clustal Omega21.
Mutation analysis of LAIR1 inserts. The number of somatic mutations in the 
LAIR1 inserts was obtained by analysing the homology of the inserts to the 
original LAIR1 genomic sequence (sequence from Ensembl genome database: 
ENSG00000167613). Amino acid sequences of LAIR1 inserts of all the antibodies 
discovered were grouped for each donor and aligned to the original unmutated 
LAIR1 sequence using Clustal Omega21. The replacement to silent mutation ratio 
(R/S) values were calculated at each codon for each donor. Mean (R/S) values above 
2.9, indicative of positive selection, were used to highlight hot spots in the LAIR1 
extracellular domain (PDB 3RP1) using the BioLuminate software (Schrödinger, 
LLC, 2016 v.2.4).
Production of recombinant antibodies, antibody variants and fusion  proteins. 
Antibody heavy and light chains were cloned into human IgG1, Igκ and Igλ 
expression vectors and expressed by transient transfection of Expi293F cells 
(ThermoFisher Scientific) using polyethylenimine (PEI). Cell lines were routinely 
tested for mycoplasma contamination. The antibodies were affinity purified by 
 protein A chromatography (GE Healthcare). Variants of the GCE536, MGD21, 
MGM1 and MGJ5 antibodies were produced by inserting or exchanging the 
mutated or unmutated LAIR1 sequences or by substituting these sequences with 
the Ig-like domains of PD1 and SLAM genes (sequences from Ensembl genome 
database: ENSG00000188389 and ENSG00000117090, respectively). The  antibody 
constructs were tested for staining of 9,215 infected erythrocytes and binding 
 values (%) at 1 µ g ml−1 antibody concentration were calculated by interpolation 
of binding curves fitted to a sigmoidal curve model (Graphpad Prism 7).
Amplification of antibody gDNA. Genomic DNA was isolated from B cell clones 
with a commercial kit (QIAGEN). For analysis of the camel-like antibody MGB47, 
3′ rapid amplification of cDNA ends (RACE)22 with the CH2-γ -REV1 primer 
(GAGACCTTGCACTTGTACTCCTTGCC) was used for amplification of trun-
cated heavy chain mRNAs. Heavy-chain variable-to-constant gDNA of MGB47 was 
amplified using an upstream 5′ VH3-21 primer (GGGTCCATATTGTGATCCT 
GAGTCTGGG) and CH2-γ -REV1 as the reverse primer. After PCR amplification 
with LongAmp Taq Polymerase (New England Biolabs), the 6,000-bp amplicon 
was cloned into a vector using the TOPO XL PCR cloning kit (ThermoFisher) and 
sequenced by plasmid-NGS sequencing (Microsynth, Switzerland). All other LAIR1 
switch and V-DJ inserts were  analysed by PCR amplification of gDNA and Sanger 
Sequencing using donor-specific forward and universal reverse  primers: donE_FW 
 (CCTGGAGGGTCTTCTGCTTGCTGGC), donF_FW (CCTCCTGCTGGTGG 
CAGCTCCC), donJ/M_FW1  (ATGGAGTTTGGGCTGAGCTGGGTTTTCC), 
donJ_FW2  (GTGAGTGAACACGAGTGAGAGAAACAGTGG), donM_FW2 
 (GAGTGAACATGAGTGAGAAAAACTGGATTTGTGTGG), donO/Q_FW 
 (ATGAAACATCTGTGGTTCTT), 3′ J6_REV (GGCATCGGAAAATCCA 
CAGAGGCTCC), IgG_CH1_REV1 (TCTTGTCCACCTTGGTGTTGCT), 
IgG_CH1_REV2 (GTAGTCCTTGACCAGGCAGC), IgM_CH2_REV1 
(GGACACCTGAATCTGCCGGGGACTGAAACCC), and IgM_CH2_REV2 
 (CTGGTCACCTTGTAGGTCGTGGGCCCAG).
Switch region PCR and Illumina sequencing. gDNA was isolated from FACS-
sorted human naive (CD19+ CD27− IgM+) or memory B cells (CD19+ CD27+ IgG+/
IgA+) using a commercial kit (QIAGEN). Switch region PCRs on memory B cell 
gDNA were performed using LongAmp Taq Polymerase (New England 
Biolabs) in 50 µ l reaction volumes with incubation for 3 min at 95 °C, followed 
by 30 cycles of 95 °C for 40 s, 60 °C for 30 s, 65 °C for 3 min and a final exten-
sion for 10 min at 65 °C. The upstream switch-µ forward primer S-µ -FW 
 (CACCCTTGAAAGTAGCCCATGCCTTCC) was combined with differ-
ent reverse primers. IgG-switched B cell DNA was amplified using S-γ -REV 
 (CCTGCCTCCCAGTGTCCTGCATTACTTCTG)23, which binds 3′ of switch-γ 
regions, or CH2-γ -REV1, which binds in the IgG-CH2 constant region, to allow 
amplification of alleles carrying a CH1 deletion. DNA deriving from IgA+-sorted 
cells was amplified with primer S-α -REV (CTCAGTCCAACACCCACCACTCC). 
All reverse primers mentioned were designed to allow amplification of various 
IgG and IgA subclasses. The switch-µ region of naive B cell gDNA was amplified 
combining the S-µ -FW primer with S-µ -REV (GGAACGCAGTGTAGACT 
CAGCTGAGG). The PCR reaction was performed using Herculase II Fusion DNA 
Polymerases (Agilent) with 1 M betaine and 3% DMSO in a 50 µ l volume at 98 °C 
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for 4 min followed by 30 cycles of 98 °C for 40 s, 58 °C for 30 s and 72 °C for 4 min, 
with a final extension for 10 min at 72 °C. Size-selected, purified switch amplicons 
were sent to GATC Biotech (Germany) for library preparation, barcoding, and 
Illumina MiSeq sequencing.
MinION sequencing. Oxford Nanopore Technology (ONT) was used to  generate 
biological and technical replicates of Illumina MiSeq sequencing runs. For 
 biological replicates, barcodes were introduced by the addition of recommended 
BC-sequences to S-µ and S-γ primers and PCR amplification. The  sequencing 
library was prepared using the Nanopore 2D sequencing kit SQK-LSK207,  followed 
by loading onto Nanopore flow cells FLO-MIN106 and sequencing with the 
MinION Mk1B sequencer for up to 20 h.
Infected erythrocyte binding assays. Recombinant monoclonal antibodies were 
produced in Expi293F cells and tested for the ability to stain 3D7-MGD21+ and 
eight Kenyan parasite isolates2 by flow cytometry. Cryopreserved infected erythro-
cytes were thawed, stained with 10 × SYBR Green I for 30 min at room temperature, 
and incubated with serial dilutions of the recombinant antibodies for 20 min at 
room temperature. Antibody binding was detected with 2.5 µ g ml−1 goat Alexa 
Fluor 647-conjugated anti-human IgG.
Selected sera were screened for the presence of LAIR1-containing antibodies 
that could bind to infected erythrocytes. A mixture of four parasite isolates 
(3D7-MGD21+, 9106, 9605 and 11019) was stained with 10 µ g ml−1 DAPI for 
30 min at room temperature and incubated with test sera at a 1/30 dilution for 
20 min at room temperature. The infected erythrocytes were then incubated with 
goat anti-human LAIR1 (R&D Systems, AF2664) for 20 min at room  temperature. 
The binding of LAIR1-containing antibodies to the infected erythrocyte  surface 
was detected by the simultaneous addition of Alexa Fluor 488-conjugated 
 donkey anti-goat IgG (Jackson ImmunoResearch, 705-546-147) and Alexa Fluor 
647- conjugated donkey anti-human IgG (Jackson ImmunoResearch, 709-606-098).
ELISA. Total IgGs were quantified using 96-well MaxiSorp plates (Nunc) coated 
with goat anti-human IgG (SouthernBiotech, 2040-01) using Certified Reference 
Material 470 (ERMs-DA470, Sigma-Aldrich) as a standard. To test specific  binding 
of antibody constructs, ELISA plates were coated with 2 µ g ml−1 of type I recom-
binant human collagen (Millipore, CC050), 2 µ g ml−1 of an anti-human LAIR1 
antibody (clone DX26, BD Biosciences 550810), 1 µ g ml−1 of recombinant human 
GM-CSF (Gentaur), 2 µ g ml−1 of an anti-PD1 or an anti-SLAM antibody (R&D 
Systems, AF1086 and AF164). Plates were blocked with 1% bovine serum albumin 
(BSA) and incubated with titrated antibodies, followed by AP-conjugated goat 
anti-human IgG, Fcγ fragment specific (Jackson Immuno Research, 109-056-098). 
Plates were then washed, substrate (p-NPP, Sigma) was added and plates were 
read at 405 nm.
Western blots. B cell supernatants containing secreted antibodies were diluted in 
H2O, 4× sample loading buffer (Life Technologies) and 10× sample reducing agent 
(Life Technologies) and loaded onto precast gels with a 4–12% acrylamide gradient 
(Invitrogen). The iBlot2 apparatus (Life Technologies) was used for protein transfer 
to PVDF membranes followed by blocking for 1 h at room temperature with 3% 
BSA in TBS. The membrane was incubated with different combinations of primary 
and secondary antibodies diluted in TBS/1% BSA for 1 h at room temperature 
with 2 sequential TBS incubations to wash the membrane between incubations. 
For detection of IgG, anti-human IgG-biotinylated antibody (Southern Biotech, 
2040-08) was used at 1 µ g ml−1, followed by 25 ng ml−1 streptavidin-horseradish 
peroxidase (HRP) (Jackson ImmunoResearch, 016-030-084). IgM isotypes were 
stained with 10 µ g ml−1 unlabelled goat anti-human IgM (Southern Biotech, 2020-01) 
and 8 ng ml−1 donkey anti-goat HRP (Jackson ImmunoResearch, 705-036-147). 
To detect LAIR1-containing antibodies, a polyclonal goat anti-human LAIR1 
 antibody (R&D) at 2 µ g ml−1 was combined with secondary donkey anti-goat HRP. 
Membranes were developed with ECL-substrate on a Las4000 imager (General 
Electric Company).
Surface staining of B cell lines. EBV immortalized B cells were stained with 
different fluorescently labelled antibodies to detect surface immunoglobulin 
expression and LAIR1 co-staining (Alexa Fluor 647-conjugated anti-human IgG, 
Jackson ImmunoResearch, 109-606-170; FITC-conjugated anti-human kappa, 
DAKO, F0434, PE-conjugated anti-human lambda, DAKO, R0437; PE-conjugated 
anti-human LAIR1 clone DX26, BD Bioscience, 550811). Cells were analysed by 
flow cytometry and FlowJo software. Dead cells were excluded from the analysis by 
4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI) staining. The time point 
of the analysis was selected for optimal BCR expression levels and for downreg-
ulation of the original LAIR1 receptor, because EBV cell lines downregulate the 
inhibitory receptor LAIR1 at an early time point after immortalization but may 
also decrease surface-Ig levels after certain passages.
Genomic insertion analysis after Illumina sequencing. We generated a compu-
tational pipeline to analyse targeted amplicons of 300 bp paired-end (PE) reads 
obtained by MiSeq Illumina sequencing methodology (Extended Data Fig. 5). 
Raw sequences reads were trimmed to remove adaptor contamination and poor- 
quality base calls using Trim Galore (http://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/, v.0.4.2, parameters–Illumina–paired -q 20–length 99). In 
addition, assessment of the PE reads was performed by average quality score per 
base position, using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Trimmed reads were aligned in paired-end mode to the GRCh37 human 
genome assembly using Burrows–Wheeler Alignment tool (v.0.7.12, parameters: 
bwa mem)24. The switch region of the IgH locus was defined on GRCh37, with 
the following coordinates: chr14:106050000–106337000. To find insertions in the 
IgH switch region locus, we selected genomic ranges when sequence coverage was 
above 2 reads and/or above 40 reads, thus, generating two respective and separated 
workflows, with a sequence length comprises between 50 bp and 2,000 bp. Genome 
coverage was processed using Bedtools (http://bedtools.readthedocs.io/en/latest/ 
index.html, v.2.26.0) and a dedicated python script using pysam (https://github.
com/pysam-developers/pysam) was written to identify potential insert. In brief, 
in both workflows (2 and 40 reads), potential inserts were assigned if they fulfilled 
the following criteria: (i) one mapping read in 5′ end is chimaeric with the switch 
region; (ii) one mapping read in 3′ end is chimaeric with the switch region; (iii) two 
discordant reads have their mates read mapped in the switch region. Afterwards, 
inserts coming from 2 and 40 minimum reads coverage were merged according 
to the following rule: if the difference between two inserts that overlap was equal 
or below 10 bp, we kept the shortest one, otherwise the longest one was kept. 
The list of potential inserts was annotated using GENCODE v.1925 and BEDOPS 
tools26 and individually validated by a de novo assembly of the contig sequence. 
Non-chimaeric, but properly paired reads mapping the insert coordinates and 
chimaeric reads corresponding to the encompassing mate pairs and spanning mate 
pairs, were extracted using SAMtools27. Reads mapping to the switch region were 
extracted only if they were spanning mate pairs related to the insert coordinates. 
Selected reads were uniquely mapped to the region of interest (no XA tag), with 
a minimum mapping quality of 5. Original read sequences were retrieved, pulled 
together and used as input files to perform a de novo assembly using the Trinity 
software28. Finally, to validate a contig sequence for each insert, we used BLAST29  
(command-line version, v.2.5.0+ ). The consensus insert sequences were ‘blasted’ 
against the switch region and we removed the inserts that had an alignment with 
at least half of their sequence length at a minimum 80% identity (parameters: -task 
megablast -dust no -perc_identity 80). Then, we blasted each contig sequence against 
the switch region sequence and the consensus insert sequence (parameters: -task 
blastn -dust no -perc_identity 70) to confirm whether the contig was made of 
the complete insert sequence and contained two flanking sequences of at least 
50 bp that matched the switch region. The shortest contig that fulfilled the criteria 
 mentioned above was selected for each insert.
Bioinformatic analysis of MinION sequencing. To analyse targeted amplicon 
2–4-kb reads obtained by ONT sequencing methodology, we developed a pipe-
line (Extended Data Fig. 6). Raw sequences reads were quality-filtered using 
Metrichor basecaller (https://metrichor.com/s/). 2D reads with a sequence length 
above 1,000 bp (or 2,000 bp depending on the primers used for the amplification) 
were aligned against GRCh37 human genome assembly with LAST software30 
(parameters: last-train and lastal -p ONT_fasta_sequences.par last-split -m1e-6). 
Then we parsed LAST output and selected reads that contain an insert (minimum 
50 bp length), two flanking regions of minimum 100 bp mapping to the switch 
region (switch locus defined as chr14:106050000–106337000) and allowing a gap 
of 100 bp maximum between the insert and the switch region. Finally, we merged 
the insert coordinates of the overlapping inserts with bedtools and annotated the 
inserts list with GENCODE v.1925 using BEDOPS tool26. Scripts are available at 
MinION and Illumina inserts coordinates were merged with Bedtools (merge 
 command with default parameter). The circular genomic representation of the 
inserts has been generated using the Circos software31. Switch inserts with genic 
(intron or exon–intron) origin were subjected to an enrichment analysis using 
EnrichR and the Human Gene Atlas as the gene-set library32,33.
Statistical analysis. The number n described in the figure legends refers to the 
number of independent experiments. The analysis of the relationship between 
the presence of LAIR1-containing antibodies and protection from malaria was 
 performed in the R statistical environment (v.3.2.5). Two-tailed Fisher’s exact 
tests were performed to investigate the association between LAIR1-containing 
 antibodies and protection from febrile malaria.
Code availability. Scripts for Illumina and MinION sequence analysis are  available 
at https://bitbucket.org/mathildefog/switchillumina and https://bitbucket.org/
mathildefog/switchminion, respectively.
Data availability. Sequence data for the monoclonal antibodies isolated in this 
study have been deposited in GenBank (https://www.ncbi.nlm.nih.gov/genbank/) 
with the accession codes indicated in Supplementary Table 1. The NGS data for 
switch region sequencing are deposited in NCBI Sequence Read Archive (SRA) 
with the accession code PRJNA382214. The analyses of these sequences are 
 provided in Supplementary Tables 2–4.
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Extended Data Figure 1 | Alignment of gDNA and cDNA sequences of LAIR1-containing antibodies. Shown is one representative antibody from each 
donor. a, MGE9 (donor E); b, MGF21 (donor F); c, MGO3 (donor O); d, MGQ4 (donor Q).
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Extended Data Figure 2 | Genomic sequences of switch regions containing LAIR1 inserts. Shown is one representative antibody for each donor;  
a, MMJ5 (donor J); b, MGM5 (donor M); c, MGB47 (donor B). The chromosome coordinates of the insertion sites are indicated in blue and green.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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LAIR1GEN (0/0) EDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERESRSTYNDTEDVSQASPSESEARFRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVK
MGM3 (6/4) - I V E
MGM4 (3/3) V E S
MGM1 (2/2) V D
MGM5 (1/1) V
MMJ16 (5/3) E V G
MGJ2 (1/1) F
MGJ5 (2/2) E V
MMJ1 (2/2) E V
MMJ2 (2/2) E V
MMJ5 (2/2) E V
MMJ6 (2/2) E V
MMJ7 (2/2) E V
MMJ8 (2/2) E V
MMJ10 (2/2) E V
MMJ23 (2/2) E V
MMJ25 (2/2) E V
MGJ1 (2/2) H E
MGJ3 (4/2) - E
MGB2 (7/5) R K E H F
MGB43 (6/6) R E T L T F
MGB47 (6/6) R TE T L F
MGF21 (30/16) G M T FKFTES V L T H F Q Q
MGF33 (21/10) N FL TE V A V A Q
MGF45 (21/10) N FL TE V A V A Q
MGF8 (28/19) MA P L N FK TE FPV F V T H V Q Q
MGF11 (31/18) M D R NK TE DA TR P T S L Q V Q
MGF39 (17/11) M R YI ES T V Q V Q
MGF58 (24/13) M A HI T DK E D T Q V Q
MGF64 (25/13) M R HI KI E D T V Q V Q
MGE9 (43/21) -A L Q G T L S S G VG K T L AR E S Q I
MGE7 (14/7) H L S T V AS
MME2 (22/12) V G S I S TT H S V AH
MME4 (21/14) T D V G G R S S T H S V AH
MME10 (23/13) V G R R S T S H S V AH E
MGQ21 (18/10) T S Q S V T Y SS E
MGQ9 (15/10) EM K F V H T SR G
MGQ22 (14/8) K T F T V A F D
MGQ1 (18/10) S VH SES E V D V
MGQ14 (18/10) S VH SES E V D V
MGQ5 (17/12) D M K DT S TE DC T D
MGQ15 (17/11) D M R T S IE DC T D
MGQ20 (16/10) D M K S TE DC T D
MGQ19 (9/6) D T FI E E
MGQ12 (12/9) A M E E V F R V F
MGQ11 (12/7) I R W E V T V
MGQ4 (10/9) V I SE E V LT V
MGQ16 (11/10) T SES E V LT V R
MGQ6 (13/9) D I SE E V T H V
MGO1 (41/22) G H DT L TE DKL HV LT L SA AG RLE
MGO2 (41/23) M F P H V DLP L SE HI A I R R L SS P F R
MGO3 (23/16) DL I I K G A S T D T V A A C Q
MGO4 (22/15) P H Q D V T RHG SR AE S Q
MGD21 (23/14) - RNYL S T NA LF SR V
MGD34 (20/13) RNYL S T NA LF SR V
MGD30 (21/10) K R TSF V Y V A D
MGD33 (19/8) K R T V Y V A D
MGD56 (20/11) K L Q L HP V SS E C
MGD47 (25/13) G A Q I AL S V A ARR D
MGD39 (18/11) D I R L S V FA DR D
MGD55 (16/10) D I L S V FA DR D
MGD16 (15/9) D ANGF S G DH
MGD23 (19/8) L A E F L AR D
MGD41 (10/7) L V P F S D V
MGD24 (9/6) L R H G D V
MGD53 (4/4) L F D V
MGC34 (16/11) IH L TE T V E T L V
MGC26 (21/15) P A I E QK L P HG L L SS M
MGC17 (19/13) E RL H DR HP L V S E K
MGC1 (18/11) AE KD I N P L V A A
MGC32 (18/11) AE KD I N P L V A A
MGC2 (10/9) H P T KD P Y L L
MGC37 (15/11) D P KDR P T L V D F
MGC28 (18/11) T T S L R SE VG L R
MGC33 (18/11) T T S L R SE VG L R
MGC35 (26/13) S L H GW-- G M R L A R
MGC4 (26/13) D H GW--R G R L IA R
MGC36 (26/13) D H GW--R G R L IA R
MGC5 (26/13) H GW--R G Q R L L I R
MGC29 (26/13) H GW--R G Q R L L I R
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Extended Data Figure 3 | Somatically mutated and conserved regions  
in the LAIR1 domains inserted in the VDJ or in the switch region.  
a, Amino acid substitutions in antibodies isolated from different donors 
and mean R/S ratios at each residue. The mutational analysis takes  
into consideration the germline LAIR1 alleles found in each donor.  
In donor C, the P98L substitution is uncoloured because it may arise  
from polymorphism, since the donor is heterozygous at this position.  
The number of nucleotide mutations and amino acid substitutions are 
reported in brackets next to the antibody names. b, Graphic representation 
of mutational hot spots (red) and of most conserved regions (blue). 
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INSERT SWITCHSWITCH
Chr 14
Chr ?
V JD J J
FW REV
INSERT SWITCHSWITCH
Illumina
reads
f ragmentation, Illumina MiSeq sequencing long read, MinION sequencing
MinION
read
Switch -µ Switch -µ/γ/α
Switch region PCR
bioinformatic analysis  and assembly of 300 bp reads bioinformatic analysis of long, error prone MinION reads
182
56
56
134
5 1
264
24
28
7
6
1
RAVER1; ANGEL2; CCNE2;
AZIN1; 3 intergenic
LCP1; CCDC57; CDC45 ;  
EBF1; HCFC1 ; 1 intergenic
chr 6 
inter-
genic
a
b c
46740227 chr 13 chr 14 switch 
LCP1 - 206 bp
chr 13  46740432switch chr 14
Illumina ……AACTGGGCTTGGCTGCACTAAGGGTTTCTACCTGGGTGGG………CTGGGTTCAAGTCCAGGCTCGAGCAGGGGGCAGGCACTGG……
||||||||||||||||||||||||||||||||||||||||   ||||||||||||||||||||||||||||  ||||||||||
MinION   ……AACTGGGCTTGGCTGCACTAAGGGTTTCTACCTGGGTGGG………CTGGGTTCAAGTCCAGGCTCGAGCAGGG--CAGGCACTGG……
Illumina ……TTTTAATGACTTTAAAGCAGCAGGTCACCTTTTCTAGCCT………GGTACTTTTATGATAACTCAGTGTAGATGCAGGTGAGCAG……
||| ||||||||||||||| |||||||||||| ||| |||   ||| | |||    |||||||| ||||||||||||||||||
MinION ……TTT-AATGACTTTAAAGCAACAGGTCACCTTT-CTAACCT………GGTGC-TTTGAAGTAACTCAGCGTAGATGCAGGTGAGCAG……
10440625  chr 19 chr 14 switch 
RAVER1 - 371 bp
chr 19  10440257switch chr 14
gDNA donor 6
PCR1 PCR2 PCR3
Illumina MinION MinION method
6.4x105 7.2x105 9.6x104 cells
22x106 1.6x104 2.2x104 reads
300 Ø 3000 Ø 1200 bp
277 32 35 inserts
gDNA donor 5
PCR1 PCR2
Illumina MinION MinION method
2.1x106 7.9x104 cells
32x106 1.7x105 1.8x104 reads
300 Ø 1200 Ø 1200 bp
247 118 23 inserts
Extended Data Figure 4 | Validation of switch region inserts 
combining Illumina and MinION technologies. a, Illumina and 
MinION workflows. Switch regions of polyclonal naive or IgG/IgA 
switched B cells were amplified by PCR. For Illumina sequencing, PCR 
amplicons were fragmented, re-amplified during library preparation 
and sequenced using the 2 ×  300 bp MiSeq system. The bioinformatic 
analysis included the assembly of contiguous, chimaeric reads. For insert 
confirmation, independently generated PCR-barcoded primary products 
were sequenced with MinION technology and analysed with a different 
bioinformatic approach for long, error-prone MinION reads. b, Multiple 
identical switch inserts for donor 6 were confirmed in biological replicate 
experiments with independent technical and analytical setups. Shown 
are the experimental designs, shared and unique reads in a Venn diagram 
and an alignment of Illumina and MinION sequences covering the switch 
insertion sites for two examples (LCP1, RAVER1). c, Shared and unique 
switch inserts in technical and biological replicate experiments of donor 5.
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FASTQ (raw) = targeted amplicon reads  (300 bp PE)
FASTQ (trimmed)
Chr14
Switch region
chr14:106050000-106337000
Chr?
insert
BAM
Chr?
insert
Chr14
Switch region
One read in 3’ is chimaeric with Switch region
One read in 5’ is chimaeric with Switch region
Two discordant reads have their mates in Switch region
FASTQ
FASTA
Quality-based trimming and adapter removal (Trim Galore, FastQC). Remove reads < 100bp a.
Align reads to human genome GRCh37 (BWA mem)b.
Select genomic ranges where coverage >= 2 (or 40) reads and 50bp <= length < 2000bpc.
Identify potential inserts like the following: d.
De novo assembly for each potential insert f.
Chr?
Filter in paired reads containing the insert
(chimaeric or non-chimaeric ones): 
encompassing mate pairs and spanning mate pairs
Filter in the spanning mate pairs
 in the Switch region
(proper paired with a chimaeric read)
De novo assembly (Trinity)
insertswitch region switch region
Chr14
Switch region
- insert sequence not homologous with Switch region
- insert sequence complete in the contig
- two flanking regions of minimum 50bp that match with Switch
      select the shortest contig sequence that fulfills the criteria
Validate insert (BLAST, Java)
(samtools, pysam)
Merge inserts coming from 2 and 40 reads coverage and annotate them with GENCODE v19 e.
(Java, BEDOPS)
  For overlapping inserts, if difference between 2 inserts <= 10bp, we keep the shortest one, otherwise we keep the longest one.
(bedtools)
(pysam)
Extended Data Figure 5 | Pipeline for data analysis using the Illumina platform. Shown is the scheme of the bioinformatics workflow used for the 
analysis of Illumina sequences.
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FAST5 (raw) = targeted amplicon reads  2-4 kb
FASTQ
MAF
FASTA
BED
Quality-based filtering: 2D reads (Metrichor)a.
Remove reads < 1000bp (or 2000bp) and convert to FASTA format b.
Reads alignment to human genome GRCh37 (LAST)c.
Merge inserts’ coordinates (for overlapping inserts) and annotate them with GENCODE v19 e.
(bedtools, BEDOPS)
FASTA
read
Chr14:106236043-106237100 Chr14:106325845-106327263Chr19:54872513-54872906
- Insert with length >= 50bp
- Two flanking regions mapping to the Switch (length >= 100bp)
- Gap <= 100bp between the insert and the Switch flanking region(s)
Parse LAST output and select reads with an insert (Java)d.
Extended Data Figure 6 | Pipeline for data analysis using the MinION technology. Shown is the scheme of the bioinformatics workflow used for the 
analysis.
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80bp320bp101bp
donor 2
37028889
37028989
donor 3
37028488
37028807
donor 5
37025017
37025096
Pax5  chromosome 9   200.91kb  reverse strand 
donor  2
36848145
36848263
EBF1  chromosome 5   403.84kb  reverse strand 
119bp
135bp
donor 5
158482178
158482312
91bp
donor 6
158348924
158349014
481bp
donor 6
158228848
158229328
multiple insert-donor genes
6 inserts SNHG1
5 inserts MALAT1
4 inserts CUX1, PAX5, LMNA, IRF8, AFF3, ACTB, AC010976.2
3 inserts TXNDC11, SLC20A1, SETBP1, EBF1, SNHG5, SND1, SETX, RPL28, PACS1, NEAT1, ENO1, CSNK1E, BCL11A, AC096579.13
2 inserts PRKD2, LCP, IKZF3, GAS2L1, FBXO11, ATG16L2, ACTG1, DGKH, HECTD4, HNRNPA1, SLAMF1, EIF3B, KDM2B, MBP, PPP2R5C, SCAPER, 
SNAPC4, ZNF423, ZZEF1, TCF4, RUFY3, RPTOR, RP11-63A11.1, MGRN1, INPP5D, HMGB1, ETS1, CDT1, FAM53B, HUWE1, RCC1, ST3GAL3, 
FANCA, L3MBTL2, MKNK2, RAB26, RPL36,   ARHGEF2, CASKIN1, CSK, EEFSEC, EIF4A2, ESR2, IKZF1, MYC, NRXN2, NUP214, PKIG, RCC2, 
ZC3H7A, WDR66, AC096579.7, AFTPH, MAML3, PHF12, WIPF2
Extended Data Figure 7 | Examples of genes that donate multiple inserts. Shown is the original position of the inserts donated by PAX5 and EBF1 as 
well as a list of genes that donated two or more inserts.
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43 AA
SH3PXD2A-270bp 105420735  chr10 chr14 - switch 
GTF2I-206bp
57 bp exon
donor  6
donor  3
chr 7  74131135 74131340 chr7switch – chr14 chr14 - switch 
74131213 74131270
chr 10  105421004switch – chr14
132 bp exon105420872 105420740
159 225
partial SH3-domain166
18 AA276 293
Illumina     CAGGGGCTGGTGGGGGCATTGTTACCTAGA……TTATTTTCTTTTTAGGAAGCCACCATTCTT……AAGTACCAGCAGAAGGTTAGGAGAAAAAGA……TTTATAGATTCTATTGTCCCTGGAGCTCAG
||   |||||||||||||||  ||||||||||||||||||||||||||||||  ||||||||||||||||||||||||||||||  ||||||||||||||| ||| |  | | |   
GTF2I   TGTCTTAGATTGTTTGCATTGTTACCTAGA……TTATTTTCTTTTTAGGAAGCCACCATTCTT……AAGTACCAGCAGAAGGTTAGGAGAAAAAGA……TTTATAGATTCTATTATCCTTAAAACACCT
SHHSSEGNEGTEMEVPAE
Illumina   CTGAGCAGTTGGCAAGCTGCGGGCTGCCCC……TTCTGCCCTCGCCAGGTGCCGACGCCACCG……AGAAGAACGAGAGCGGTGAGTTCAGGGCTCAGAGAT
|    |    |  ||||||||||||||| |||||||||||||||||||||||||||||| ||||||||||||||||||||| |   |  ||  |  
SH3PXD2A GAGCTGCGAGCCCCGGCTGCGGGCTGCCCC……TTCTGCCCTCGCCAGGTGCCGACGCCACCG……AGAAGAACGAGAGCGGTGAGTGCCCTGGCCAATGGC
ADATAEPMILEQYVVVSNYKKQENSELSLQAGEVVDVIEKNES
Extended Data Figure 8 | Examples of potentially functional inserts. Shown is the alignment of the contig sequence and the genomic region from 
which the insert was derived, as well as the potential amino acid sequence inserted between the VH and CH1.
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Extended Data Figure 9 | Relationship between LAIR1-IgG or 
LAIR1-IgM status and protection from febrile malaria. Shown is the 
clinical status of 551 members of the Malian cohort, stratified by LAIR1-
containing IgG (a) or LAIR1-containing IgM (b) status, over the years 
2012 and 2013. Febrile malaria is defined as parasite density ≥ 2,500 
asexual parasites per microlitre of blood and an axillary temperature 
of ≥ 37.5 °C.
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Extended Data Table 1 | V gene and insert usage of LAIR1-containing antibodies
Isotype and V(D)J gene usage of heavy chain and light chain of mAbs containing LAIR1 in the switch or in the VDJ region. D genes of the monoclonal antibodies containing a 
V(D)J insert cannot always be properly predicted by IMGT. Mutations of the LAIR1 insert are shown as % of identity to the genomic unmutated LAIR1 exon. GL, germline;  
nd, not determined.
Donor mAb Isotype Heavy chain VDJ genes 
(% identity to GL)
Light chain VJ genes
(% identity to GL)
LAIR1 mutations
(% identity to GL)
Sw
itc
h 
re
gi
on
M
(Malian)
MGM1 IgG1 λ VH3-30 (79.5) D3-16 JH4 (89.4) VL3-10 (88.2) JL1 (81.1) (99.3)
MGM3 IgG1 λ VH3-30 (86.8) D3-16 JH4 (87.2) VL3-10 (88.5) JL1 (78.4) (98.0)
MGM4 IgG1 λ VH3-30 (93.4) D3-16 JH4 (91.5) VL3-10 (97.1) JL1 (83.8) (99.0)
MGM5 IgG1 λ VH3-30 (88.5) D3-16 JH4 (83.0) VL3-10 (91.0) JL1 (81.1) (99.7)
J
(Tanzanian)
MGJ1 IgG1 κ VH3-20 (83.0) D6-25 JH3 (87.8) VK1-5 (89.3) JK3 (91.9) (99.3)
MGJ2 IgG3 κ VH3-20 (90.6) D6-19 JH3 (91.8) VK1-5 (96.1) JK3 (91.9) (99.7)
MGJ3 IgG1 κ VH3-20 (85.4) D2-21 JH3 (89.8) VK1-5 (88.5) JK3 (89.2) (98.6)
MGJ5 IgG1 κ VH3-20 (87.5) D6-19 JH3 (89.8) VK1-5 (98.9) JK3 (97.4) (99.3)
MMJ1 IgM κ VH3-20 (88.2) D6-19 JH3 (85.7) VK1-5 (90.0) JK3 (86.5) (99.3)
MMJ2 IgM κ VH3-20 (90.6) D6-19 JH3 (81.6) VK1-5 (93.2) JK3 (86.5) (99.3)
MMJ5 IgM κ VH3-20 (91.7) D6-19 JH3 (83.7) VK1-5 (92.5) JK3 (86.5) (99.3)
MMJ6 IgM κ VH3-20 (91.0) D6-19 JH3 (79.6) VK1-5 (91.4) JK3 (86.5) (99.3)
MMJ7 IgM κ VH3-20 (90.6) D6-19 JH3 (81.6) VK1-5 (92.8) JK3 (86.5) (99.3)
MMJ8 IgM κ VH3-20 (90.6) D6-19 JH3 (81.6) VK1-5 (93.2) JK3 (86.5) (99.3)
MMJ10 IgM κ VH3-20 (90.6) D6-19 JH3 (81.6) VK1-5 (93.2) JK3 (86.8) (99.3)
MMJ16 IgM κ VH3-20 (90.6) D6-19 JH3 (81.6) VK1-5 (93.2) JK3 (86.5) (98.3)
MMJ23 IgM κ VH3-20 (91.7) D6-19 JH3 (83.7) VK1-5 (92.5) JK3 (86.5) (99.3)
MMJ25 IgM κ VH3-20 (90.6) D6-19 JH3 (83.7) VK1-5 (92.1) JK3 (86.5) (99.3)
B
(Kenyan)
MGB2 IgG3 nd nd (nd) nd nd (nd) nd (nd) nd (nd) (97.6)
MGB43 IgG3 nd nd (nd) nd nd (nd) nd (nd) nd (nd) (98.0)
MGB47 IgG3 nd nd (nd) nd nd (nd) nd (nd) nd (nd) (98.0)
VD
J 
re
gi
on
E
(Tanzanian)
MGE7 IgG1 λ VH1-46 (89.9) D2-15 JH3 (85.7) VL2-14 (91.3) JL7 (86.5) (95.2)
MGE9 IgG1 λ VH1-46 (88.5) D3-10 JH3 (91.8) VL2-14 (93.4) JL7 (91.9) (85.4)
MME2 IgM λ VH1-46 (86.1) D1-26 JH3 (87.8) VL2-14 (94.4) JL7 (91.7) (92.5)
MME4 IgM λ VH1-46 (86.8) D2-21 JH3 (91.8) VL2-14 (93.4) JL7 (85.7) (92.9)
MME10 IgM λ VH1-46 (86.8) D1-26 JH3 (91.8) VL2-14 (92.4) JL7 (88.6) (92.2)
F
(Tanzanian)
MGF8 IgG2 κ VH4-38-2 (93.8) D5-18 JH5 (90.0) VK3-15 (94.3) JK2 (92.1) (90.5)
MGF11 IgG1 κ VH4-38-2 (92.4) D5-18 JH5 (96.0) VK3-15 (92.5) JK2 (94.7) (89.5)
MGF21 IgG1 κ VH4-38-2 (88.5) D7-27 JH5 (92.0) VK3-15 (92.8) JK2 (92.1) (89.8)
MGF33 IgG1 κ VH4-38-2 (91.3) D3-3 JH5 (92.0) VK3-15 (92.1) JK2 (97.4) (92.9)
MGF39 IgG1 κ VH4-38-2 (94.1) D5-18 JH5 (96.0) VK3-15 (95.0) JK2 (92.3) (94.2)
MGF45 IgG1 κ VH4-38-2 (91.3) D3-3 JH5 (92.0) VK3-15 (91.8) JK2 (97.4) (92.9)
MGF58 IgG1 κ VH4-38-2 (92.4) D5-18 JH5 (92.0) VK3-20 (97.2) JK2 (97.4) (91.8)
MGF64 IgG1 κ VH4-38-2 (91.3) D5-18 JH5 (96.0) VK3-15 (91.8) JK2 (97.4) (91.5)
O
(Malian)
MGO1 IgG1 κ VH4-59 (87.4) D3-10 JH4 (87.2) VK3D-20 (90.4) JK5 (100.0) (86.1)
MGO2 IgG1 κ VH4-59 (89.8) D2-2 JH4 (85.1) VK3D-20 (94.0) JK5 (97.3) (86.1)
MGO3 IgG1 κ VH4-59 (89.1) D3-10 JH4 (85.1) VK3D-20 (90.8) JK5 (92.1) (92.2)
MGO4 IgG1 κ VH4-59 (91.6) D3-10 JH4 (80.9) VK3D-20 (94.3) JK5 (97.3) (92.5)
Q
(Malian)
MGQ1 IgG1 κ VH4-59 (90.9) D3-10 JH3 (98.0) VK2-30 (95.9) JK1 (94.1) (93.9)
MGQ4 IgG1 κ VH4-59 (94.0) D3-10 JH3 (98.0) VK2-30 (94.2) JK1 (91.2) (96.6)
MGQ5 IgG2 κ VH4-59 (89.9) D3-10 JH3 (100.0) VK2-30 (91.8) JK1 (85.3) (94.2)
MGQ6 IgG1 κ VH4-59 (94.0) D3-10 JH3 (98.0) VK2-30 (95.6) JK1 (94.1) (95.6)
MGQ9 IgG1 κ VH4-59 (92.3) D3-10 JH3 (100.0) VK2-30 (95.6) JK1 (97.1) (94.9)
MGQ11 IgG1 κ VH4-59 (93.3) D3-10 JH3 (95.9) VK2-30 (95.9) JK1 (100.0) (95.9)
MGQ12 IgG1 κ VH4-59 (92.7) D3-10 JH3 (100.0) VK2-30 (94.2) JK1 (94.1) (95.9)
MGQ14 IgG1 κ VH4-59 (90.2) D3-10 JH3 (98.0) VK2-30 (95.6) JK1 (94.1) (93.9)
MGQ15 IgG2 κ VH4-59 (91.2) D3-10 JH3 (100.0) VK2-30 (92.5) JK1 (85.3) (94.2)
MGQ16 IgG1 κ VH4-59 (94.4) D3-10 JH3 (98.0) VK2-30 (96.3) JK1 (97.1) (96.3)
MGQ19 IgG1 κ VH4-59 (95.4) D3-10 JH3 (95.4) VK2-30 (97.3) JK1 (97.1) (96.9)
MGQ20 IgG2 κ VH4-59 (90.5) D3-10 JH3 (100.0) VK2-30 (95.9) JK1 (91.2) (94.6)
MGQ21 IgG1 κ VH4-59 (92.6) D3-10 JH3 (100.0) VK2-30 (97.6) JK1 (100.0) (93.9)
MGQ22 IgG1 κ VH4-59 (88.1) D3-10 JH3 (100.0) VK2-30 (93.8) JK1 (100.0) (95.2)
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